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Chapter 1 Introduction
1.1 General introduction
Prostate cancer is the most common cancer in Dutch men with an incidence in 2009 
of 102 in 100.000 men [1]. This means an estimated 9600 new cases are diagnosed 
each year. With the ageing population the number of newly diagnosed patients is 
expected to rise to an estimated 15,000 in 2015. It is currently the second leading 
cause of cancer death after lung carcinoma. The lifetime chance of prostate cancer 
in Dutch men is the largest of all cancers with almost 10% [2].
Although 70% of these men is older than 65 years, and prostate cancer is mainly 
a disease of the elderly, a shift is seen towards younger age. Several factors have 
contributed to this increase of prostate cancer diagnosis over the last decades. 
The most important has been the introduction of serum PSA measurements into 
medical practice, which has led to dramatic changes in the incidence of prostate 
cancer, i.e., increased detection rates and a stage reduction at the time of diagnosis. 
Another significant factor was the expanding use of transrectal ultrasound-guided 
needle biopsies. The PSA threshold for biopsies has declined with time due to the 
detection of significant cancers in low PSA ranges [3]. The trend towards earlier 
detection was accompanied by a lower mean age at diagnosis, and subsequently 
an increased number of curative treatments were applied with an improved 5-year 
relative survival [4]. In spite of the high prevalence of this disease, the chance of 
dying of it is much smaller. Autopsy studies have shown that approximately 60% of 
men in their sixth and seventh decade of life have prostate cancer and generally 
do not die of it [5]. This means significant over detection of prostate cancer that 
can lead to excessive curative treatments and treatment-related complications.
Classically, the curative treatment options for localized prostate cancer are 
radical prostatectomy and radiotherapy (external beam radiotherapy (EBRT) and 
brachytherapy). Significant side effects have been described for both surgery 
and radiotherapy, and include urinary incontinence, erectile dysfunction and 
radiation related toxicity to the surrounding tissues, i.e., bladder, anal canal and 
rectal mucosa. Rectal toxicity is one of the limiting factors and is directly related 
to the total radiation dose prescribed and the volume of the rectal wall receiving 
a high dose [6]. On the long run radiotherapy related malignancies are described 
as well. The concept of dose escalation in EBRT has gained popularity amongst 
radiation oncologists as the clinical outcome has improved with lower PSA 
recurrence rates [7]. The prostate is a moving target, which necessitates wider 
treatment margins around the prostate for adequate irradiation of the tumor [8]. 
As a consequence, the total radiation dose to surrounding healthy tissues is one 
of the limiting factors. New developments in radiotherapy techniques are focusing 
on measures to deliver high-dose radiation to the prostate with smaller margins 
around the organ. Treatment techniques have improved and intensity-modulated 
radiation therapy (IMRT) modulates radiation dose to the organ more accurately 
than three-dimensional conformal radiotherapy (3D-CRT). A second means of 
reducing complication rates is by precisely targeting the organ with image-guided 
radiotherapy and fiducial intraprostatic gold markers. These markers are used for 
daily position verification and correction of the prostate gland and the clinical 
benefits are being investigated at this moment. Recently, the implantation of gold 
markers in the prostate bed for salvage radiotherapy after radical prostatectomy 
was introduced as well [9], but complication rates of this procedure have not been 
described before. Further, little is known about the side effects of the intraprostatic 
marker implantation and therefore these were investigated by us. Another means 
of influencing irradiation to surrounding tissues is by reduction of the organ 
volume and tumor size with the use of neoadjuvant hormonal therapy. Volume 
reduction leads to better local tumor control and perhaps to less treatment-related 
side effects of surrounding tissues [10]. The duration of hormonal pre-treatment 
is a matter of discussion. It is influenced both by the synergistic effect between 
hormonal therapy and radiotherapy on one hand, and by the potential of maximal 
prostate volume reduction on the other hand.
The percentage of men in the Netherlands undergoing radical prostatectomy 
almost doubled to 20% between 2004 and 2006. Active surveillance was chosen 
less often from 38% in 1989 to 9% in 2006 [4]. Radical prostatectomy, both open, 
laparoscopically, and robot assisted comes with a substantial number of side 
effects and therefore a range of alternative treatment strategies for localized 
disease, i.e., high intensity focused ultrasound (HIFU) and cryosurgery were 
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developed. In the early 60s, prostate cryosurgery using liquid nitrogen resulted in 
severe and frequent complications such as incontinence, and rectourethral fistulas 
[11]. Therefore, cryosurgery was abandoned until the late 1980s. More accurate 
TRUS-guided transperineal placement of ultrathin cryoprobes and gas-based 
cryosurgery [12], with real-time monitoring of the freezing process and a urethral-
warming catheter has significantly decreased the number of complications.
So far, the curative treatment options for a local recurrence after radiotherapy 
were limited to salvage surgery and complication rates, especially incontinence, 
were more prominent (45%) than with primary radical prostatectomy [13]. Third-
generation cryosurgery can potentially be an alternative treatment option and is 
currently being explored worldwide for its use in this setting. Further, an increasing 
interest in focal therapy with the use of cryosurgery has been developed.
Hormonal therapy is mainly administered in metastatic disease for long periods of 
time. Prostate cancer is expected to become castrate resistant after an average of 
2 years. The early side effects of this chemical castration are substantial, and consist 
of hot flushes, fatigue, loss of libido, and erectile dysfunction. On the long run 
osteoporosis, anemia, loss of muscle mass, metabolic syndrome, and an increased 
cardiovascular risk are seen [14,15]. In an attempt to improve these complication 
rates, hormonal therapy can be administered in an intermittent schedule. Pre-
clinical studies have shown an improved time to progression and a delay of the 
castrate resistant state [16,17], but human studies have not confirmed these 
findings. Other potential advantages of intermittent therapy are the improvement 
of quality of life during the off-treatment intervals and the prevention of long-term 
side effects. The patient selection seems critical, but little is known so far about 
which patients would benefit most of such a treatment regimen.
In this thesis the aforementioned developments in prostate cancer treatment and 
the complication rates are analyzed and discussed.
1.2 Outline of the thesis
There is a growing concern about the complication rates of curative prostate cancer 
treatment. A shift is seen towards earlier diagnosed disease, potentially leading to 
treatment of indolent prostate cancers. Hormonal therapy for metastatic prostate 
cancer is often administered for several years and the long term complication 
rates seem substantial. In this thesis, several clinical studies of prostate cancer 
treatment are described, which aim at improvement of complication rates without 
compromising the oncological results.
During a course of EBRT the prostate moves in different directions and is therefore 
called a ‘moving target’. It is critical to visualize the organ on a day-to-day basis 
for adequate targeting of the prostate and to correct for these movements. This 
can be done with the aid of fiducial intraprostatic gold markers that are visible 
on electronic portal images. In chapter 2 the effects of gold marker-based 
prostate position verification and correction on planning target volume and on 
radiation doses to surrounding healthy tissues are described. The gold markers 
are implanted in the prostate without anesthesia, either transrectally or perineally 
by transrectal ultrasound guidance. As marker implantation is an important 
tool for prostate localization during EBRT nowadays, the acceptance among 
radiotherapists and urologists is high. The patient, however, will only accept 
this procedure if complication rates are low. For a large cohort of patients the 
complication rate and risk factors for complications, after transrectal implantation 
of gold markers, were analyzed and are described in chapter 3. The role of 
gold markers is expanding and only recently its use in radiotherapy for a local 
recurrence after radical prostatectomy has been introduced. In chapter 4 the 
technique and complications of transrectal implantation of gold markers in the 
prostate bed are analyzed. Urologists are increasingly searching for alternative 
treatment options for localized disease, with potentially less side effects than 
surgery or EBRT. For local recurrences after EBRT only salvage surgery remains 
a treatment option. Cryosurgery was developed as an alternative minimally 
invasive curative treatment option for localized disease and for local recurrences 
of prostate cancer after EBRT. In chapter 5 an outline is given of the scientific 
evidence for the use of third-generation cryosurgery by a systematic review of the 
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literature. In chapter 6 an introduction is given for the role of neoadjuvant and 
intermittent hormonal therapy. The optimal duration of androgen deprivation for 
maximal prostate volume reduction, in a cohort of patients scheduled for EBRT, is 
described in chapter 7. Finally, an analysis was performed to identify subgroups 
of patients with metastatic prostate cancer that could benefit from intermittent 
hormonal therapy. The goals of the study, described in chapter 8, were to analyze 
the predictive value of PSA for progression and the role of testosterone kinetics on 
quality of life in patients with metastatic disease during continuous or intermittent 
hormonal therapy.
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Hoofdstuk 1 Introductie
1.3 Algemene introductie
Prostaatkanker is de meest voorkomende kanker bij Nederlandse mannen met 
een incidentie van 102 per 100.000 mannen in 2009 [1]. Dit komt neer op een 
geschat aantal nieuwe gevallen van 9600 per jaar. Het aantal nieuwe patiënten 
met prostaatkanker zal waarschijnlijk stijgen tot rond de 15.000 in 2015 door de 
vergrijzing van de bevolking. Na longkanker is het momenteel de tweede oorzaak 
van overlijden aan kanker. De kans op prostaatkanker bij Nederlandse mannen 
gedurende het leven is bijna 10% en daarmee de hoogste van alle kankers [2].
Prostaatkanker is voornamelijk een ziekte van oudere mannen en 70% is boven de 
65 jaar, maar er wordt een verandering gezien van presentatie naar jongere leeftijd. 
De toename van de diagnose prostaatkanker in de laatste decennia komt door een 
aantal factoren. De belangrijkste is de introductie van de serum PSA-meting in de 
dagelijkse praktijk geweest, met als gevolg een enorme verandering in incidentie 
van prostaatkanker met niet alleen een toename van detectie als gevolg maar 
ook een verschuiving naar lagere stadia tijdens de diagnose. Een andere factor 
is het toegenomen gebruik van transrectale echografie met biopten. Met de tijd 
is de ondergrens van PSA voor het nemen van biopten gezakt, omdat ook bij 
lagere PSA waarden significante prostaatkanker werd gevonden [3]. Door deze 
trend naar vroege detectie is de leeftijd van patiënten bij de diagnose verlaagd 
met als gevolg daarvan het inzetten van meer curatieve behandelingen en een 
verbetering van de relatieve 5-jaars overleving [4]. Ondanks de hoge prevalentie 
van de ziekte is de kans om eraan te overlijden veel kleiner. Uit obductiestudies 
is gebleken dat ongeveer 60% van de mannen in de leeftijd van 60 tot 80 jaar 
prostaatkanker heeft maar hieraan over het algemeen niet overlijdt [5]. Dit betekent 
dat er sprake is van significante overdetectie van prostaatkanker die kan leiden tot 
overmatige curatieve therapie met een toename van behandelingsgerelateerde 
complicaties.
Van oudsher zijn de curatieve behandelingsopties voor gelokaliseerd 
prostaatcarcinoom de radicale prostatectomie en radiotherapie (uitwendige 
radiotherapie en brachytherapie). Bij chirurgie en radiotherapie worden significante 
bijwerkingen door de behandeling beschreven, waaronder urine-incontinentie, 
erectiele disfunctie en bestralingsgerelateerde effecten op de omgevende weefsels 
zoals de blaas, het anale kanaal en het rectum. Rectum toxiciteit is een beperkende 
factor en is direct gerelateerd aan de totale bestralingsdosis en het rectumvolume 
dat een hoge dosis krijgt [6]. Er worden ook secundaire maligniteiten gezien ten 
gevolge van de radiotherapie op de lange termijn. Het concept van dosis-escalatie 
bij uitwendige radiotherapie heeft aan populariteit gewonnen bij oncologische 
radiotherapeuten door de betere klinische resultaten met lagere PSA recidief 
kansen [7]. De prostaat is echter een bewegend orgaan en daardoor zijn ruimere 
behandelingsmarges rondom de prostaat nodig om adequate bestraling van de 
tumor te bewerkstelligen [8]. Als gevolg daarvan is de totale bestralingsdosis 
van de omgevende gezonde weefsels een belangrijke beperkende factor. Bij 
de nieuwe ontwikkelingen in de radiotherapie ligt de nadruk op technieken die 
afgifte van hoge bestralingsdosis op de prostaat met kleine marges eromheen 
mogelijk maken. De behandelingstechnieken zijn verbeterd en met de komst 
van intensiteitgemoduleerde radiotherapie (IMRT) wordt de bestralingsdosis 
beter verdeeld over het orgaan dan bij 3-dimensionale conformele radiotherapie 
(3D-CRT). Een andere manier om de bijwerkingen te verminderen is door exacte 
lokalisering van de prostaat met beeldgeleide radiotherapie en goudmarkers. 
Deze markers worden gebruikt voor het dagelijks verifiëren en corrigeren van de 
positie van de prostaat en de klinische voordelen worden momenteel onderzocht. 
Zeer recent werd ook de implantatie van goudmarkers in de prostaatloge na een 
radicale prostatectomie geïntroduceerd ten behoeve van ‘salvage’ bestraling 
[9], maar de complicaties hiervan werden nog niet eerder beschreven. Verder 
is er weinig bekend over de complicaties van implantatie van goudmarkers in 
de prostaat en dit werd daarom door ons onderzocht. Een andere manier om 
bestraling van omgevende weefels te verminderen is door het orgaanvolume en 
de tumorafmetingen te reduceren met behulp van hormonale voorbehandeling. 
De volumereductie geeft een betere lokale tumorcontrole en mogelijk minder 
behandelingsgerelateerde bijwerkingen van de omgevende weefsels [10]. Er is een 
discussie gaande over de duur van hormonale voorbehandeling. De optimale duur 
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wordt bepaald door het synergistische effect van de combinatie van hormonale 
therapie en radiotherapie aan de ene kant en het maximale volumereducerende-
effect aan de andere kant.
Het percentage mannen in Nederland dat een radicale prostatectomie 
onderging tussen 2004 en 2006 is bijna verdubbeld tot 20%. De keuze voor 
‘active surveillance’ daalde van 38% in 1989 naar 9% in 2006 [4]. De radicale 
prostatectomie, zowel open als laparoscopisch en robot-geassisteerd, geeft 
een significant aantal bijwerkingen en dit heeft geleid tot de ontwikkeling van 
een aantal alternatieve behandelmethoden voor gelokaliseerde ziekte zoals 
hoge-intensiteit gefocusseerde echografie (HIFU) en cryochirurgie. In de vroege 
jaren 60 werd cryochirurgie van de prostaat verricht met vloeibare stikstof en dit 
leidde vaak tot ernstige complicaties zoals incontinentie en rectourethrale fistels 
[11]. Cryochirurgie werd daarom tijdelijk verlaten tot de late jaren 80. Met de 
introductie van gasgebaseerde cryochirurgie, die exacte plaatsing van zeer dunne 
cryonaalden mogelijk maakte door middel van transrectale echografie, een urethra 
verwarmingskatheter in situ en het ‘real-time’ monitoren van het vriesproces [12], 
is het aantal complicaties significant afgenomen.
Tot zeer recent waren de opties voor behandeling van een lokaal recidief na 
radiotherapie beperkt tot ‘salvage’ chirurgie met nog meer complicaties tot 
gevolg, zoals incontinentie bij 45% van de patiënten, dan bij primaire radicale 
prostatectomie [13]. De toepassing van een potentiële alternatieve therapie voor 
deze indicatie, de derde-generatie cryochirurgie, wordt momenteel wereldwijd 
geëxploreerd. Verder is er een toenemende interesse gaande in focale therapie 
met gebruik van cryochirurgie.
Hormonale therapie wordt voornamelijk toegepast bij gemetastaseerde 
ziekte gedurende langere perioden. Na gemiddeld 2 jaar worden tumoren 
echter castratieresistent. Er zijn aanzienlijke bijwerkingen bekend op korte 
termijn van chemische castratie zoals opvliegers, vermoeidheid, libidoverlies 
en erectiestoornissen. Op langere termijn worden osteoporose, anemie, 
spiermassaverlies, metaboolsyndroom en een verhoogd cardiovasculair risico 
gezien [14,15]. Met behulp van intermitterende therapie wordt getracht deze 
bijwerkingen te verminderen. In preklinische studies werd een langere tijd tot 
progressie en een vertraging van castratieresistentie aangetoond [16,17], maar 
dit werd niet bevestigd in studies bij de mens. Een verbetering van kwaliteit van 
leven tijdens de tussenliggende periodes zonder hormonen en preventie van 
bijwerkingen op langere termijn zijn andere potentiële voordelen. Patiëntenselectie 
lijkt hierbij essentieel, maar tot op heden is weinig bekend over welke patiënten 
de meeste baat hebben bij deze manier van behandelen.
In dit proefschrift worden de hiervoor genoemde ontwikkelingen in de behandeling 
van prostaatkanker en de complicaties ervan geanalyseerd en bediscussieerd.
1.4 Overzicht van het proefschrift
In toenemende mate komt er aandacht voor de complicaties van curatieve 
behandelingen bij prostaatkanker. Er is een trend naar vroege diagnostiek van 
de ziekte met als gevolg een potentiële toename van behandeling van indolente 
prostaatkanker. Bij gemetastaseerde ziekte wordt vaak meerdere jaren hormonale 
therapie gegeven met aanzienlijke bijwerkingen op de lange termijn. In dit 
proefschrift worden enkele klinische studies naar behandeling van prostaatkanker 
beschreven die als oogmerk een afname van complicaties hebben zonder de 
oncologische resultaten te verminderen.
De prostaat beweegt in verschillende richtingen tijdens een radiotherapie 
behandeling en wordt daarom wel een ‘moving target’ genoemd. Het is essentieel 
om dit orgaan dagelijks tijdens de behandeling in beeld te brengen voor een 
adequate instelling van de bestraling en voor correctie van de bewegingen van 
de prostaat. Dit is met behulp van goudmarkers in de prostaat, die zichtbaar zijn 
op elektronische ‘portal images’, te bewerkstelligen. In hoofdstuk 2 worden de 
effecten beschreven van de op goudmarkers gebaseerde verificatie en correctie 
van de prostaatpositie op het geplande doelvolume en op de bestralingsdosis die 
het omliggende gezonde weefsel krijgt toegediend. Deze goudmarkers worden 
zonder anesthesie transrectaal of perineaal ingebracht in de prostaat met behulp 
van transrectale echografie. Dit is tegenwoordig een geaccepteerde procedure 
IntroductieHoofdstuk 1
22 23
References
 
[1] NCR; http://www.ikcnet.nl
[2]  http://www.kwfkankerbestrijding.nl/index.jsp?objectid=15458
[3]  Naughton CK, Miller DC, Mager DE et al. A prospective randomized trial comparing 
6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000; 164: 388-
92.
[4]  Cremers RG, Karim-Kos HE, Houterman S et al. Prostate cancer: trends in incidence, 
survival and mortality in the Netherlands, 1989-2006. Eur J Cancer 2010; 46: 2077-87.
[5]  Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intraepithelial neoplasia 
(HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study 
of 249 cases. In Vivo 1994; 8: 439-43.
[6]  Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: 
Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 
2002; 53: 1097–1105.
[7]  Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-
dose conformal radiation therapy in clinically localized adenocarcinoma of the 
prostate: A randomized controlled trial. JAMA 2005; 294: 1233-9.
[8]  Langen KM, Jones DT. Organ motion and its management. Int J Radiat Oncol Biol 
Phys 2001; 50: 265-78.
[9]  Kupelian PA, Langen KM, Willoughby TR et al. Daily variations in the position of the 
prostate bed in patients with prostate cancer receiving postoperative external beam 
radiation therapy. Int J Radiat Oncol Biol Phys 2006; 66: 593-6.
[10]  Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for 
prostate cancer: reducing the potential morbidity of therapy. Urology 1997; 49 (suppl 
3A): 38-45.
[11]  Gonder MJ, Soanes WA, Smith V. Experimental prostate cryosurgery. Invest Urol 1964; 
1: 610–9.
[12]  Chin JL, Downey DB, Mulligan M, Fenster A. Three-dimensional transrectal ultrasound 
guided cryoablation for localized prostate cancer in nonsurgical candidates: a 
feasibility study and report of early results. J Urol 1998; 159: 910–4.
[13]  Touma NJ, Izawa JI, Chin JL. Current status of local salvage therapies following 
radiation failure for prostate cancer. J Urol 2005; 173: 373–9.
onder radiotherapeuten en urologen omdat de goudmarkers een belangrijke 
hulp zijn voor lokalisatie van de prostaat tijdens de radiotherapie. Voor de patiënt 
is de procedure echter alleen acceptabel als het aantal complicaties laag is. Het 
aantal complicaties en de risicofactoren voor complicaties werden geanalyseerd 
in een groot cohort van patiënten, na transrectale implantatie van goudmarkers en 
beschreven in hoofdstuk 3. De rol van goudmarkers is recent uitgebreid met het 
gebruik ervan bij radiotherapie van een lokaal recidief na radicale prostatectomie. 
In hoofdstuk 4 worden de techniek en complicaties van transrectale implantatie 
van goudmarkers in de prostaatloge geanalyseerd. Urologen zijn steeds op 
zoek naar alternatieve behandelingen voor gelokaliseerde ziekte met potentieel 
minder bijwerkingen dan chirurgie of uitwendige radiotherapie. Bij het lokale 
recidief na uitwendige radiotherapie blijft alleen nog ‘salvage’ chirurgie een 
behandelmogelijkheid. Cryochirurgie werd ontwikkeld als alternatieve en minimaal 
invasieve curatieve behandeling voor gelokaliseerde ziekte en voor lokale 
recidieven van prostaatcarcinoom na uitwendige radiotherapie. In hoofdstuk 5 
wordt door middel van een systematische review van de literatuur een uiteenzetting 
gegeven van het wetenschappelijk bewijs voor het gebruik van derde-generatie 
cryochirurgie. Hoofdstuk 6 bevat een introductie voor de rol van hormonale 
voorbehandeling en intermitterende hormonale therapie. In een cohort patiënten 
die uitwendige radiotherapie ondergingen wordt in hoofdstuk 7 de optimale duur 
van hormonale behandeling voor een maximale volume-afname van de prostaat 
beschreven. Tot slot werd een analyse verricht ter identificatie van subgroepen 
van patiënten met gemetastaseerd prostaatcarcinoom die baat zouden kunnen 
hebben bij intermitterende hormonale therapie. De doelstellingen van de studie 
in hoofdstuk 8 waren het analyseren van de voorspellende waarde van PSA 
voor progressie en de rol van de testosteronkinetiek voor kwaliteit van leven bij 
patiënten met gemetastaseerde ziekte tijdens hun continue of intermitterende 
hormonale therapie.
IntroductieHoofdstuk 1
24 25
[14]  Higano CS. Side effects of androgen deprivation therapy: Monitoring and minimizing 
toxicity. Urology 2003; 61 (2 suppl 1): 32-8.
[15]  Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate 
cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 
3979-83.
[16]  Akakura K, Bruchovsky N, Rennie PS, et al. Effects of intermittent androgen suppression 
on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the 
Shionogi carcinoma. J Steroid Biochem Mol Biol 1996; 59: 501-11.
[17]  Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays 
progression to androgen-independent regulation of prostate-specific antigen gene 
in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996; 58: 139-46.
Hoofdstuk 1
Johan F. Langenhuijsen • Robert Jan Smeenk • Robert J.W. Louwe 
Peter van Kollenburg • Johannes H.A.M. Kaanders • J. Alfred Witjes • Emile N.J.Th. van Lin
Reduction of radiotherapy margins  
with intraprostatic gold markers
02
Chapter
26 27
Chapter 2
Reduction of treatment volume and radiation doses to surrounding 
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Abstract
Background: High-precision radiotherapy with gold marker implantation is a 
standard technique for prostate cancer treatment. To provide insight into the 
beneficial effect of gold markers, the influence on treatment volume and radiation 
doses to healthy tissues was investigated.
Patients and Methods: Three consecutive treatment margins were constructed, 
for 10 patients with localized prostate cancer, to show the reduction of planning 
target volume: PTV 10 mm (no markers), PTV 7 mm (markers), and PTV 7/5 mm 
(markers and online correction). On planning computed tomography (CT) scan, 
the prostate, bladder, rectal wall, and anal canal were contoured. The treatment 
volume and radiation doses to surrounding organs were calculated. In 65 patients, 
with the online protocol and gold markers, late toxicity was evaluated.
Results: With gold markers a significant PTV reduction of 27% was achieved 
(P < 0.001). Subsequently, radiation dose reductions to the mean of 17% (±4.5%) 
to the bladder, 19% (±4.7%) to the anal canal, and 12% (±3%) to the rectal wall, 
respectively were seen (P < 0.001). With 5-mm posterior margins an additional PTV 
reduction of 3.7% (P < 0.001) and total radiation dose reduction to the mean of 
24% (±4%), and 16% (±4.5%) to anal canal and rectal wall, respectively were seen 
(P < 0.001). Late grade 1–2 genitourinary and gastrointestinal toxicity was seen in 
32%, and 33%, respectively. Grade 3 toxicity was less than 10%.
Conclusions: This study showed a significant reduction of treatment volume and 
radiation doses to healthy tissues with intraprostatic gold markers.
Introduction
Clinical trials have shown a dose-response relationship in external beam 
radiotherapy (EBRT) for prostate cancer [1-4]. Dose escalation with higher 
radiation doses to the surrounding tissues, e.g., bladder, rectum, and anal canal, 
however, increases toxicity rates [5]. Also, prostate motion is an important source 
of treatment error, with day-to-day gland displacements of 3–5 mm [6]. 3D 
treatment margins around the gland are defined to account for these prostate 
movements and to deliver an adequate dose to the gland. This so called planning 
target volume (PTV) inevitably leads to higher radiation doses to the surrounding 
organs. Therefore, strategies to control the patient set-up variations and organ 
motion have been developed in order to enable minimizing these margins. Among 
other modalities of image-guided radiotherapy (e.g., cone-beam computed 
tomography [CT]), an important strategy is to implant gold markers as fiducials 
for the prostate position and for daily alignment of the gland before radiation 
is administered. Gold markers have an excellent visibility on electronic portal 
images that are made during radiotherapy, enabling precise prostate localization 
and thereby the use of smaller treatment margins. Therefore, intraprostatic gold 
marker implantation for prostate localization and correction is now becoming the 
standard in EBRT [7]. Besides implantation by radiation-oncologists with prostate 
brachytherapy experience, gold markers are often implanted by urologists and 
2 groups have described their technique of marker implantation [8,9]. There are 
few data quantifying the degree of spared healthy tissue with image-guided 
radiotherapy even in radiation oncology literature. Recently, a dosimetry 
planning study was reported about the impact of smaller margins and sparing 
of healthy tissues [10]. The objective of this study is to comprehensively describe 
the advantages of gold markers for high-precision radiotherapy, especially for 
urologists who are involved in gold marker implantation, and to report toxicity 
rates of patients who were treated according to the latest radiation technique.
Therefore, the influence of gold marker-based prostate position correction on 
treatment volume and radiation doses to surrounding tissues was measured.
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Patients and Methods
Planning target volume margins
In the past decennium, EBRT, prostate imaging, and patient positioning and 
verification techniques have gradually evolved in our radiation oncology 
department. Three time frames can be distinguished, in which different correction 
strategies were applied, each strategy allowing for specific treatment margins.
Until 2002, no markers were implanted. The daily positioning, during 3D-
conformation radiotherapy (3D-CRT), was based on skin marks and reference laser 
lines. In addition, an offline correction strategy was used in which portal images 
were obtained during the first treatment fractions. The bony structures of the 
pelvis on these portal images were compared with a reference image, obtained 
during the radiotherapy preparation, to estimate the systematic position error. 
Using an offline correction strategy, large systematic errors in patient position were 
then corrected for in the subsequent fractions. However, the day-to-day patient 
set-up variation and the interfraction prostate movement could inherently not be 
corrected for, because the prostate itself was not visible and the bony structures 
only served as a surrogate for the gland. Consequently, the margins around the 
prostate were chosen relatively wide, i.e., 10 mm in all directions.
In 2002, intraprostatic gold marker implantation was introduced in our hospital. 
The excellent visibility of these markers on the portal images enabled verification 
of the actual prostate position and subsequently correction of possible positioning 
errors (Figure 1). The improvement in patient positioning obtained in this way 
allowed for a margin reduction to 7 mm in all directions. However, day-to-day 
prostate variations, e.g., under influence of variable bladder and rectum filling, 
were still uncorrected for.
From 2004, online correction protocols were used, characterized by position 
verification and correction prior to each treatment fraction. Initially, only an online 
protocol in the anteroposterior direction was applied to limit the workload on 
the treatment machines. As published previously, the online correction strategy 
resulted in a reduction in position variation, which allowed a margin reduction 
to 5 mm posterior [11]. In the other directions, no online correction was applied 
and consequently, the margins remained 7 mm. Recently, a remotely-controllable 
treatment couch became available, and the online correction protocol can now 
be executed in all directions without increasing the workload. In addition to 
smaller treatment margins, intensity-modulated radiotherapy (IMRT) has gradually 
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Figure 1 
Position verification and correction of the prostate with gold markers: (a) Portal image of 
anteroposterior (AP) radiotherapy treatment beam, with 3 intraprostatic gold markers. (b) AP 
reconstruction of a planning computed tomography (CT) scan image for reference of portal image 
(c) Daily position verification and correction of gold markers. In white, the intraprostatic gold marker 
position on that specific treatment day. In green, the gold marker position as intended for that 
treatment day. Image taken before matching. (d) After correction, executed with a fully automated 
treatment table, the gold marker position matches with the intended marker position.
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replaced 3D-CRT for improved normal tissue sparing. Since 2005, all prostate 
patients have been irradiated with an endorectal balloon for anorectal sparing 
[12]. Although the previously-mentioned reductions in treatment margins seem 
small, the effect on treatment volume is large, as is demonstrated by the following, 
hypothetical, example. When the prostate is seen as a sphere with a diameter of 
4 cm, and 3D treatment margins of 10 mm are applied, the treated volume equals 
4/3 x π x radius3 = 4/3 x π x 33 = 113 cm3. When these margins are reduced to 5 
mm, the same calculation leads to a treated volume of only 65 cm3. In this study, 
the effect of these reductions on anorectal and bladder doses is investigated.
Patients
In 10 consecutive patients with localized prostate cancer (T1-3N0M0), 3 IMRT plans 
were constructed per patient. All patients were referred to the radiation oncology 
department for EBRT with curative intent and have actually been treated according 
to the latest online correction protocol with IMRT. Prior to treatment planning, 
each patient received 3 cylindrical intraprostatic gold markers transrectally, 1.2 
mm in diameter and 5 mm in length (QLRAD, Zwolle, The Netherlands), in an 
outpatient setting.
Treatment planning
From each patient, a planning CT scan of the pelvic region (AcQSim big-bore 
spiral CT scanner; Philips Medical Systems) with 3 mm slice thickness was obtained 
in a supine position. The patients were asked to empty the bladder and rectum 
and drink half a liter of fluid, 1 hour before the CT scan. On the CT scan slices the 
prostate, bladder, rectal wall, and anal canal were contoured using the Pinnacle3 
radiation treatment planning system (Philips Medical Systems).
After defining the treatment volume, the 3 investigated PTVs were constructed, 
simulating the previously-mentioned situations: PTV 10 mm (no markers), PTV 
7 mm (markers), and PTV 7/5 mm (markers and online correction), respectively 
(Figure 2). The treatment was planned with a 5-field IMRT arrangement with a 
prescribed dose of 78 Gy in 2-Gy daily fractions using 10-megavolt photon beams. 
The radiation doses, applied to the surrounding organs, were calculated by this 
treatment planning system.
Dose volume histogram analysis
For each treatment plan, dose volume histograms (DVH) were generated for the 
organs at risk, to visualize the relative organ volume (y-axis) exposed to a radiation 
dose (Gy) equal to or higher than the value on the x-axis.
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Figure 2
Planning target volume (PTV) constructions: (a) Transverse plane of computed tomography 
(CT) scan image. PTV 10 mm (white line), PTV 7 mm (red line) and PTV 7/5 mm (yellow line) are 
outlined. Gold markers are visible. (b) Reconstruction of sagittal plane with different PTVs outlined. 
(c) Reconstruction of coronal plane. 
Organs outlined: bladder (blue line), rectum (green line). Prostate and anal canal are entirely filled 
out (blue, light blue).
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Toxicity
From 2008, a consecutive group of 93 patients irradiated in our hospital, with 
3D-CRT or IMRT, using an online correction protocol with gold markers and an 
endorectal balloon, prospectively filled out the Expanded Prostate Cancer Index 
Composite (EPIC) questionnaires. The acute genitourinary (GU) and gastrointestinal 
(GI) toxicity rates were scored within 3 months with the modified Radiation Therapy 
Oncology Group (RTOG) system [13]. For a subgroup of patients, with minimum of 
3 years follow-up, the late toxicity rates could be evaluated.
Statistical analysis
The statistical analysis was performed with SPSS 16.0 for Windows (SPSS Inc., 1989-
2005). Paired samples t tests were used to calculate the volume differences between 
the 3 investigated PTVs. Furthermore, the corresponding relative reductions in 
radiation doses to the bladder, anal canal, and rectal wall were calculated by the 
same tests. Differences with P < 0.05 were considered statistically significant.
Results
Planning target volumes
In all treatment plans, the PTV was adequately covered by the prescribed radiation 
dose. The mean prostate volume was 43 ml with a subsequent mean PTV 10 mm 
of 157 ml. For the PTV 7 mm and PTV 7/5 mm treatment plans, the mean irradiated 
volumes were 115 ml and 111 ml, respectively (Table 1). This corresponded to a 
significant mean PTV reduction of 27% as a result of using gold markers (P < 0.001). 
A further PTV reduction of 3.7% (P < 0.001) was achieved with 5 mm posterior 
margins. The largest PTV reduction occurred in a small prostate (35%), and the 
smallest reduction in a large prostate (25%).
Normal tissues
The mean radiation doses to the bladder, anal canal, and rectal wall are outlined 
in Table 2. The PTV 7 mm plans showed a significant reduction to the mean of 
radiation doses to surrounding tissues. A reduction of 17% ± 4.5% (standard 
deviation) to the bladder, 19% (±4.7%) to the anal canal, and 12% (±3.1%) to 
the rectal wall, respectively, was achieved (P < 0.001). The PTV 7/5 mm plans did 
not significantly influence the mean bladder dose. The mean doses to the anal 
canal and rectal wall, however, showed a 24% (±4%) and 16% (±4.5%) reduction, 
respectively, as compared with the PTV 10 mm plan (P < 0.001).
In Figure 3, the mean DVHs of all treatment plans are shown. The consequences 
of margin reductions for the exposure of the surrounding tissues to high dose 
radiation are illustrated. When the percentage of rectum and anal canal receiving 
70 Gy is considered, i.e., the dose that predicts for bowel toxicity [10], a clear 
reduction is seen with gold markers and an even further reduction with 5 mm 
posterior margins.
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Patient  
Number
Prostate 
Volume (ml)
PTV 10 mm 
(ml)
PTV 7 mm 
(ml)
PTV 7/5 mm 
(ml)
1 41 166 120 115
2 49 172 128 123
3 110 310 240 233
4 40 159 115 111
5 33 135 96 93
6 59 194 146 141
7 18 96 65 63
8 22 114 79 74
9 36 140 101 97
10 18 87 60 57
Mean Volume 43 157 115 111
Standard  
Deviation
27 64 52 51
Table 1
Planning Target Volume (PTV) for different treatment margins in prostate cancer radiotherapy.
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Toxicity
Acute Grade 1–2 GI and GU toxicity was seen in 27%, and 29%, respectively (Table 
3). Acute Grade 3 toxicity was rare and no Grade 4 toxicity occurred. In 57% of 
these patients radiation treatment was performed with 3D-CRT. Late Grade 1–2 
GI and GU toxicity was found in 33%, and 32%, respectively after mainly 3D-CRT 
(94%). Late Grade 3 toxicity was less than 10%.
Discussion
In our clinic every patient referred for EBRT receives intraprostatic gold markers. 
This study was performed to demonstrate the positive effect of gold marker- based 
margin reductions on radiation doses that are applied to surrounding healthy 
tissues. In 10 consecutive patients a margin reduction of 3 mm circumferentially, 
because of the use of gold markers, led to a mean PTV reduction of 27%. The 
PTV reduction was more prominent in small prostates. The mean doses to the 
surrounding tissues, i.e., the bladder, anal canal, and rectal wall, have decreased 
significantly with 17%, 19%, and 12%, respectively. After the introduction of a 5-mm 
posterior margin, in the online protocol, a further reduction of radiation doses to 
the anorectal tissues was achieved.
Systematic set-up errors and interfraction prostate motion form important sources 
of treatment errors [14]. With gold markers, for daily localization of the prostate, 
the margins around the gland can be reduced. Several feasibility studies have 
shown the reliability of fiducial markers for prostate position verification during 
radiotherapy [15,16]. The marker position in the prostate is stable and migration or 
dislocation of markers is rare [17-19]. The interuser variability of marker detection 
is low and in our experience the transrectal implantation technique is easy and 
the complication rates of implantation are low [20]. Besides the transrectal 
implantation, the transperineal implantation under local anesthetic was also 
shown to be feasible and safe without negatively influencing the patients’ quality 
of life [21]. Two reports that were recently published have shown the feasibility of 
marker placement in an outpatient setting [8,9], which we have performed in all 
patients as well.
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Table 2
Mean radiation doses to surrounding tissues of the prostate in different treatment plans.
Data are presented as mean (± SD). Abbreviation: PTV = planning target volume.
Toxicity Grade Gastrointestinal Genitourinary
A. Acute Toxicity
0  67 (73)  62 (67)
1  21  (23)  16 (17)
2  4  (4)  11 (12)
3 0  4 (4)
B. Late Toxicity
0  41 (64)  38 (59)
1  19 (30)  4 (6)
2  2 (3)  17 (26)
3  2 (3)  6 (9)
Table 3
Toxicity rates for online radiation therapy protocol with gold markers, 3D-CRT, IMRT, and 
endorectal balloon.
Data are presented as n (%). Abbreviations: CRT = conformation radiotherapy; IMRT = intensity-
modulated radiotherapy.
Mean Radiation Dose PTV 10 mm PTV 7 mm PTV 7/5 mm
Bladder (Gy) 25   (± 10.9) 21   (±   9.6) 21   (±   9.7)
Anal canal (Gy) 35   (± 11.0) 28   (± 10.1) 26   (±   9.2)
Rectal wall (Gy) 29   (±   4.6) 25   (±   4.3) 24   (±   4.4)
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Figure 3
Mean dose volume histograms (DVH) of 3 different treatment plans: On the y-axis the relative 
organ volume exposed to a dose (Gy) equal to or higher than the value on the x-axis for (a) the 
bladder, (b) the rectal wall (Rwall), and (c) the anal canal (Acanal).
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Several studies report on a dose-effect relation for anorectal toxicity (i.e., a higher 
dose to these organs leads to higher toxicity rates) [22,23]. Our results have shown 
that smaller margins with intraprostatic gold markers led to reduced irradiation 
of healthy surrounding tissues. This will probably result in lower toxicity. Others 
have indicated that dose coverage to the prostate with intraprostatic markers and 
image-guided radiotherapy is adequate, in spite of these smaller margins [24].
In our series, the acute toxicity rates compare favorably with a series published 
by Chung et al. [24]. They found acute Grade 1–2 GI and GU toxicity rates of 
image-guided IMRT with gold markers, and 2–3 mm circumferential margins of 
60%, and 100%, respectively. No acute Grade 3 toxicity was seen. On the contrary, 
Zelefsky et al. [25] reported acute Grade 1–2 GI and GU toxicity rates of 26%, and 
66%, respectively, in 772 patients undergoing high-dose IMRT without markers. 
No acute Grade 3 GI toxicity occurred, and Grade 3 GU toxicity in only 1 patient. 
Our 3-year follow-up shows a relatively high rate of late Grade ≥ 2 GU toxicity, 
compared with other series, in which 15% was shown for IMRT [26]. In spite of 
this, most complaints were mild and consisted of micturition frequency more than 
twice the pretreatment frequency. One explanation could be the use of 3D-CRT 
instead to IMRT. Zelefsky et al. compared conventional 3D-CRT and IMRT, and 
found dose-dependent acute symptoms, which were precursors of late toxicity, 
and further a reduced risk for GI toxicity with IMRT. In spite of the use of 3D-CRT, 
late Grade ≥ 2 GI toxicity rate was low in our series. The 5-mm posterior margins 
and the endorectal balloon might have contributed significantly to reduced late 
rectal toxicity, which was shown before in a comparative study of 3D-CRT with 
endorectal balloon [12]. Given the previously-mentioned dose-effect relations for 
anorectal and bladder toxicity, application of smaller margins, as is discussed in 
the present study, might lead to a reduction in these toxicity rates. Comparing 
the toxicity profiles between different studies is difficult, because the radiation 
techniques, doses, and treatment margins are different.
The long-term clinical benefits of intraprostatic gold markers for the correction of 
prostate position during EBRT have not been investigated extensively. Although 
it seems reasonable to presume that gold markers have a favorable impact on 
late toxicity profiles, this needs further investigation. As the clinical advantages 
of gold marker implantation for localization purposes are so obvious, prospective 
randomized studies will probably never be performed. At least, a precise long-term 
follow-up should be pursued to get a clear view of the late toxicity advantages.
Conclusions
Because of the excellent visibility of gold markers, the prostate localization and 
position correction is more accurate. As a result, the margins around the prostate 
involving healthy tissues can be reduced. In this study, a margin reduction of 
3 mm circumferentially, because of gold markers, leads to a mean treatment 
volume reduction of 27%. This results in a significant decrease of radiation 
doses to surrounding healthy tissues. A further reduction is seen with an online 
correction protocol with 5-mm posterior margins. As dose-escalation protocols 
will increase toxicity rates, the use of intraprostatic gold markers for margin 
reduction has become important. The effect on late toxicity profiles needs further 
investigation.
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Ultrasound-guided transrectal implantation of gold markers 
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complication rate and risk factors
Johan F. Langenhuijsen, Emile N. J. T. Van Lin, Lambertus A. Kiemeney, Lisette P. 
van der Vight, Gill M. McColl, Andries G. Visser, J. Alfred Witjes
Int J Radiat Oncol Biol Phys 2007; 69: 671-76.
Abstract
Purpose: To report the complication rate and risk factors of transrectally implanted 
gold markers, used for prostate position verification and correction procedures.
Methods and Materials: In 209 consecutive men with localized prostate cancer, four 
gold markers (1 × 7 mm) were inserted under ultrasound guidance in an outpatient 
setting, and the toxicity was analyzed. All patients received a questionnaire 
regarding complications after marker implantation. The complications and risk 
factors were further evaluated by reviewing the medical charts.
Results: Of the 209 men, 13 (6.2%) had a moderate complication, consisting 
of pain and fever that resolved after treatment with oral medication. In 1.9% 
of the men, minor voiding complaints were observed. Other minor transient 
complications, defined as hematuria lasting > 3 days, hematospermia, and rectal 
bleeding, occurred in 3.8%, 18.5%, and 9.1% of the patients, respectively. These 
complications were seen more often in patients with advanced tumor stage, 
younger age, and shorter duration of hormonal therapy.
Conclusion: Transrectal gold marker implantation for high-precision prostate 
radiotherapy is a safe and well tolerated procedure.
Introduction
Dose escalation in external beam radiotherapy (RT) for localized prostate cancer 
improves the outcome, with a lower prostate-specific antigen recurrence rate [1, 
2]. Rectal toxicity is one of the limiting factors and is directly related to the total 
radiation dose prescribed and the volume of the rectal wall receiving a high dose 
[3]. Prostate motion is considered a source of treatment error, with day-to-day 
gland displacements of 3–5 mm [4]. To account for these prostate movements, 
treatment margins of ≤ 10–15 mm must be defined around the gland, resulting 
in additional irradiation of the surrounding tissues. To enable margin reduction, 
radiopaque markers implanted in the prostate have been used as an aid for exact 
localization of the prostate during RT [5-8]. Electronic portal imaging systems are 
widely used for daily prostate position verification and correction procedures 
[9-12]. The markers are implanted before acquisition of the planning computed 
tomography (CT) scan. Gold markers are easily visible fiducials on pretreatment 
imaging (CT, magnetic resonance imaging [MRI]) studies and megavolt portal 
imaging during RT sessions. Marker migration within the prostate during the 
course of RT has been negligible [13]. Therefore, implanted gold marker detection 
is a reliable method for repetitive position verification.
Although the use of gold markers is increasingly common, the complication rates 
have not been reported in a large patient population. The goals of this study were 
to report on the complication rate in patients with localized prostate cancer in 
whom gold markers were implanted transrectally and to identify the risk factors 
for the complications.
Methods and Materials
Patients and gold marker implantation
In all patients referred for RT for localized prostate cancer (Stage T1-T3N0M0), 
gold marker implantation was performed in the urology outpatient clinic. No 
preceding enema or anesthesia was used. A prophylactic antibiotic, ciprofloxacin 
500 mg twice daily, for 3 days, was given. Anticoagulant medication was stopped 
3–7 days before marker implantation.
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Patients were placed in the lateral decubitus position. First, the urologist measured 
the prostate volume with an ultrasound Kretz Voluson 530D device (GE Kretz, Zipf, 
Austria) with an endorectal transducer. Next, the gold markers were placed, under 
ultrasound guidance, with a standard 18-gauge prostate biopsy tool (Microvasive 
Topnotch, Boston Scientific, Natick, MA) mounted onto the endorectal ultrasound 
transducer (Fig. 1a). Fine gold markers 1 mm in diameter and 7 mm in length were 
used (Hospimed International BV, Dalfsen, The Netherlands; Fig. 1b). The length 
was chosen because of visibility on the portal images, CT scans, and MRI scans. 
Two markers were placed on the left and right at the base, one in the central part 
next to the urethra, and one at the apex of the prostate. After at least 1 week, 
to allow the swelling of the gland to resolve after implantation, the planning CT 
scan (3-mm slice thickness) was obtained. In Fig. 1c, an example of a portal image 
showing the implanted markers is displayed.
Complications and risk factors
All patients received a questionnaire from a research nurse after the implantation 
regarding any complications after marker implantation. This questionnaire was 
completed in the patient’s home and returned to the nurse. The questionnaire 
asked for the presence or absence of hematuria, hematospermia, rectal bleeding, 
fever, and pain. Specifically, questions regarding the daily frequency of symptoms 
and total duration in days were included. Patients were also asked to report other 
complaints, symptoms, and additional medications (including names, dosages, 
duration, and effects) taken after implantation. Pain was scored on a 0–10 scale 
(0, no pain to 10, the worst pain imaginable). Patients were asked to compare the 
pain experienced during marker implantation with the pain experienced at the 
diagnostic prostate biopsy procedure. In cases of problems with the questionnaire 
or general problems, patients were instructed to contact the nurse.
Minor complications were defined as side effects with transient minimal discomfort 
and requiring no additional medical intervention. The complications that resulted 
in moderate discomfort and required additional treatment were considered 
moderate complications.
In most cases (184 of 209), the questionnaires were sent to the patients by mail 
after marker implantation. For this particular retrospective analysis, inconsistencies 
were verified with the patient by the nurse and researchers. The notes made by 
the urologist or radiation oncologist during marker implantation were checked 
retrospectively, and all other occurring complications were noted.
Possible risk factors for developing any moderate or any bleeding complications 
(e.g., hematuria, hematospermia, or rectal blood loss) were evaluated by 
reviewing the medical charts. The tumor stage, urologist performing the marker 
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Figure 1 
(a) Marker implantation tool, mounted on ultrasound probe. 
(b) Fine gold markers. 
(c)  Portal image of anteroposterior radiotherapy treatment beam, with four implanted gold 
markers in situ.
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implantation, use of anticoagulant therapy, previous transurethral resection of the 
prostate, previous prostatitis, presence of diabetes, prednisone use, patient age, 
duration of hormonal therapy, and prostate volume were recorded.
Statistical analysis was performed using t tests to compare continuous variables 
and Fisher’s exact test (2 × 2 tables) or chi-square test (3 × 3 tables) to compare 
categorical variables. A P value of < 0.05 was considered statistically significant. 
To analyze the effect of the retrospective analysis, the patients who received the 
questionnaire directly after the procedure were evaluated separately and the 
outcomes were compared with the data obtained retrospectively.
Results
Patients and gold marker implantation
Between January 2001 and September 2005, gold markers were implanted in 236 
patients. The mean age was 70 years (range, 40–84 years). Of the 236 patients, 
27 were lost to follow-up because of death (n=9) or other factors (n=18). For 209 
patients, the toxicity outcome could be analyzed, and the results reported concern 
this group of 209 patients. Of these 209 patients, the tumor was Stage T1 in 18, T2 
in 64, and T3 in 127.
In 8 patients, marker misplacement outside the gland boundaries was observed 
during the treatment planning CT scan. This occurred seven times into the 
bladder and once into the rectum. On average, the whole implantation procedure 
took 10 minutes. Of the 209 patients, 79 were receiving anticoagulant therapy: 
acetylsalicylic acid (n=64), acenocoumarol (n=12), or other (n=3). Hormonal 
therapy was started in 202 patients, mainly before marker implantation, with a 
mean interval of 7 weeks (range, 0–40) until the procedure. The mean interval 
between implantation and the start of RT was 26 days (range, 10–49 days). The 
encountered complications did not cause a delay in the start of RT in any patient. 
The prostate volume was 5–136 cm³ (mean, 40). None of the investigated patients 
complained of rectal bleeding or other symptoms of inflammatory bowel disease 
before marker implantation. For the retrospective complications analysis, the 
questionnaire was completed at a mean of 90 weeks after marker implantation.
Complications and risk factors
In Table 1, the observed complication rates are listed. No statistically significant 
differences in any of the complications were found between the patients who 
answered the questionnaire directly after the procedure and those patients
who performed this later (data not shown).
Minor complications
In all cases, hematuria was self-limiting within 7 days. Hematospermia was noted by 
15 of the 81 patients who reported having had ejaculations. The average duration 
of rectal bleeding was 2.5 days. In 13 of 19 patients, the rectal bleeding lasted for 1 
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Table 1
Complication rates.
Complication           Patients (%)
Minor
Hematuria > 3 d  8       (3.8)
Hematospermia*  15 (18.5)
Rectal bleeding  19 (9.1)
Voiding complaints  4 (1.9)
Moderate
Pain requiring analgesics  6 (2.9)
Fever  4 (1.9)
Nausea/vomiting  2 (1.0)
Allergic reaction to antibiotic  1 (0.5)
Data in parentheses are percentages.
* Of 81 patients reporting ejaculations.
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day. One patient reported repeated minor blood loss during 21 days. The voiding 
complaints consisted of either an increase of previous complaints or dysuria.
Moderate complications
For the patients with a moderate complication, no admission to the hospital was 
necessary. Patients with fever received additional antibiotics, and their temperature 
normalized within a few days. The patient with the allergic reaction to ciprofloxacin 
recovered after termination of this antibiotic.
Pain
The mean pain score was 3.2 (range, 0–9). Of the 209 patients, 48% scored the 
pain as 0–2, 37% as 3–5, and 15% as 6–9. Also, 50% of the patients reported that 
the marker implantation procedure was less painful than the prostate biopsy 
procedure, 40% recorded comparable pain, and 10% noted more pain.
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Table 2
Risk factors and complication rates (Fisher’s exact test)
Abbreviation: TURP = transurethral resection of prostate.* = Chi-square test.
Risk factor Bleeding 
complication 
(%)
p Moderate 
complications 
(%)
p
Tumor stage
T1  5.6 (1/18) 0.026*  0 (0/18) 0.57*
T2  9.4 (6/64)  6.3 (4/64)
T3  22.8 (29/127)  5.5 (7/127)
Anticoagulant
Yes 20.3 (16/79) 0.45  5.1 (4/79) 1.00
No 15.4 (20/130)  5.4 (7/130)
TURP
Yes  3.7 (1/27) 0.054  0 (0/27) 0.37
No  19.2 (35/182)  6 (11/182)
Prostatitis
Yes  16.7 (2/12) 1.00  8.3 (1/12) 0.49
No  17.3 (34/197)  5.1 (10/197)
Diabetes
Yes  22.2 (4/18) 0.52  0 (0/18) 0.60
No  16.8 (32/191)  5.8 (11/191)
Prednisone
Yes  0 (0/1) 1.00  0 (0/1) 1.00
No  17.3 (36/208)  5.3 (11/208)
Table 3
Risk factors and complication rates (t test).
Complication Mean age (y) Mean duration 
of hormonal 
therapy (wk)
Prostate 
volume (cm3)
Bleeding
Yes 68 4.4 43
No 71 7.2 39
p 0.022 0.028 0.38
Moderate
Yes 71 5.1 46
No 70 6.8 39
p 0.85 0.51 0.11
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Risk factors
Significantly increased bleeding complications were seen in patients with advanced 
tumor stage, younger age, and shorter duration of hormonal treatment (Tables 2 
and 3). The use of anticoagulants yielded no increase in rectal bleeding or other 
complication rates. None of the investigated risk factors correlated significantly 
with any moderate complication.
Discussion
In this study, the complications and risk factors were studied after transrectal 
implantation, under ultrasound guidance, of gold markers for position verification 
during prostate cancer RT. This is the first study reporting the marker-induced toxicity 
of a large patient group. Minor complications such as hematuria and hematospermia 
were observed in 3.8% and 18.5% of the patients, respectively. Rectal bleeding was 
seen in 9.1% of the patients and lasted for an average of 2.5 days. Henry et al. 
[14] reported on 12 patients in whom gold markers were implanted transperineally. 
Three patients noted hematuria, one hematospermia, and one rectal bleeding 
that occurred after the marker was most likely implanted through the rectal wall. 
No infections were seen. The transperineal route is thought to result in less rectal 
bleeding than the transrectal route. In the study by Henry et al., the duration of 
hematuria was not mentioned. Maximally, three markers were implanted, which 
could have been a factor in causing less rectal bleeding or hematospermia. Henry et 
al. [14] reported severe pain during implantation in 3 patients and 1 patient needed 
analgesics. A comparison with our results was difficult because of the difference 
in patient numbers. The second study that reported on implanted marker toxicity 
was of 10 patients, with a maximum of three fiducial markers implanted under 
ultrasound guidance [7]. Three patients reported transient hematuria the first 24 
hours after implantation and seven reported an episode of rectal bleeding. Again, 
a comparison with our results was difficult because we only reported hematuria 
that lasted for > 3 days. In their study, the occurrence of hematospermia was not 
reported, and no moderate or major complications were observed.
Owing to the lack of reports on complication rates after marker implantation, a 
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comparison was done with the complications occurring after prostate biopsy, 
although one should realize this procedure is performed for other purposes and 
under different circumstances and, therefore, the data are not fully comparable. 
After prostate biopsy, the incidence of minor complications (i.e., hematuria and 
hematospermia) has been reported at 64–78% [15-18]. Moderate complications, 
mostly infections, are seen infrequently, with a maximal rate of 4% [15,19]. Two 
studies noted a rate of 23% of hematuria lasting > 3 days, a rate of 45% for 
hematospermia, and a rate of 1.7% for rectal bleeding [20,21]. The range of rectal 
bleeding complications after prostate biopsy is wide (1.3–37%), with an average 
of 9.0% [16,18-23], comparable to our rates. We have no suggestion on how to 
reduce the rates we have reported, except for possibly reducing the number of 
implanted markers. We chose four markers to implant for reasons of redundancy 
and the certainty of visibility. With our present experience, we believe that 
geometric accuracy can be maintained with three markers. After prostate biopsy, 
the percentage of voiding complaints has varied from 1% to 12% [18, 21-23].
In some studies of transrectal ultrasound and transrectal prostate biopsy, minor 
or no discomfort was reported in up to 92% of patients and patient acceptance 
has been high [18,19]. However, studies have also reported severe discomfort 
in up to 30% of patients [16]. Irani et al. [24] evaluated 81 patients undergoing 
prostate biopsy. They found a mean pain score of 3, but 16% had significant 
discomfort (score > 5). We found similar results, with a mean pain score of 3.2 and 
15% of patients having severe pain during implantation. Only 6 of the patients 
who reported pain needed analgesics. One-half of the patients reported that the 
marker implantation procedure was less painful than the diagnostic biopsy. This 
might be because only four markers were implanted in contrast to the multiple (six 
to eight) biopsy cores taken. Furthermore, the uncertainty of the diagnosis during 
the biopsy procedure could play a role in patients experiencing more pain.
Only 1.9% of our patients had fever after marker implantation, less than most 
others reported after prostate biopsy [15,16,18-23]. It was shown that an antibiotic 
prescribed for 3 days and started 1 day before the prostate biopsy reduced the 
number of infectious complications [15]. We also started ciprofloxacin 1 day before 
marker implantation and continued it for 3 days. Two patients had nausea and 
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vomiting after implantation. This could be a consequence of the procedure and a 
manifestation of bacteremia [23]. These patients, however, did not have fever, and 
the complaints resolved spontaneously.
Anticoagulant medication was stopped 3–7 days before implantation. As a result, 
no extra or longer bleeding complications occurred in this group. We have shown 
that patients with advanced tumor stage, younger age, and a shorter duration 
of hormonal treatment had significantly more bleeding complications. In these 
patients, increased prostatic vascularization might have played a role. This could 
be explained by the testosterone dependency of normal prostatic tissue growth 
and prostate cancer. In vivo studies have shown that androgen withdrawal leads 
to increased angiogenesis inhibitor production and decreased vascularization 
in the normal rat prostate. In human androgen-dependent prostate cancer, the 
expression of angiogenesis inhibitor correlates inversely with blood vessel density 
[25]. The growth and spread of prostate cancer in the elderly is often prolonged, 
and studies on mice have shown that the tumor growth rate is altered with older 
age because of the reduced capacity to vascularize tumors owing to a lack of 
angiogenic factors or the presence of host inhibitors [26]. It might be advisable 
to wait to perform implantation until shortly before RT, so that the hormonal 
therapy has caused a maximal reduction in the tumor volume and decreased 
vascularization. As we have experienced, a disadvantage of a smaller prostate can 
be technical difficulties in marker implantation. Studies have shown that younger 
patients experience more pain during prostate biopsies [16,18]. This could not 
be confirmed in our study. Raaijmakers et al. [21] have identified risk factors for 
complications after prostate biopsy. An earlier episode of prostatitis was associated 
with more pain and hospital admission. Prostate volume was a predictor of urinary 
retention. In our study, no specific risk factors for complications could be identified, 
and urinary retention did not occur in any of the 209 studied patients.
In each prostate cancer patient referred to our department, gold markers are 
implanted transrectally. The role of the markers in accurate position verification and 
correction has been well established [10-12,27]. Recently, the first clinical data have 
been published of a new type of implantable radiofrequency emitting device that 
continuously measures the position of the prostate during treatment [28]. Implantation 
under ultrasound guidance of these markers, in size comparable to gold markers, 
also yielded no severe complications. In addition to verification purposes, we have 
been using the gold markers for high-precision magnetic resonance imaging-CT 
fusion and prostate delineation during the treatment planning process [29].
Conclusion
Transrectal gold marker implantation for prostate position verification is safe and 
appears to be a well-tolerated procedure. In only 1.9% of the studied patients were 
minor voiding complaints observed. Other minor transient complications, defined 
as hematuria lasting > 3 days, hematospermia, and rectal bleeding, occurred 
in 3.8%, 18.5%, and 9.1% of the implanted patients, respectively. These minor 
bleeding complications were more frequently seen in patients with an advanced 
tumor stage, younger age, and shorter duration of hormonal therapy. Moderate 
complications were rare (6.2%) and consisted mainly of pain and fever. These were 
treated with oral medication, which resolved the complaints quickly.
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Abstract
Background and Purpose: Postprostatectomy radiotherapy offers survival benefit 
in adjuvant or salvage setting. The implantation technique and complication rate 
of gold markers in the prostate bed for high-precision radiotherapy is analyzed.
Material and Methods: Men undergoing postprostatectomy radiotherapy for 
PSA relapse or high-risk disease were enrolled. Under transrectal ultrasound 
guidance, three fine gold markers were implanted transrectally in the prostate 
bed and technical difficulties on insertion were documented. Patients received 
self-designed questionnaires regarding complications and pain. The influence of 
anticoagulants or coumarines on bleeding and potential risk factors on pain was 
analyzed.
Results: In 77 consecutive men, failure of marker implantation or migration was 
seen in 6 patients. Rectal bleeding was reported by 10 patients and voiding 
complaints by one. Hematuria occurred in only 12 patients for maximal 3 days. 
Other complications were rectal discomfort (n=2), nausea (n=1), abdominal 
discomfort (n=1), and pain requiring analgesics (n=4). No major complications 
were reported. The mean pain score was 3.7 on a 0–10 visual analogue scale. No 
clinical significant risk factors for complications were identified.
Conclusions: Transrectal implantation of gold markers in the prostate bed is 
feasible and safe. The potential advantages of marker implantation for high-
precision postprostatectomy radiotherapy outweigh the minor risks.
Introduction
The implantation of intraprostatic gold markers for external beam radiotherapy 
(EBRT) of prostate cancer has become a standard technique for daily position 
verification and correction of patient setup errors and prostate motion [1,2]. A long-
term experience with gold marker implantation has been reported recently [3], 
and complication rates were shown to be low [4]. With dose-escalation improved 
biochemical control rates are found [5,6]. With increasing doses, however, both 
delineation of the target volume and high-precision of dose delivery are important 
to prevent increased toxicity to surrounding organs [7].
Radiation therapy after radical prostatectomy offers an overall or biochemical 
relapse-free survival benefit when applied in an adjuvant or salvage setting [8-10]. 
In contrast with the published data on prostate motion [11-14], few data exist on 
patient setup uncertainties and prostate bed motion during postprostatectomy 
radiotherapy [15-17]. To our knowledge, the use of gold markers in this setting 
has been described only twice [16,17]. According to Ost et al. [18], the prostate 
bed motion is similar to the intact prostate gland motion. Daily electronic portal 
imaging of gold markers may be a valuable method to correct for interfraction 
target motions and to improve precision in EBRT delivery [16]. The correction of 
target positioning errors is especially critical when small prostate bed-only fields 
are irradiated. Small shifts of target volume have the potential to significantly alter 
the dose distribution delivered to adjacent organs.
The side effects of postprostatectomy gold marker implantation may differ from 
those after implantation in the highly vascularized prostate gland. Theoretically, 
less bleeding complications may occur. However, the anatomic changes may 
prevent recognition of the implantation site and make the procedure technically 
more challenging. As the anastomosis is located distally in the pelvis this may lead 
to misplacement of markers or pain during implantation. Due to fibrosis around the 
bladder-urethra anastomosis pain may be more prominent. Therefore, the aim of 
this study is to evaluate the technique and complication rate of postprostatectomy 
transrectal implantation of gold markers, and to analyze potential risk factors for 
complications.
Technique and complications of postprostatectomy gold markers
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Materials and Methods
Technique of gold marker implantation 
During the study period, in all patients with PSA relapse or high-risk prostate 
cancer, i.e. pT3 and/or positive surgical margins after radical prostatectomy, gold 
marker implantation was performed in an outpatient setting of two referral centres. 
No preceding enema or local anesthesia was used. Ciprofloxacin 500 mg twice 
daily was given as prophylaxis, for 3 days. Anticoagulant therapy was continued 
in one centre (Radboud University Nijmegen Medical Centre, RUNMC), based on 
the low bleeding risk after intraprostatic gold marker implantation [4], or stopped 
for a week (Medical Centre Alkmaar, MCA). Coumarines were stopped 3 days in 
advance with INR < 2.0 during marker implantation. Patients were placed in the 
lateral decubitus (RUNMC) or dorsal lithotomy position (MCA) for the procedure. 
The transrectal ultrasound (TRUS) -guided gold marker implantation was 
performed by two physicians (JAW, RD), with a B-K Medical Pro Focus 2202 (B-K 
Medical, Herlev, Denmark) or a B-K Medical Falcon 2102 EXL ultrasound device 
(B-K Medical, Wilmington, USA). Three fine gold markers, 1.2 mm in diameter and 
5 mm in length, preloaded in needles (QLRAD, Zwolle, the Netherlands) were 
implanted. A standard length of markers was chosen because of visibility on portal 
images and planning CT scans (3-mm slice thickness). Two markers were placed 
at the right and left dorsal bladder base, and one next to the anastomosis. The 
implantation was performed at least two weeks before the planning CT scan, for 
prostate bed edema to resolve. With portal imaging and planning CT scans the 
migration or loss of gold markers from the prostate bed was recorded.
Complication registration
The patients received questionnaires directly after the implantation procedure 
and filled them out during the first week. A group of patients that already had 
the markers implanted received the questionnaires by mail for retrospective 
analysis. All patients were contacted by one of the researchers (JFL), to clear any 
inconsistencies and to clarify details of medical history that could not be extracted 
from the medical charts. As no validated questionnaires for this procedure exist, a 
self-designed questionnaire was used regarding complications that are commonly 
described after prostate biopsy and intraprostatic gold marker implantation 
procedures, containing the following items: presence of hematuria, rectal 
bleeding, fever, pain, voiding problems or any other complaints. The frequency and 
duration of symptoms, and the need for medication (names, dosages, duration, 
and effects) were evaluated. Patients reported if the implantation was bothersome 
and scored the pain on a 0–10 visual analogue scale (0, no pain; 10, worst pain 
imaginable). Patients were asked to compare the pain with the pain that they had 
experienced after diagnostic prostate biopsies. Complications were defined as: 
minor, for transient minimal discomfort without medical intervention; moderate, 
for moderate discomfort or requirement of additional treatment; major, when 
hospital admission was necessary. To analyze any bias in complication registration, 
the retrospectively gathered data were compared with the prospective data.
Potential risk factors for complications were evaluated by reviewing the medical 
charts and by contacting all patients. The primary hypothesis was that the use of 
anticoagulants and/or coumarines could be a risk factor for bleeding. A secondary 
hypothesis was that local tumor infiltration and wider surgical excision, the surgical 
technique itself, and strictures, for which endodilatation or bladder neck incision 
were necessary or incontinence may have stimulated fibrosis formation and more 
pain during marker implantation. Therefore, the initial pathological tumor stage, 
the surgical technique, the presence of incontinence or strictures, the time interval 
since surgery, and the age were evaluated for their influence on pain during the 
procedure.
Statistical analysis of bleeding complications was performed using Fisher’s exact 
tests to compare categorical variables. Differences in VAS scores by potential 
risk factor were tested for statistical significance by using the parameter free 
Mann-Whitney U test for 2 groups or the Kruskal-Wallis test for 3 groups. The 
correlation between continuous variables and the VAS pain scores was quantified 
with Spearman correlation coefficients (SPSS 16.0 for Windows (© SPSS Inc., 1989-
2005)). A two-sided P value < 0.05 was considered statistically significant.
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Results
Between February 2008 and February 2011, gold markers were implanted in 77 
consecutive men with PSA relapse (n=70) or high-risk disease (n=7) after radical 
prostatectomy. All patients during this period were included in the study. The 
mean age was 65 years (range, 54–77). Patients had been operated by open radical 
(n=48), laparoscopic (n=10), or robot assisted laparoscopic radical prostatectomy 
(n=19). The pathological tumor stage was T2 (n=33), T3 (n=43), or T4 (n=1). The 
mean time interval since surgery until marker implantation was 29 months (range, 
2–147). The mean time interval between marker implantation and EBRT was 3.8 
weeks (range, 2–19). The encountered complications did not cause any delay of 
radiotherapy. Twelve patients were on anticoagulant therapy, 4 on coumarines 
and one on both. No inflammatory bowel disease was present before marker 
implantation, but one patient suffered from rectal bleeding due to hemorrhoids. 
Forty-one patients filled out the questionnaires retrospectively, at a mean 18 
months (range, 3–36) after marker implantation.
Feasibility of gold marker implantation
In one patient a substitute gold marker was placed because misplacement into 
the bladder wall was observed during TRUS. In another patient marker placement 
failed due to an empty bladder and the procedure was performed successfully one 
week later. Because the anastomosis was located very distally in one patient, only 
two markers could be placed. Bleeding was observed during the procedure with 
TRUS in one patient. The physicians noticed technical challenges with implantation 
of most of the distal markers, because of the steep angle of the ultrasound probe 
and fibrosis. In 3 patients, a marker was missing on planning CT scan. In general, 
gold markers were easily distinguishable from surgical clips on portal images. 
Figure 1 shows an example of an anterior portal image of gold markers.
Complications
The complication rate of 76 patients could be analyzed because one patient was 
lost to follow-up after emigration (Table 1).
Minor complications
No hematuria > 3 days occurred, but 12 patients had hematuria for 1 day, two for 
2 days, and one patient for 3 days. Rectal bleeding was always self-limiting within 
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Figure 1 
Anterior portal image of three gold markers in prostate bed.
Table 1
Complication rate after gold marker implantation in the prostate bed.
Complication Patients (%)
Minor
Hematuria > 3 days 0  (0%)
Rectal bleeding 10  (13%)
Voiding complaints (urgency) 1  (1%)
Moderate
Pain requiring analgesics 4  (5%)
Rectal discomfort 2  (3%)
Fever 0  (0%)
Nausea 1  (1%) 
Other 1  (1%)
Major 0  (0%)
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a day. No significant differences in bleeding incidence occurred between the 
prospective and retrospective groups (36% and 20%, respectively; Fisher’s exact 
test: P = 0.13).
Moderate complications
One patient reported nausea for 2 days. Rectal discomfort lasted for 1 day (n=1) 
or 1 week (n=1) after implantation, and required no analgesics. One patient 
reported abdominal discomfort and diarrhea for a week. No major complications 
occurred.
Pain
Twenty-five patients (33%) considered the procedure bothersome and the mean 
VAS score was 3.7: 41% scored the pain as 0–2, 37% as 3–5, and 22% as 6–10. No 
significant differences were seen between prospective and retrospective groups 
(data not shown). The procedure was experienced as being less painful than 
prostate biopsies by 43%, comparable by 38%, and more painful by 16%. Two 
patients (3%) had no previous biopsies.
Potential risk factors
In Tables 2 and 3, the potential risk factors are shown. In patients who stopped 
anticoagulants, a trend was seen for less bleeding compared to those who 
continued anticoagulants (14% and 80%, respectively (P = 0.072)). Old patients 
showed a trend of less pain than the younger ones. Extensive surgery and 
anastomotic strictures did not increase pain during marker implantation.
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Table 2
Potential risk factors for bleeding complications after gold marker implantation in the prostate 
bed (Fisher’s exact test).
Risk factor Bleeding complication % (n) P-value
Use of anticoagulant or coumarine
Yes 44       (7/16)
No 23       (14/60) 0,12
 Anticoagulant stopped before marker implantation
Yes 14            (1/7)
No 80        (4/5) 0.072
Table 3
Potential risk factors for pain measured by Visual Analogue Score (VAS) during marker implantation 
in the prostate bed.
IQR=interquartile range; OP=open prostatectomy; LP=laparoscopic prostatectomy; 
RALP=robot assisted laparoscopic prostatectomy
Risk factor Median VAS score (IQR) P-value
Pathological tumor stage
T2  (33/76) 3.3  (5.0)
T3-4  (43/76) 5.0  (5.0) 0.087
Surgical technique
OP  (47/76) 3.5  (5.0)
LP  (10/76) 5.0  (4.0)
RALP  (19/76) 4.3  (5.0) 0.595
Incontinence
Yes  (35/76) 5.0  (5.0)
No  (41/76) 3.3  (3.5) 0.360
Stricture
Yes  (11/76) 5.0  (5.0)
No  (65/76) 3.5  (3.5) 0.893
Spearman correlation coefficient
Age -0.19 0.097
Time interval since surgery -0.09 0.458
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Discussion
In this study, the ultrasound-guided transrectal implantation of gold markers for 
postprostatectomy radiotherapy appeared feasible with a low complication rate. 
Moman et al. [3] showed the feasibility, side effects, and QOL of transrectal and 
transperineal intraprostatic implantation of gold markers in 914 patients. Marker 
migration led to discontinuation of marker-based IMRT in 5 patients. One marker 
was lost and marker displacement ranged from 3 to 4 mm. In general, migration 
of intraprostatic markers is negligible. One report about marker migration in the 
prostate bed showed an interfraction variation of intermarker distance of 0.4 mm 
to 0.9 mm [16]. The authors concluded that gold markers can serve as reliable 
fiducials to mark the target volume over the course of salvage or adjuvant EBRT. 
In our series, difficulties in marker placement occurred in 3 patients and markers 
were missing on planning CT scan in another 3 patients. Alternative alignment 
procedures were necessary and interfraction prostate bed motion could not be 
assessed. Discrimination between gold markers and surgical clips on imaging has 
been suggested to be difficult [18]. This was not experienced by our radiation 
oncologists.
This is the first report specifically evaluating complications of gold marker 
implantation in the prostate bed. No hematuria > 3 days was found and rectal 
bleeding was self-limiting within one day. In a large patient group, hematuria 
> 3 days was reported in 3.8%, and rectal bleeding in 9.1% for an average 2.5 
days after intraprostatic gold markers [4]. Others have found similar complication 
rates, in smaller series, for both transrectal and transperineal intraprostatic marker 
implantation [19,20]. Moman et al. [3] found hematuria in 39% and rectal discomfort 
in 8% of patients after transrectal intraprostatic markers. Only 0.5% of patients 
had grade 3 toxicity (urosepsis). No urosepsis was found in our patients, possibly 
because of less vascularization compared to the prostate gland and low potential 
of systemic spread of bacteria. Also, pathological exams often show infectious 
focus of the prostate gland. The lower incidence of hematuria than after prostate 
marker implantation may be explained by the fibrosis of the prostate bed. The 
anastomosis was clearly visible during TRUS-guided marker implantation, provided 
the bladder was not empty, and the chance of urethra perforation and hematuria 
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was therefore low. The somewhat higher occurrence of rectal bleeding may be 
due to the distal placement of markers and the steep angle of the transducer with 
traction on the rectal wall. Because bleeding was minor and self-limiting when 
using anticoagulant medication, this therapy should be continued in patients 
with high-risk for thrombo-embolic events. Although a trend was observed, our 
primary hypothesis of higher bleeding risk with anticoagulants use was withdrawn. 
The INR should be kept < 2.0 for safety reasons. Few moderate complications 
occurred, but one patient reported nausea which could have been caused by 
bacteremia or ciprofloxacin use.
Most patients had undergone diagnostic prostate biopsies, possibly leading 
to a higher level of acceptance of gold marker implantation. In a study with 
differentiated QOL assessments for intraprostatic gold markers, no significant 
differences between pre- and post-implantation measurements were found [3].
Concerning the secondary hypothesis about risk factors, the influence of strictures 
after radical prostatectomy on pain during marker implantation was evaluated. It 
has been suggested by others that anastomotic leakage may lead to excessive 
fibrosis and stricture formation [21]. Some men who develop anastomotic strictures 
may even have a generalized tendency to develop a hypertrophic scar [22]. These 
patients may have more pain during marker implantation in rigid fibrotic tissues. 
In our series, the hypothesis that extensive surgery and strictures may increase 
the pain was not confirmed. The marker implantation was bothersome in 30% of 
patients, with an average VAS score of 3.7. This is somewhat higher than in our 
previous study when 4 intraprostatic gold markers were implanted [4]. Although 
fewer small markers were implanted, the steep angle of the ultrasound transducer, 
especially with implantation of the distal marker, and fibrosis may have caused 
more pain. The prophylactic use of analgesics can therefore be advocated, 
especially in young patients.
The shortcomings of this study are that the questionnaires were completed 
retrospectively by 41 patients, which may have caused underreporting of 
complications due to a recall bias, although no significant differences were seen 
compared with the rest. Due to the sample size, the number of uncommon serious 
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side effects (e.g. profuse rectal bleeding or urosepsis) may also be underestimated. 
Further, no VAS score was recorded during prostate biopsy procedures making 
the comparison with the marker implantation procedure less reliable.
In our centres, the TRUS-guided transrectal implantation of gold markers for 
postprostatectomy radiotherapy is standard care. Although it should be realized 
that the implantation of gold markers is an invasive procedure, which may 
potentially lead to serious complications, in our experience, the complication 
rate is negligible. Future research should focus on clinical outcome, i.e. tumor 
control rate and normal tissue toxicity, in patients receiving postprostatectomy 
radiotherapy with daily gold marker-based correction procedures.
Conclusions
Transrectal ultrasound-guided gold marker implantation in the prostate bed is 
feasible and safe. The complication rate is comparable to or even less than the 
complication rate observed after intraprostatic gold marker placement. The pain 
is slightly more prominent and may be caused by fibrosis, but extensive surgery 
and anastomotic strictures did not increase pain. The potential advantages of gold 
marker implantation for high-precision postprostatectomy radiotherapy outweigh 
the minor risks.
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Abstract
Context: Cryosurgery is an evolving treatment for localized prostate cancer in 
European centers. Modern cryotechnology is associated with a low complication 
rate, but its definitive role in the spectrum of different treatment modalities 
remains to be determined.
Objective: The primary objective of this review is to analyze the oncological results 
and complication rates of modern cryosurgery for prostate cancer. Secondarily, the 
impact of patient selection and the criteria for treatment success are discussed. 
Evidence acquisition: A structured literature review was performed by an online 
Pubmed search for data of primary and salvage cryosurgery of the prostate. 
Papers with relevant information on clinical outcome and complication rates were 
selected.
Evidence synthesis: The introduction of gas-based third-generation 
cryotechnology has significantly decreased side effects with similar oncological 
results compared to older techniques. The occurrence of severe complications 
like rectourethral fistulas (< 1%) has almost been eradicated, but the rates of 
erectile dysfunction remain high (90%). With salvage cryosurgery more side effects 
can be expected with an average incontinence rate of 8% and fistulas up to 3.4%. 
Nevertheless, this minimal invasive treatment remains an option for radiorecurrent 
prostate cancer. Focal cryosurgery is considered experimental, but is an interesting 
new development in cryosurgery. The intermediate-term biochemical disease 
free survival rates of 60%–90% are comparable to the results of other treatment 
modalities. However, the current data of cryosurgery in literature are of low-level 
evidence which should be discussed when counselling patients.
Conclusions: Modern cryosurgery is reliable and results are promising with minimal 
morbidity. Focal cryosurgery in selected patients aims to reduce side effects, but 
is currently experimental treatment. Randomized trials comparing the outcomes 
of the different treatment modalities and long-term follow-up data are needed 
to define the ultimate role of cryosurgery in the treatment of localized prostate 
cancer.
Introduction
Cryosurgery for prostate cancer was first applied in 1964 by Gonder et al. using 
liquid nitrogen [1]. The technique encompassed transurethral freezing of the 
prostate with the inability to position the cryoneedles precisely and to monitor 
the extent of freezing. This resulted in severe and frequent complications such as 
incontinence, urethral sloughing and rectourethral fistulas. Therefore, cryosurgery 
of the prostate was abandoned until the late 1980s, when Onik et al. [2] refined the 
technique by using interventional radiologic procedures and transrectal ultrasound 
(TRUS). The accurate TRUS-guided transperineal placement of cryoprobes 
with real-time monitoring and control of the freezing process has significantly 
decreased the number of complications [3,4]. The use of a urethral-warming 
catheter decreased the sloughing rate of the urethral mucosa and subsequently 
the risk of obstructive problems [5,6]. Consequently, cryosurgery was recognized 
by the American Urological Association (AUA) as a therapeutic option for localized 
prostate cancer in 1996.
Since the use of thermosensors in Denonvilliers’ fascia and nearby the neurovascular 
bundles [7] and the application of gas-based cryosurgery [8], complication rates 
have further decreased. The introduction of argon gas for freezing and helium gas 
for thawing, permitted a dramatic reduction in the diameter of the cryoprobes. 
The ultrathin 17-gauge (1.47mm) cryoneedles have a very sharp tip, that allows for 
a direct transperineal placement into the prostate [9]. The cryoneedles are inserted 
through a brachytherapylike template and because of the smaller diameter 
more needles can be placed. This enables a precise contouring of the ice ball, 
subsequently resulting in a more effective ablation of the gland. The track dilatation 
and insertion kit, that were needed for older generation cryoprobes (3.5–5.5mm), 
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are no longer necessary [9-11]. This development has significantly minimized the 
scrotal swelling and perineal ecchymosis occurring after the procedure [12]. By 
active instead of passive warming the procedure can be performed much quicker 
which is advantageous for the patient’s recovery. Most patients are discharged 
from the hospital either the same day or the following day after treatment [13].
These technical improvements have made modern cryosurgery a minimal 
invasive procedure. Most reports in the literature are from the USA and Canada, 
but cryosurgery is evolving in European centers [13,14]. Therefore, an update is 
provided of the latest results of modern cryosurgery as a primary treatment option 
or as a salvage procedure for radiorecurrent prostate cancer. We specifically 
discuss the impact of patient selection and criteria of treatment success on 
the oncological results. Also, developments such as focal- and nervesparing 
cryosurgery are discussed.
Evidence acquisition
The aim of this review is to put the results of third-generation cryosurgery in 
perspective with older techniques. Therefore, a structured literature review was 
performed by an electronic Pubmed search from January 1960 until June 2008. 
Data of primary- and salvage cryosurgery of the prostate with the following search 
terms: ‘cryosurgery and prostate cancer’ (rendering 426 articles), ‘cryotherapy 
of the prostate and prostate cancer’ (rendering 83 articles) and ‘cryoablation 
and prostate cancer’ (rendering 446 articles) were retrieved. We only selected 
papers with relevant information on clinical outcome and treatment-induced 
complication rates. As data on overall survival and cancer-specific survival were 
lacking in most studies, predominantly biochemical disease-free survival (bDFS) 
rates were included.
We applied the following criteria for identification of articles to be clinically 
relevant:
- English language.
- Original papers with the elimination of review articles.
-  Screening of reports for overlap of patient data by checking the center of   
treatment, co-authorship and time frame of patient selection.
- Any report of third-generation gas-based cryosurgery.
- A few large series on older techniques with a minimum of 12 months follow-up.
Evidence synthesis
Primary cryosurgery of the prostate
In most studies with intermediate-term follow-up both liquid nitrogen- and gas-
based cryosurgery techniques have been used. In general, these show an actuarial 
biochemical disease-free survival (bDFS) of 60%–90% at 7 years [15,16]. Long-term 
overall survival data have not been published yet and one report shows a 5-year 
overall survival of 89% [17]. The bDFS for gas-based third-generation cryosurgery 
is comparable to the results in previous reports of older techniques [12,14,18]. 
Table 1 summarizes the results of recently published series, concerning primary 
cryosurgery of prostate cancer.
Clinical outcome
The PSA value is often used as a surrogate endpoint for treatment success in 
cryosurgery. The PSA-based definition of biochemical failure in literature varies 
considerably, complicating the comparison of outcomes. For instance, Long et al. 
[16] performed a retrospective outcome analysis of a database of 975 patients from 
five institutions, who underwent cryosurgery as primary treatment for localized or 
locally advanced prostate cancer. The median follow-up was 24 months. Using a 
PSA threshold of < 0.5 ng/ml and < 1.0 ng/ml, the 5-year actuarial bDFS ranged 
from 36%–61% and 45%–76%, respectively, depending on risk category of the 
patients. Bahn et al. [15] retrospectively reviewed a series of 590 patients, with a 
mean follow-up of 5.4 years. This data set of patients was also used by Long et 
al. [16]. Using a PSA threshold of < 0.5 ng/ml, they found a 7-year actuarial bDFS 
for low-, intermediate- and high-risk patients of 61%, 68% and 61%, respectively. 
For a PSA threshold of < 1.0 ng/ml the respective bDFS rates were 87%, 79% 
and 71%. However, using the American Society for Therapeutic Radiology and 
Oncology (ASTRO) definition of biochemical failure (three successive increases 
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of PSA level), the bDFS was 92%, 89% and 89%, respectively. The outcome of the 
largest database for primary cryosurgery [19] shows a 5-year actuarial bDFS of 
77% according to the ASTRO criteria, for mainly intermediate to high risk patients. 
This Cryo On Line Data (COLD) Registry encompasses assembled results from 
academic and community centers. A significant overlap in patient data exists with 
previously reported papers (Table 1).
Uniform criteria for treatment success are currently not agreed upon, but the 
combination of a static threshold with the need for a rising PSA trend with time 
seems reasonable. For instance, Shinohara et al. [20] evaluating 110 patients 
after cryosurgery for prostate cancer defined biochemical disease recurrence as 
a subsequent rise in PSA of > 0.2 ng/ml from nadir. Patients with a PSA nadir 
of < 0.1 ng/ml had a 7% biopsy failure rate. Those with nadir values of 0.1 to 
0.4 ng/ml had 22% biopsy failures. Patients with a PSA nadir of ≥ 0.5 ng/ml had 
60% biopsy failures. Apparently low PSA levels must be achieved after cryosurgery 
and therefore they suggested a threshold value of PSA ≤ 0.4 ng/ml for defining a 
successful outcome.
Although cryosurgery is an ablative therapy, detectable levels of PSA are not 
necessarily associated with persistence of cancer cells, because there is usually 
preservation of some tissue surrounding the urethra that can be benign and may
release PSA. Thus, the definition of treatment success that is just on the threshold of 
PSA detection (PSA < 0.1 ng/ml) may be unreasonable to apply for cryosurgery.
In radiotherapy the ASTRO definition is accepted, but because this is a tumour 
selective therapy targeting dividing over non-dividing cells it is unknown whether 
it can apply to cryosurgery as well. It is also questionable whether the newer 
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Ref. (with  
actuarial data)
No. 
pa-
tients
Median 
follow-up 
in months 
(range)
Tech-
nique
PSA 
thres-
hold
Low 
risk
b DFS
(%)
Inter-
mediate 
risk
High 
risk a)
nADT
(%)
Duplication 
data b) : y/n 
(reference) 
Long et al.  [16] 
(5-year data)
975 24 
(SD ± 
16.5)
LN/Ar < 0.5
< 1.0
60
76
61
71
36
45
33 y 
(15)
Donnelly et al.  [17] 
(5-year data)
76 61 (35-85) LN < 0.3
< 1.0
60
75
77
89
48
76
34 y 
(19)
Bahn et al.  [15] 
(7-year data)
590 68 (NA) LN/Ar < 0.5
< 1.0
ASTRO
61
87
92
68
79
89
61
71
89
91 y
 (16,19)
Ellis et al.  [65] 
(3-month data)
75 3 (NA) Ar < 0.4 84 
(all risk 
groups)
NA n
Han et al.  [12] 
(1-year data)
122 12 (NA) Ar < 0.4 78 NA 71 37 n
Cytron et al.  [66] 
(NA)
23 11 (mean) 
(9-18)
Ar < 0.5 78 
(all risk 
groups)
NA n
Prepelica et al.  [18] 
(6-year data)
65 35 (4-77) Ar ASTRO 83 
(most 
high 
risk)
68 y 
(19)
Creswell et al.  [14] 
(1-year data)
31 9 (1.5-18) Ar < 0.5 60 NA 60 NA n
Polascik et al.  [67] 
(NA)
50 18 (3-43) Ar < 0.5 90 
(all risk 
groups)
26 n
Jones et al.  [19] 
(5-year data)
1198 24 
 (SD ± 26)
LN/Ar ASTRO
Phoenix
85
91
73
79
75
62
NA y 
(15,17,18)
Hubosky et al.  [68] 
(2-year data)
89 11 (1-32) Ar < 0.4 74 70 60 35 n
ASTRO 94 
(all risk 
groups)
Cohen et al.  [62] 
(10-year data)
204 12.6 
(9.7-15.0)
LN ASTRO 56 
(all risk 
groups)
0 n
Phoenix 81 74 46
Chin et al.  [23] 
(4-year data)
33 19 (NA) Ar ASTRO 13 
(all risk 
groups)
100 n
Houston 36 
(all risk 
groups)
Table 1  Results of primary cryosurgery
a)  d’Amico risk stratification (1992 American Joint Committee on Cancer ): low risk = PSA < 10 
ng/ml and Gleason biopsy ≤ 6 and clinical stage T1c-T2a; intermediate risk = PSA 10-20 ng/ml 
or Gleason biopsy 7 or clinical stage T2b; high risk = PSA > 20 ng/ml or Gleason biopsy ≥ 8 or 
clinical stage ≥ T2c; nADT, neoadjuvant androgen deprivation therapy.
b)  Duplication of reporting some patient data likely: yes or no (reference). 
NA, not available; SD, standard deviation; LN, liquid nitrogen; Ar, argon gas; bDFS, bioche-
mical disease free survival; ASTRO = three successive rises in PSA; Houston/Phoenix = PSA 2 
ng/ml above nadir.
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Phoenix or Houston definition may be appropriate for prostate cryosurgery. 
According to this definition any increase of 2 ng/ml above the nadir value during 
follow-up is considered to indicate a biochemical recurrence [21]. Because a PSA 
nadir after prostate cryosurgery is typically achieved, unlike radiation, by 3 months 
after the procedure, the use of this definition may be reasonable. Lacking uniform 
criteria for treatment success we propose to define biochemical failure using a 
PSA threshold of 0.5 ng/ ml as well as the Phoenix/Houston definition.
Not only the PSA-based definitions of biochemical failure, but also a stratification 
of patients into risk groups determines the outcome. Success rates appear to 
be worse for high risk patients with a PSA > 10 ng/ml and Gleason scores > 7 
[15,16]. However, a recent study [18] showed that even in the presence of a PSA 
≥ 10 ng/ml and Gleason score ≥ 8, a favourable outcome could be achieved in 
80% of patients. The numbers of patients in this study were low and these results 
should be interpreted cautiously. Besides, the results are probably influenced by 
concomitant hormonal therapy in 67% of patients. These patients generally have 
low serum testosteron levels for at least 2 months after cessation of treatment and 
therefore PSA levels after cryosurgery may be influenced by hormonal therapy.
From the early 1960s, cryosurgery was used as a treatment option for localized 
prostate cancer, that resulted in survival rates that approximated those of surgery 
and radiotherapy for all stages of disease [22]. Donnelly et al. [17] stated that 
the current treatment modalities for low-risk disease as watchful waiting, radical 
prostatectomy, external beam radiotherapy (EBRT) and brachytherapy achieve 
excellent local and systemic control. They compared the 5-year bDFS of these 
modalities to their cryosurgical results of a liquid nitrogen system for intermediate 
and high-risk patients, using PSA threshold values of < 0.5 ng/ml and < 1.0 
ng/ml. The efficacy of cryosurgery appeared to be superior to both EBRT and 
three-dimensional conformed RT (3DCRT) for high-risk patients and to EBRT for 
intermediate-risk patients. Furthermore, the results of their series were comparable 
to radical prostatectomy as well as brachytherapy for intermediate and high-risk 
patients and to 3DCRT for intermediate-risk patients. Also the incontinence rates 
in this series compared favourably with the complications of the other treatment 
modalities. Although these results are encouraging, the patient numbers are 
small making valuable comparison difficult and possibly inappropriate. Other 
studies confirm that the 5-year to 7-year bDFS and positive biopsy rates after 
cryosurgery are comparable to matching outcomes reported after EBRT, 3DCRT 
and brachytherapy with similar morbidity rates [15,16].
Despite the relative deficiency in patient numbers and trial design, in a randomized 
trial comparing third-generation cryosurgery with EBRT for locally advanced 
prostate cancer it was concluded that the results of cryosurgery were less favourable 
compared to those of EBRT and cryosurgery was considered suboptimal primary 
treatment in these patients [23]. Although the bDFS at 4 years was clearly in favour 
of EBRT (13% and 47%, respectively), the disease-specific and overall survival were 
identical. However, a major advantage of cryosurgery over radiation therapy is 
that it can be repeated for residual disease without increasing the side effects.
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Ref. No.  
Patients
Tech-
nique
Fistula Slough Reten-
tion
Inconti-
nence
Impo-
tence
UTI Peri-
neal 
pain
Long et al.  [16] 975 LN/Ar 0.4 NA 10 7.5 93 NA NA
Donnelly et al. [17] 76 LN NA 3.9 NA 1.3 100 
(53: >3 
yr)
NA NA
Bahn et al. [15] 590 LN/Ar 0.004 NA 5.5 4.3 95 NA NA
Ellis et al. [65] 75 Ar 0 6.7 6.7 5.4 82 NA NA
Han et al.  [12] 122 Ar 0 4.9 NA 3 87 NA 6
Prepelica et al. [18] 65 Ar 0 NA 3.1 3.1 NA NA 3.1
Jones et al.  [19] 1198 LN/Ar 0.4 NA NA 2.9 91 NA NA
Hubosky et al. [68] 89 Ar 1 2 4 2 NA 1 6
Table 2  Complications (%) after primary cryosurgery
  
UTI, urinary tract infection; NA, not available; LN, liquid nitrogen; Ar, argon gas.
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Complication rates
The current technology of primary cryosurgery has minimal severe side effects 
(Table 2). In the COLD Registry database [19] the incontinence rate necessitating 
the use of pads was 2.9%. Rectal fistulas occurred in 0.4% and impotence in 91%. 
Very early series of first-generation cryosurgery reported high rates of rectourethral 
fistulas which have been virtually eliminated by third-generation cryosurgery [14]. 
The morbidity that was reported in second-generation series of liquid nitrogen-
based systems was mainly due to the use of older ultrasound equipment with 
less controllable freezing of the gland. This resulted in complications like urethral 
slough and retention in 10–23% and incontinence in 8–15% [24-26]. The temporal 
restriction by the US Food and Drug Administration on the type of urethral 
warming catheter that was used in 1994 was another important factor increasing 
the rates of slough [5,16]. Once the warming catheter was reintroduced to 
practice, the sloughing level decreased to the 4% that was seen just before 1994 
[5]. As some studies have shown that 66% and 45% of prostate cancers is located 
within 5 mm and 1 mm from the urethra respectively, the increased risk of residual 
periurethral tumour due to sublethal periurethral temperatures caused by the use 
of a warming catheter should be taken into consideration [27]. The only adverse 
event that affects most patients (80–90%) nowadays is erectile dysfunction. Some 
reports suggest a recovery of sexual function, because the neurons for erectile 
function are not killed but injured and axonal regeneration after freeze injury may 
lead to functional recovery [28]. Despite this phenomenon cryosurgery should 
not be offered to patients who are willing to keep their potency. There are few 
published data on the effect of primary cryosurgery on quality of life. One study 
showed that the quality of life will generally return to the level before treatment by 
one year after cryosurgery [29].
Nerve-sparing and focal cryosurgery
The application of nerve-sparing cryosurgery can improve the functional outcome 
after treatment with better potency rates. It is known, from incidental autopsy 
studies that up to 20–30% of prostate cancers are solitary and unilateral [30]. The 
use of saturation prostate biopsies (up to 24 cores) could delineate monofocal 
compared to multifocal prostate cancer. In a recent report radical prostatectomy 
specimens from patients with clinically localized prostate cancer were analyzed 
[31]. Completely unilateral cancers were identified in 18% of patients and the 
majority of these tumours (72%) were low volume. In this study it was suggested 
that only a select group of men would be amenable to focal cryosurgery targeting 
one lobe. The feasibility of nerve-sparing cryosurgery by active warming of the 
neurovascular bundle (NVB) was evaluated in a canine model [32]. In this model 
NVB preservation was possible but not consistently reproducible. In some cases 
NVB preservation with active warming may result in incomplete peripheral prostate 
tissue ablation. The authors conclude that these results have significant clinical 
meaning when attempting nerve-sparing cryosurgery. Because of the possible 
compromising effect on oncological outcome, nerve-sparing focal therapy should 
be considered experimental. In a preliminary study 9 patients were treated with 
focal, unilateral nerve-sparing cryosurgery [33]. After a mean follow-up of 36 
months, all patients had a stable PSA and negative biopsies. Seven patients 
remained potent. The authors have appreciated the problem of multifocality in 
many prostate cancers and advised the patients to undergo repeated biopsies 
at a stable PSA level. Lambert et al. [34] reported the safety and efficacy of focal 
cryosurgery to preserve genitourinary function in men with localized, unifocal 
disease. With a median follow-up of 28 months, 84% were without biochemical 
failure and 68% remained potent. No patient had worsened LUTS, incontinence, 
rectal pain, perineal discomfort or fistula formation. Based on a 3-year observation 
period, focal cryosurgery of the prostate appeared to be associated with minimal 
morbidity and a promising efficacy.
Modern imaging techniques like 3-T endorectal coil MR imaging, dynamic 
contrast enhanced MRI and 3D MR spectroscopy have emerged with promising 
features in prostate cancer delineation [35,36]. Although these modalities are not 
widely available yet, an improvement in the detection of tumour volume and local 
extension as well as precise image-guided prostate biopsies is possible. Further, 
the results of focal therapy can be monitored with these techniques. Other 
innovations like real-time ‘cellular’ imaging [37] and computer planned positioning 
of the probes will improve efficacy and safety of the treatment.
Salvage cryosurgery of the prostate
In the EAU guidelines 2007 it is stated that achieving a PSA nadir after radiotherapy 
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of less than 0.5 ng/ml seems to be associated with a favourable outcome. The 
interval before reaching the nadir PSA may take up to 3 years or more. A PSA rising 
more than 2 ng/ml above the nadir PSA is the current definition of biochemical 
failure after radiotherapy. Also, the PSA doubling time following radiotherapy 
appears to aid in predicting the time to prostate cancer-specific death. Local 
recurrence rates after curative radiotherapy, confirmed by prostate biopsy, vary 
between 25% and 30% [38-41] and even a percentage of over 90% has been 
reported [42]. Recently, Touma et al. [43] reviewed the published data of salvage 
therapies following radiation failure. The authors state that the final success rate 
of curative radiotherapy depends on the modality being used, like conventional 
radiotherapy, 3DCRT or intensity modulated conformal radiotherapy (IMRT). It has 
been proven that dose escalation is an independent predictive factor of outcome. 
Also, local failure was found to be a strong predictor of distant metastasis. Others 
have suggested that recurrent prostate cancers are biologically more aggressive, 
either because of cytological evolution, perhaps induced by radiation or due to 
the progression of an innately aggressive tumour already resistant to radiation 
[44]. Therefore, in a patient with low risk of systemic disease (pre-treatment tumour 
stage, negative restaging imaging and greater than 12 months’ PSA doubling 
time) and a life expectancy of more than 10 years salvage cryosurgery may be 
applied when PSA reaches 2 ng/ml above nadir after an interval from radiotherapy 
of at least 18 months.
Because of the relatively high rates of local disease recurrence after radiotherapy 
and its implications for outcome, salvage treatment options with curative intent 
have been applied since 1985 when the first series of salvage radical prostatectomy 
was published [45]. Five-year bDFS rates after salvage radical prostatectomy have 
been reported varying from 55% to 69% [43].
Clinical outcome
Biochemical failure rates of salvage cryosurgery also depend on the PSA threshold 
being used. Again, like for primary cryosurgery, there is no clear definition of 
failure. In an older series of salvage cryosurgery Pisters et al. [4] reported on 150 
patients comparing a single and a double freeze-thaw cycle for local recurrence 
after radiotherapy. The mean follow-up was 13.5 months and the PSA threshold 
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Table 3  Results of salvage cryosurgery
a)  d’Amico risk stratification (1992 American Joint Committee on Cancer ): low risk = PSA < 10 
ng/ml and Gleason biopsy ≤ 6 and clinical stage T1c-T2a; intermediate risk = PSA 10-20 ng/ml 
or Gleason biopsy 7 or clinical stage T2b; high risk = PSA > 20 ng/ml or Gleason biopsy ≥ 8 or 
clinical stage ≥ T2c; nADT, neoadjuvant androgen deprivation therapy.
b)  Duplication of reporting some patient data likely: yes or no (reference). 
NA, not available; SD, standard deviation; LN, liquid nitrogen; Ar, argon gas; bDFS, bioche-
mical disease free survival; ASTRO = three successive rises in PSA; Houston/Phoenix = PSA 2 
ng/ml above nadir.
Ref. (with  
actuarial data)
No. 
pa-
tients
Median 
follow-up 
in months 
(range)
Tech-
nique
PSA 
thres-
hold
Low 
risk
b DFS
(%)
Inter-
mediate 
risk
High 
risk a)
nADT
(%)
Duplication 
data b) : y/n 
(reference) 
de la Taille et al. [54] 
(1-year data)
43 22 (mean) 
(1-54)
LN/Ar < 0.1 66 
(all risk 
groups)
100 y (57)
Chin et al.  [48] 
(5-year data)
118 19 (3-54) Ar < 0.5 NA NA 34 60 y (58)
Ghafar et al.  [57] 
(2-year data)
38 21 (mean) 
(3-37)
Ar Nadir + 
0.3
74 
(all risk 
groups)
100 y (54)
Han et al.  [11] 
(1-year data)
18 12 (NA) Ar < 0.4 77
(all risk 
groups)
NA n
Bahn et al.  [69] 
(7-year data)
59 82 (NA) Ar < 0.5 59 
(all risk 
groups)
NA y (47)
Creswell et al.  [14] 
(1-year data)
20 9 (1.5-18) Ar < 0.5 67 
(all risk 
groups)
NA n
Ismail et al.  [13] 
(5-year data)
100 33 (mean) 
(12-79)
Ar < 0.5
ASTRO
73
59 
(all risk 
groups)
45 11 46 n
Ng et al.  [58] 
(8-year data)
187 39 (mean) 
(NA)
Ar Houston 56 NA 14 71 y (48)
Pisters et al.  [47] 
(5-year data)
279 22 
(SD ± 25)
LN/Ar ASTRO
Phoenix
59 
(all risk 
groups)
55
 (all risk 
groups)
NA y (69)
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was < 0.1 ng/ml. Six months after a double freeze-thaw cycle, a higher negative 
biopsy rate was found of 93% compared to 71% after a single freeze-thaw cycle. 
The biochemical response rate after a double freeze was favourable with a bDFS 
of 56%. Data from Allegheny General Hospital, Pittsburgh, USA, with different 
cryosurgery techniques being used, demonstrate a 10-year bDFS of 57%. The PSA 
nadir level was < 0.4 ng/ml and failure was defined as two consecutive rises in PSA 
level of 50% or more [46]. Data from the largest database on salvage cryosurgery 
(COLD Registry) [47], in which 14 physicians participated and 277 patients were 
treated with either liquid nitrogen or gas-based technology, the five-year actuarial 
bDFS was 59% according to the ASTRO definition of biochemical failure. Again, 
the results of this database are assembled from many centers which leads to 
overlap of reporting. The results of the latest series of third-generation salvage 
cryosurgery are comparable to or even better than the previous techniques (Table 
3). Several authors have defined predisposing factors for a worse outcome of 
salvage cryosurgery, including high PSA > 10 ng/ml and high Gleason score > 8 
[48-50]. Also, patients with clinical stage T3 or T4 disease have an unfavourable 
outcome [48,49]. Complete ablation of the prostate is usually not attained in salvage 
cryosurgery, subsequently resulting in the release of PSA. In two series of salvage 
cryosurgery viable benign prostate tissue was identified in a substantial number 
of prostates, even though the biopsies after cryosurgery were negative for cancer 
[51,52]. This suggests incomplete ablation of the prostate was performed, but 
recurrence rates after salvage cryosurgery were not associated with this presence 
of benign prostate tissue [52].
Complication rates
Salvage radical prostatectomy is technically more challenging than primary 
prostatectomy. Significant complications will occur because of tissue plane 
obliteration, fibrosis and radiation-induced vasculitis. The average rates of rectal 
injury, anastomotic stricture and urinary incontinence are 6.6%, 18% and 45%, 
respectively [43]. Therefore, cryosurgery has emerged as a feasible minimal invasive 
treatment, although the complication rates are higher than those of primary 
cryosurgery (Table 4). This is especially true for incontinence rates and pelvic pain 
[53,54]. Initial salvage cryosurgery series reported incontinence rates of 73% or 
higher [4,55]. With third-generation techniques a significant decrease in serious 
side effects, such as incontinence and rectourethral fistulas, was found [46,56,57]. 
Currently, the average incontinence rate is 8% (range 3%–13%), depending on 
the definition of incontinence. Mostly, incontinence is defined as the daily use 
of one or more pads [54]. In the COLD Registry database [47] a rectourethral 
fistula rate of 1.2% and incontinence rate of 3.8% was reported. The incidence 
of other complications, like urethral sloughing and strictures vary from 10%–15% 
to as low as 0%–5%, with the application of a urethral warming catheter and the 
newer cryotechnology [48,54,57]. Less frequently reported complications, but 
nevertheless bothersome are lower urinary tract symptoms (LUTS), occurring in 
up to 16% of patients [13,57,58]. The rates of impotence after salvage cryosurgery 
are high but many patients already have significant erectile dysfunction as 
a consequence of the foregoing radiotherapy. Perrotte et al. [59] found that 
quality of life was adversely affected especially by perineal pain, not so much 
by incontinence or impotence. They showed that treatment without an effective 
urethral warming catheter was highly associated with incontinence, perineal pain 
and slough. They concluded that salvage cryosurgery does not seem to have any 
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Table 4  Complications (%) after salvage cryosurgery
UTI, urinary tract infection; NA, not available; LN, liquid nitrogen; Ar, argon gas.
Ref. No. 
Patients
Tech-
nique
Fistula Slough Reten-
tion
Inconti-
nence
Impo-
tence
UTI Peri-
neal 
pain
de la Taille et al. [54] 43 LN/Ar 0 0 4 9 NA 9 26
Chin et al.  [48] 118 Ar 3.3 5.1 8.5 6.7 NA NA NA
Ghafar et al. [57] 38 Ar 0 0 0 7.9 NA 2.6 39.5
Han et al. [11] 18 Ar 0 11 0 11 86 NA 5.6
Bahn et al. [69] 59 Ar 3.4 NA NA 8 NA NA NA
Ismail et al.       [13] 100 Ar 1 2 2 13 86 NA 4
Ng et al.  [58] 187 Ar 2 NA 21 3 NA 10 14
Pisters et al.      [47] 279 LN/Ar 1.2 3.2 NA 4.4 NA NA NA
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advantage compared to salvage prostatectomy in terms of morbidity and quality 
of life. Another study, in which quality of life was prospectively evaluated two 
years after salvage cryosurgery, showed that QOL returned to preoperative levels 
in all domains by 24 months after treatment, with the exception of urinary- and 
sexual functioning [60]. The overall QOL score was high and the satisfaction rates 
competed with the alternative of radical prostatectomy or androgen deprivation 
therapy. A single institution study, comparing quality of life between primary and 
salvage cryosurgery showed better physical and social functioning of the primary 
cryosurgery patients [61]. Overall QOL scores were high and the symptom scale 
pain scores were low for both treatment groups.
Evaluation
Despite the encouraging results urologists should be cautious when counseling 
patients about the outcomes of cryosurgery for a number of reasons. First of all, 
in many study protocols different cryosurgery systems have been used making 
comparison of outcome difficult. Because a uniform definition of treatment 
success is lacking, the end-points vary considerably. Usually varying definitions of 
biochemical recurrence are used as surrogate endpoints. Concomitant androgen 
deprivation therapy has an influence on short-term treatment results and must 
be taken into consideration (Tables 1 and 3). Most studies report the results of 
retrospective, single-institute case series and only one peer-reviewed publication 
of a randomized trial comparing cryosurgery with radiotherapy is available. 
Moreover, long-term follow-up data on disease-specific and overall survival are 
not available yet. Only one report of long-term bDFS with a median follow-up 
of 12.55 years has been published with a 10-year negative biopsy rate of 77% 
[62]. Furthermore, it should be realized that many studies are from only a few 
leading centers of excellence in the USA and Canada with considerable overlap in 
reporting of patient data (Tables 1 and 3). This typically leads to publication bias 
of positive studies and the results should be interpreted with caution. According 
to a recent Cochrane analysis, it must be concluded that results of cryosurgery 
are of low-level evidence [63]. Cryosurgery is a technically demanding procedure 
and the learning curve to reach an acceptable expertise level has been 200 cases 
in earlier days [64]. Since then, new computer planning programs and guidance 
systems have greatly facilitated the procedure, but cryosurgery should be done 
only after adequate training.
Conclusions
There are increasing numbers of European centers applying cryosurgery for 
prostate cancer. The long learning curve has declined with new computer 
planning programs and guidance systems which greatly facilitate the procedure. 
Modern cryotechnology is therefore highly reliable and results are promising. 
The introduction of gas-based third-generation cryosurgery has decreased the 
complication rates significantly with similar clinical outcome when compared to 
older techniques. Salvage cryosurgery has more adverse effects, but remains an 
option for radiorecurrent prostate cancer patients. Stratifying patients into risk 
groups is an important aid for the urologist to select patients for cryosurgery. 
Further, a specific definition of treatment success is urgently needed. New 
developments like focal- and nerve-sparing cryosurgery for unifocal prostate 
cancer aim at further reducing the side effects but are still considered experimental. 
In counselling patients it is important to discuss the possible therapeutic gain 
of cryosurgery, the associated side effects and the impact on quality of life. The 
current data are derived from studies of low level evidence and this should be 
taken into consideration when making treatment decisions. Although biochemical 
disease free survival rates seem to be comparable to those of other treatment 
modalities, randomized trials with long-term follow-up are needed to define the 
role of cryosurgery in the treatment of localized prostate cancer.
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6.1 Neoadjuvant hormonal therapy
Introduction
The standard options for curative treatment of localized prostate cancer are 
radical prostatectomy and external beam radiotherapy (EBRT). In general, with 
these treatment options the local control is adequate. After radical prostatectomy 
an average 27%–53% of patients will have a biochemical recurrence within 10 
years (rising prostate specific antigen (PSA)). The outcome is significantly worse 
for patients with T3 disease, high Gleason score ≥ 7 and lymph node metastases 
[1]. A biochemical recurrence after EBRT is seen in 30% of patients within 4 years 
[2]. Local tumor control is worse in locally advanced disease with subsequently 
more distant metastases as a result. These patients will benefit from additional 
treatment, for instance neoadjuvant androgen deprivation therapy (ADT).
Neoadjuvant ADT consists of treatment with a luteinizing-hormone releasing 
hormone (LHRH) agonist, an anti-androgen or a combination of LHRH agonists 
and anti-androgens (maximal androgen blockade). The prostate volume and 
tumor volume are reduced by neoadjuvant ADT. After the reduction of tumor 
volume less radiation dose is required for complete tumor destruction. The area of 
irradiated tissue is smaller which possibly leads to a reduction of radiation damage 
to the bladder and rectal tissues [3]. A synergistic effect of neoadjuvant ADT and 
radiotherapy has been described. An increase of the sensitivity to radiation is 
accomplished by reducing the hypoxic fraction of the tumor with ADT. In several 
in vitro- and in vivo studies this effect was shown [4]. By these means a better local 
control is achieved with combined EBRT. Further, apoptosis of micrometastases 
can be induced by hormonal treatment. The ultimate goal of therapy is of course 
a survival benefit. The duration of neoadjuvant ADT remains a matter of debate, 
but for maximal volume reduction 8 months of ADT may be necessary [5]. Most of 
the literature on this subject is based on conventional radiation techniques. The 
complication rate has decreased significantly with modern techniques, such as 
3D-conformation radiotherapy and intensity-modulated radiation therapy (IMRT) 
[6]. With these conformality techniques a precise radiation of the target volume is 
achieved with a higher dose than the conventional radiation techniques (up to 81 
Gy). Therefore, a better local control is expected with sparing of surrounding tissues 
of bladder and rectum. No long-term results are known for these techniques. The 
role of neoadjuvant ADT with IMRT technique has not been extensively studied.
Oncological outcome
The oncological results of neoadjuvant ADT combined with EBRT have been 
described in several prominent articles [7-9]. The duration of neoadjuvant ADT in 
these studies varied between 3 to 8 months, and the patients mainly had locally 
advanced prostate cancer. In the RTOG 86–10 trial with 8 years of follow-up, patients 
with bulky tumors were treated with 2 months neoadjuvant ADT and 2 months 
of hormones concomitant with radiation therapy [7]. A significant improvement 
of local tumor control, disease-free and disease-specific survival were seen. For 
a subgroup of patients with Gleason 2–6, the overall survival improved as well 
(70% vs. 52%, P = 0.015). Surprisingly, patients with Gleason 7–10 showed no 
improvement of local control or survival. This finding seems in contradiction with 
the outcomes of other studies on the subject. However, the patients with Gleason 
scores 2–6 had an advanced clinical stage and high PSA, making them more or less 
high-risk patients with a considerable risk for metastases. A significant advantage 
for local tumor control, disease-specific and disease-free survival, after 6 months 
of neoadjuvant ADT, was shown by Denham et al. in the Trans-Tasman Radiation 
Oncology Group study [8]. All patients in this study had high-risk prostate cancer 
(Gleason score ≥ 8, PSA > 20 ng/ml, T3-T4). Laverdière et al. [9] showed an 
improved disease-free survival after 3 months of neoadjuvant ADT. Patients with 
localized prostate carcinoma (cT2) were included in that study as well.
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Neoadjuvant ADT has been studied before radical prostatectomy as well and 
the goals are better local control, less positive surgical margins and downstaging 
in case of a locally advanced tumor. In a Cochrane review and meta-analysis, 
neoadjuvant ADT did not improve overall survival [10]. However, there was a 
significant reduction in positive surgical margin rates and significant improvement 
in other pathological variables such as lymph node involvement, pathological 
staging and organ confined rates. Follow-up was 7 years and patients were 
mainly treated with maximal androgen blockade. The use of longer duration of 
neoadjuvant hormones, that is either 6 or 8 months prior to prostatectomy, was 
associated with a significant reduction in positive surgical margins.
Duration of treatment
The debate on the sequence of hormonal therapy and EBRT continues, but also 
on the duration of neoadjuvant ADT. In a Canadian study, neoadjuvant ADT for 3 
months was compared with 8 months [11]. A trend was seen for improved disease-
free survival after 8 months for high-risk patients, but numbers were not statistically 
significant. As said before, in the Denham study a better disease-specific survival 
was shown for high-risk patients with 6 months versus 3 months of neoadjuvant 
ADT.
Summary
The role of neoadjuvant ADT combined with EBRT or before surgery has often 
been discussed in the literature. A better local control, disease-specific and 
disease-free survival is achieved with neoadjuvant ADT and EBRT, even for high-
risk patients. A gain in overall survival may be possible, but needs confirmation in 
studies with longer follow-up. Therefore, neoadjuvant ADT before EBRT is often 
beneficial. The necessary duration of neoadjuvant ADT remains a matter of debate 
and seems to lie in between 3–6 months. The role of neoadjuvant ADT before 
surgery is limited. A better local control can be achieved but no improvement of 
survival is apparent.
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6.2 Intermittent hormonal therapy
Introduction
Androgen deprivation therapy (ADT) has become the standard treatment for 
advanced and metastatic prostate cancer, and can be achieved with surgical or 
chemical castration. With chemical castration, medication is used that is either 
blocking the testosterone synthesis (luteinizing-hormone releasing hormone 
(LHRH) agonists) or the peripheral mechanism of testosterone (steroidal or non-
steroidal antiandrogens). When these medications are combined it is referred 
to as maximal androgen blockade (MAB). A good response and a normalization 
of prostate specific antigen (PSA) are seen in about 60%–80% of patients. Cell 
proliferation is inhibited by ADT and apoptosis occurs. Some of the stem cells 
survive ADT and proliferate into androgen-independent cells [1]. This process may 
already occur soon after the start of ADT. After a mean of 24 months prostate 
carcinoma becomes androgen-independent or, so called, castrate-resistant 
and the disease will progress. Theoretically, when ADT is stopped temporarily 
growth of androgen-dependent stem cells only may be initiated. The stem cells 
might remain hormone-sensitive in the next cycles of ADT. This is the basis of 
intermittent hormonal therapy. The development of androgen-independent 
tumors may therefore be delayed by intermittent hormonal therapy. Another 
claimed advantage of intermittent hormonal therapy is the preservation of quality 
of life (QOL) by a reduction in side effects that characterize ADT (loss of libido, 
erectile dysfunction, fatigue, loss of muscle mass, anemia, and osteoporosis). An 
obvious advantage of intermittent therapy is cost reduction by using less LHRH 
analogue depots. In the first study, in which the concept of intermittent therapy 
was applied in the clinical setting, using diethylstilbestrol (DES) or flutamide, in 9 
out of 10 patients with erectile dysfunction after ADT, a return of sexual function 
was seen during intermittent hormonal therapy [2]. Potency recovered at a mean 
of 3 months after stopping ADT. In several phase II clinical studies, a recovery of 
sexual functions and better QOL was shown once ADT was seized [3,4]. In most 
studies on intermittent hormonal therapy, ADT was stopped after PSA decline to 
the nadir (lowest value). Restart of ADT was initiated with a predefined PSA rise 
or with clinical progression. During this regimen, many patients have been off-
therapy for several months.
Oncological outcome and toxicity
Phase II studies have shown the feasibility of intermittent hormonal therapy for 
recurrent prostate cancer after curative treatment and for metastatic disease. Both 
PSA response and clinical improvement were comparable to continuous ADT. 
Only few prospective randomized studies were performed to analyze the time 
to progression and survival. In the SWOG 9346 study, 1134 men with metastatic 
prostate cancer were randomized for intermittent- or continuous ADT, after 7 
months induction course and PSA < 4 ng/ml [5]. No survival difference was seen 
between both groups. The PSA decline appeared to be a strong prognostic 
factor. Survival of patients with PSA < 0.2 ng/ml, < 4 ng/ml, and > 4 ng/ml was 
75 months, 44 months, and 13 months, respectively. In a multicenter prospective 
randomized open-label study, with a follow-up of 30.8 months, 68 patients were 
included [6]. Patients were randomized between intermittent or continuous ADT, 
after 3–6 months of MAB induction course and a PSA £ 4 ng/ml on two separate 
occasions. The median duration of treatment cycles (maximal 6 months of MAB 
plus the off-therapy period) was 9 months, and 54% of the patients had ≥ 3 cycles. 
The median percentage of patients being off-therapy during study was 59.5%. The 
median 3-years progression rate for intermittent and continuous ADT was 7%, and 
38.9%, respectively. The duration of the off-therapy period decreased in a linear 
way in subsequent cycles. Time to progression for intermittent and continuous 
ADT was 28 months versus 20.6 months. In another cohort study of 75 patients, 
intermittent therapy was started after 9 months of induction ADT treatment, and 
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a PSA < 4 ng/ml or a PSA decline ≥ 90% compared with the pre-treatment PSA 
value [7]. With a PSA rise > 20 ng/ml another cycle of 9-months ADT was started. 
Median survival was 95 months for patients with localized or locally advanced 
prostate carcinoma, and 87 months for patients with metastatic prostate cancer. 
Castrate-resistant tumors developed earlier in patients with metastatic prostate 
cancer. The 5-year survival rate for patients on intermittent therapy with locally 
advanced and metastatic prostate carcinoma was 100%, and 70%, respectively. 
Therefore, intermittent hormonal therapy is shown to be feasible in patients with 
advanced prostate cancer and progression-free survival is at least comparable to 
continuous ADT.
The characteristics of intermittent treatment with off-therapy periods seems 
beneficial to the patient. Costs are reduced and sexual functions improved, and 
QOL may be better. No data exist about long-term advantages of intermittent 
therapy for side effects like osteoporosis. The effects on long-term survival (> 10 
years) have not been published yet. When future research will confirm an equal 
survival to continuous ADT with intermittent therapy, a better QOL and lower 
costs this treatment could replace continuous ADT. Finally, the results of the 
National Cancer Institute of Canada - Clinical Trials Group have recently been 
presented at the 2011 American Society of Clinical Oncology conference [8]. This 
randomized study on the effect of intermittent hormonal therapy on survival, after 
radiotherapy-recurrent prostate cancer, showed fewer hot flushes, and longer 
time to castrate-resistance in the intermittent group. There were no differences in 
fractures, osteoporosis, or heart attacks. Although the overall survival rates were 
similar, men on intermittent therapy were more likely to die of prostate cancer 
but less likely to die of other diseases. The death rate from prostate cancer in 
men on continuous therapy was 14%, but in the intermittent group it was 17.3%, 
a 26% higher death rate from prostate cancer. At the same time, the death rate 
from other causes was 60% in men on continuous therapy vs. 52.3% in men on 
intermittent therapy. That difference amounted to a 14% higher death rate from 
other causes in the men getting continuous therapy. Therefore, men need to be 
carefully counseled about the overall outcome, the tradeoff of a lower incidence 
of adverse effects, and a delay in the development of hormone refractory disease, 
but a greater likelihood of dying from prostate cancer.
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Abstract
Objectives: For locally advanced prostate cancer, the results of radiotherapy are 
improved by combination with androgen deprivation therapy. Volume reduction 
achieved with neoadjuvant hormonal treatment can facilitate dose escalation 
without increasing the toxicity. The optimal duration of hormonal treatment, 
however, is unknown. The endpoint of this study is the optimal duration of androgen 
deprivation for prostate volume reduction in a cohort of patients scheduled for 
external beam radiotherapy.
Patients and methods: Twenty patients scheduled for external beam radiotherapy 
with cT2-3No/xMo prostate cancer were treated with a luteinizing hormone releasing 
hormone agonist (busereline) and nonsteroidal anti-androgen (nilutamide) for 9 
months consecutively. Repeated CT scan examination was performed 3-monthly 
to measure prostate volumes until the start of radiation therapy. The analysis of 
volume reduction was performed with the Wilcoxon signed ranks test.
Results: The baseline median prostate volume for the cohort of patients was 82 
cc (95% CI: 61–104 cc) with a median volume reduction of 31% (95% CI: 26%–35%) 
(P < 0.0001) after 3 months of androgen deprivation. Between 3 and 6 months, a 
median volume reduction of 9% (95% CI: 4%–14%) (P < 0.0001) was observed. The 
effect was more pronounced in large prostates (> 60 cc) than in small prostates 
(≤ 60 cc). In the total cohort of patients no significant volume reduction occurred 
between 6 and 9 months of maximal androgen blockade (MAB).
Conclusions: In this study, we have shown that the most significant prostate volume 
reduction is achieved after 3 months of MAB with a maximum reduction after 6 
months. Therefore, the optimal duration of neoadjuvant androgen deprivation to 
reduce prostate volume before prostate cancer radiotherapy is 6 months. In small 
prostates 3 months of hormonal treatment may be enough for maximal volume 
reduction.
Introduction
The outcome of external beam radiotherapy for patients with locally advanced 
and bulky prostatic tumors can be improved with the application of neoadjuvant 
androgen deprivation. In vitro models have shown a radiation-sensitizing effect 
of androgen deprivation therapy [1]. Joon et al. [2] reported a supra-additive 
apoptosis with combination therapy in an in vivo study using Dunning rat prostate 
tumors. Several clinical studies have proven a significant advantage for the 
combination of radiotherapy and androgen deprivation relative to radiotherapy 
alone for selected patients with prostate cancer. As a result, in a review by the 
M.D. Anderson Cancer Center in Houston, Texas [3] recommendations were made 
for the duration of hormonal therapy. The author’s advice is to include 6 months 
of androgen deprivation beginning 2 months neoadjuvantly for intermediate 
risk patients (T2b or Gleason 7 or prostate specific antigen (PSA) > 10–20). For 
patients with locally advanced (≥ T3) or high-risk prostate cancer (Gleason 8–10 or 
PSA > 20), longer-term androgen deprivation is recommended (e.g., 28 months). 
Low-risk patients (T1c-T2a or ≤ Gleason ≤ 6 or PSA ≤ 10) should not routinely 
receive androgen deprivation except in the setting of very large prostate volumes 
to improve dosimetric parameters. For brachytherapy in prostates > 60 cc, it is 
also common practice to combine the treatment with neoadjuvant androgen 
deprivation therapy for reasons of ‘downsizing’ the prostate to make the procedure 
technically more feasible [4].
The frequently asked questions about hormonal pretreatment are whether 
the amount of volume reduction depends on the initial prostate volume and, 
subsequently for how long the androgen deprivation should be administered. 
Hypothetically, these data can assist both radiation oncologists and urologists in 
determining the treatment schedule of androgen deprivation and radiotherapy 
based on the individual characteristics of the prostate.
Chapter 7 Neoadjuvant androgen deprivation for radiotherapy
116 117
The endpoint of this study is the optimal duration of androgen deprivation for 
prostate volume reduction in a cohort of patients scheduled for external beam 
radiotherapy.
Patients and methods
From August 2001 to May 2003, 20 patients with histologically confirmed 
localized prostate cancer cT2-3No/xMo, who were scheduled for external beam 
radiotherapy, were included in this phase II clinical trial. The study protocol was 
approved by the medical ethics review committee of our institution. If patients 
were eligible for enrolment into the study protocol, an informed consent was 
obtained. The initial diagnostic work-up included a clinical staging with digital 
rectal examination and/or MRI of the prostate, a bone scan, and pelvic CT scan. 
Demographics and medical history were taken and a baseline blood sample for 
PSA, hepatic-, and renal functions was obtained prior to the start of hormones. 
Patients had not received hormonal treatment or chemotherapy for prostate 
cancer in the past. An invasive neoplasm other than nonmelanoma skin cancer 
during the previous 5 years, hepatic failure, and severe respiratory insufficiency 
were exclusion criteria.
All patients received MAB using a 3-monthly subcutaneous depot of 9.9 mg 
luteinizing hormone releasing hormone (LHRH) agonist (buserelin) together with 
an oral nonsteroidal anti-androgen (nilutamide) 300 mg daily for 4 weeks, and 150 
mg daily thereafter. Nine months after the start of hormonal therapy and within 
the fifteenth week following the last LHRH depot administration radiotherapy was 
planned.
Repeated CT scans were scheduled every 3 months (Fig. 1). The patients were 
asked to empty the bladder and rectum and drink half a liter of fluid, one hour 
before every CT scan, to ensure a comparable amount of bladder and rectum 
filling during the investigations. The CT scan (AcQSim big-bore spiral CT scanner; 
Philips Medical Systems, Bothell, WA) was taken with 3 mm slice thickness from 
the upper part of the sacro-iliac joints down to the perineum (the first CT scan 
from lumbar vertebra IV). The baseline CT scan, which was made before the start 
of androgen deprivation therapy, was used for diagnostic purposes of the pelvic 
lymph nodes as well. Processing of the CT scan images encompassed manual 
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Figure 1 
Prostate volume reduction (purple) shown on sagital plane of CT scans; CT1 = baseline; 
CT2 = after 3 months of MAB; CT3 = after 6 months of MAB; CT4 = after 9 months of MAB.
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delineation of the prostate gland (excluding seminal vesicles) by a single observer 
(EvL), who was blinded for the duration of androgen deprivation, on all transverse 
slices where the prostate was visible and an automated volume measurement. On 
each CT scan the prostate was contoured using the Pinnacle³ radiation treatment 
planning system (Philips Medical Systems, Andover, MA). Prostate volumes were 
computed using the commonly applied voxel count method. Further, to evaluate 
if a certain volume of the prostate requires a specific duration of androgen 
deprivation, a comparison was made between small prostates of ≤ 60 cc and large 
prostates of > 60 cc. The CT scan at 9 months was ultimately used for the actual 
treatment planning of external beam radiotherapy.
Statistics
Statistical analysis was performed with SPSS for Windows version 9.0 (SPSS, 
Chicago, IL) or higher. A Wilcoxon signed ranks test was used to compare prostate 
volumes at specific time points during treatment. The null hypothesis was that 
prostate volumes would not change under influence of androgen deprivation 
therapy. A significance level of 0.05 was used to reject the null hypothesis. A 
Spearman correlation coefficient was calculated to evaluate if any linear correlation 
existed between numerical variables, namely PSA, Gleason score, the percentage 
of positive biopsies, and the relative volume reduction of the prostate after 3 and 
6 months.
Results
Twenty-one patients were eligible for the study (Table 1). One patient died because 
of leukemia before the first CT scan evaluation and was excluded from the study. 
One patient died of cardiac arrest after 7 months of hormonal treatment. As a 
consequence, the prostate volume data of this patient were available until the CT 
scan evaluation at 6 months.
Fig. 2 shows the time trend of prostate volume reduction for the cohort of 
patients. The baseline median prostate volume was 82 cc (95% CI: 61 cc–104 cc). 
After 3 months of MAB a significant median volume reduction of 31% (95% CI: 
26%–35%) (P < 0.0001) was achieved (Table 2). This volume reduction was seen 
in the subgroup of patients (n=15) with large prostates (> 60 cc) as well, with a 
median reduction of 31% (95% CI: 23%–37%) (P < 0.0001) (Table 3).
When evaluating prostate volumes at 6 months compared with 3 months, a 
significant volume reduction of 9% (95% CI: 4%–14%) (P < 0.0001) was observed 
for the cohort of patients. For large prostates, the reduction was 10% (95% CI: 
4%–18%) (P < 0.001). Between 6 and 9 months, there was no statistically significant 
reduction in prostate volume for the cohort of patients. In this study, every patient 
showed a reduction of prostate volume during the first 6 months of MAB.
Since the group of patients with prostates of ≤ 60 cc was small (n=5), no statistical 
analysis was performed. The volume reduction after 3 months of MAB was equal 
to the level that was achieved in large prostates (31%). After 3 to 6 months of MAB 
the volume reduction appeared less than in large prostates (8%).
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Table 1
Demographics of included patients (n=20).
Mean age (years) 71  (56-79)
T category
T2 10
T3 10
Gleason
≤ 6 13
7   4
8   3
PSA (ng/ml) 12  (5-30)
120 121
There was no correlation found between the PSA, Gleason score, the percentage 
of positive biopsies, and the relative volume reduction after 3 months and after 6 
months.
Discussion
The synergistic effect of neoadjuvant androgen deprivation therapy and external 
beam radiotherapy can improve outcome in prostate cancer treatment. In an in 
vivo study, using Dunning rat prostate tumors, a supra-additive interaction of 
radiotherapy and androgen deprivation has been demonstrated [2]. This means 
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Figure 2
Graphic delineation of prostate volume reduction for study cohort during 9 months of MAB.
Table 2
Median prostate volumes during 9 months of MAB for the cohort of patients.
Table 3
Median prostate volumes during 9 months of MAB for patients with large prostates (> 60 cc).
Patients (n) Median pros-
tate volume (cc)
95% CI (cc)
Baseline 20 82 61 - 104
3 months 20 58 45 - 66
6 months 20 52 41 - 63
9 months 19 49 38 - 72
Patients (n) Median pros-
tate volume (cc)
95% CI (cc)
Baseline 15 86 79 - 127
3 months 15 65 50 - 85
6 months 15 56 41 - 82
9 months 15 54 46 - 76
that the effect on tumor cell kill due to the combination of treatments was 
greater than would be expected from the addition of the effects of the individual 
components. Further, it was described that the effect was specific for the sequence 
of external beam radiotherapy and androgen deprivation. The effect was time 
limited with a declining interaction after a longer interval between castration 
and the start of radiotherapy. It is currently unknown to what extent this delay of 
the start of radiotherapy can negatively influence the oncologic outcome in the 
clinical situation.
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In localized prostate cancer, the final success rates of curative radiotherapy are 
dependent on the modality being used, such as conventional radiotherapy [5,6], 3D 
conformal radiotherapy (3D-CRT) [7], or intensity modulated radiotherapy (IMRT) 
[8]. The latter two allow for dose escalation, which is of paramount significance for 
the success of external beam radiotherapy. Improved treatment outcome by dose 
escalation has previously been reported, especially for intermediate- and high-risk 
patients [9-14]. In a retrospective analysis from the RTOG an improved survival in 
patients with high-dose radiotherapy was suggested [15].
The increased radiation dose harbors the risk of increasing the toxicity. With 3D-
CRT, dose escalation is feasible though without a significant increase of grade III-
IV toxicity of normal tissues surrounding the target volume [16]. However, the role 
of dose-escalated 3D-CRT for men with locally advanced (T3–4) prostate cancers 
is uncertain. In these patients, the increase of the target dose seems important 
for an improved local control but, especially in bulky tumors, it may be associated 
with increased side effects on the normal tissues of rectal wall and bladder. The 
volume of normal tissue that is exposed to high dose levels of radiation is an 
important predictive factor of the development of late toxicity [17]. Therefore, 
new techniques were developed in 3D-CRT and IMRT such as intra-prostatic 
implantation of gold markers and the use of electronic portal imaging systems 
for daily prostate position verification and correction procedures to decrease the 
margins of the radiation field [18-20]. By these means, dose escalation can be 
applied for bulky tumors as well.
An additional measure to confine toxicity in dose-escalated radiotherapy is to 
reduce the prostate volume with neoadjuvant androgen deprivation therapy. A 
target volume reduction of 30%–50% with androgen deprivation therapy may 
enable sparing of the surrounding normal tissues [21-23]. Some have shown that 
3 months of androgen deprivation can significantly reduce the rectal volume 
included in the target volume [21,23]. Others have described a clear volume 
reduction of the prostate of 40% after 6 months of androgen deprivation, whereas 
the mean rectal volume receiving high-dose radiation decreased only 20% [24]. 
Therefore, the exact impact of prostate volume reduction on rectal toxicity has 
still to be determined.
The optimal duration of androgen deprivation has been a matter of discussion, 
and LHRH agonists are usually given for 3 to 6 months prior to the start of radiation 
treatment. Lilleby et al. [25] reported that the maximal reduction of prostate volume 
is achieved after 9 months, although the most pronounced changes occurred 
during the first 3 months. They advocated an extended duration of neoadjuvant 
androgen deprivation of more than 6 months. In our study, we have confirmed that 
the most significant reduction of prostate volume occurs during the first 3 months 
of MAB. On the other hand, we have found a maximal prostate volume reduction 
after 6 months of MAB without a significant reduction beyond this period. For 
large prostates, this may justify an extended duration of MAB for 6 months. For 
small prostates, 3 months of MAB may in fact be enough for the achievement of 
maximal prostate volume reduction. Although some reports have shown patient 
groups with prostate sizes of > 60 cc as well the median pretreatment prostate 
volume in this study was large compared to most prior reported studies. Therefore, 
this group may not be representative for patients undergoing hormonal pre-
treatment in general.
We found no correlation between PSA, tumor grade, the percentage of positive 
biopsies, and prostate volume reduction. The numbers in this report are small 
though and further study about the influence of tumor characteristics on volume
reduction would be of interest.
The accuracy of CT scan for prostate delineation and volume measurement has 
been a matter of debate in the literature. CT derived prostate volumes are larger 
than MR derived volumes with an average ratio of 1.3 [26]. Therefore, the use of 
MRI for delineation of the prostate is recommended, but since CT-MRI matching 
is not routinely available in all institutes, CT scan is considered a good alternative 
[27]. One report has shown an overestimation of prostate volume measurement 
by CT scan compared to TRUS, although the discrepancy between CT assessed 
and TRUS assessed volumes decreased in large glands and was shown to be 
negligible in prostates > 40 cc [28]. Badiozamani et al. [29] found that CT scan did 
not overestimate prostate volume when compared to TRUS, even for prostates 
< 40 cc.
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In prostate brachytherapy reports 7%–69% of men that are treated for prostate 
cancer receive androgen deprivation therapy in some form. The goal is to 
downsize the prostate to make the brachytherapy procedure technically more 
feasible, although no substantial effects on disease-free survival are apparent, and 
treatment-related morbidity may be increased. For patients who were scheduled 
for brachytherapy, a more prominent volume reduction for large prostates was 
shown in one report [30], which is in agreement with our findings. The effect 
on volume reduction was greater with MAB versus LHRH agonists alone. All 
our patients were treated with MAB and we can therefore neither confirm nor 
invalidate these findings.
Lee et al. [31] describe that it is important to note that approximately 10% of men 
will have no significant prostate volume reduction under androgen deprivation 
therapy. In our cohort of patients, we found a consistent volume reduction in all 
patients during the first 6 months of MAB.
As a result of hormonal pretreatment, a delay between the initial diagnosis and 
the definitive treatment of localized prostate cancer occurs. In general, a delay 
of 3 months is considered to be without any clinical relevance. In daily practice, 
delay periods of more than 3 months are not unusual due to operation waiting 
lists and staging procedures. Whether this delay influences the outcome of these 
most often slowly growing tumors is an essential question. In literature, there is 
no consistent evidence found of a significant effect of surgical treatment delay 
on biochemical disease recurrence [32,33]. One study has shown an increased 
risk of biochemical progression in men with a delay of more than 6 months until 
surgery [34]. A treatment delay of no more than 6 months is therefore advocated. 
Others have not found a negative influence of treatment delay even for patients 
with a high risk of recurrence [35,36]. In one report, a delay beyond 9 months 
before radiotherapy was started did not seem to influence outcome [37], although 
another study showed that even a treatment delay of 2.5 months for high-risk 
disease adversely affected PSA outcome [38]. In all these studies about the impact 
of treatment delay, patients with neoadjuvant androgen deprivation were excluded 
from the analysis. In our opinion, a delay of 6 months from the initial diagnosis until 
definitive therapy for localized prostate cancer should not significantly influence 
outcome, especially under neoadjuvant androgen deprivation therapy.
Conclusions
A supra-additive interaction between androgen deprivation therapy and 
radiotherapy has been established for prostate tumors. The treatment outcome 
for external beam radiotherapy of localized prostate cancer is improved with dose 
escalation. A means to prevent increased toxicity is to downsize the prostate with 
androgen deprivation therapy.
In this study, we have evaluated the reduction of prostate volumes in patients 
who were assigned to MAB during 9 months before receiving external beam 
radiotherapy. The prostate volume measurements were done by repeated CT 
scan evaluations at 3-monthly intervals up to 9 months of MAB. The results of this 
limited series show that the maximal reduction of prostate volume was achieved 
after 6 months. The total prostate volume reduction was more pronounced for 
the cohort of patients with large prostates (> 60 cc) than for the group with small 
prostates (≤ 60 cc). The patient numbers in this study are small though. Especially 
for patients with small prostates, this comes with limitations in making conclusions 
about the required duration of androgen deprivation therapy.
By determining baseline prostate volumes, both radiation oncologists and 
urologists may have a tool to compose an individual treatment plan, and to adjust 
the duration of neoadjuvant androgen deprivation therapy according to prostate 
size. Taking into consideration the delay of definitive local treatment, we propose 
neoadjuvant androgen deprivation therapy of 6 months before radiotherapy. In 
small prostates, 3 months of hormonal treatment may be enough for maximal 
volume reduction.
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Abstract
Objectives: To analyze the predictive value of PSA for progression and the role 
of testosterone for quality of life (QOL) in patients with androgen deprivation 
therapy (ADT) for metastatic prostate cancer.
Materials and Methods: PSA and testosterone data were used from a phase III 
trial randomizing patients without progression and PSA < 4 ng/ml (n=193), after 
6 months induction course, between continuous (CAD) (n=96) and intermittent 
(IAD) (n=97) ADT. The 2-year risk of progression was calculated for baseline PSA, 
‘fast’ and ‘slow’ PSA decline to < 4 ng/ml (60 days cut-off), PSA nadir, performance 
status and pain. Testosterone kinetics and QOL were also evaluated. Univariate 
Kaplan Meier survival analysis and log rank tests were used to compare the risk of 
progression.
Results: For progression analysis, 173 patients’ data were available. The 2-year 
risk of progression for baseline PSA < 50 ng/ml, 50 to < 500 ng/ml, and ≥ 500 
ng/ml was 25%, 55%, and 76% (P = 0.03) in CAD, and 38%, 64%, and 85% 
(P = 0.006) in IAD, respectively. The 2-year risk of progression for PSA nadir ≤ 0.2 ng/
ml, and > 0.2 to 4 ng/ml in CAD was 31% and 70% (P < 0.001), respectively. In the 
IAD group, a similar trend was seen. Patients with PSA nadir ≤ 0.2 ng/ml, though 
had significantly higher 2-year risk of progression compared to CAD (53% vs. 31% 
(P = 0.03)), respectively. PSA decline showed no predictive value. Patients without 
pain had a significantly lower 2-year risk of progression in both groups. Without 
ADT testosterone remained at castrate level for 4 months. After the first and 
second IAD cycle 92% and 46%, respectively, had a normalized testosterone. No 
QOL difference was found, although more side effects occurred in CAD.
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Conclusions: Metastatic prostate cancer patients with high baseline PSA, pain, 
and high PSA nadir have a poor prognosis with ADT. Patients with low PSA nadir 
do significantly worse with IAD compared with CAD. Low testosterone after ADT 
and incomplete testosterone recovery may explain similar QOL. Therefore, IAD is 
not a good treatment option for many metastatic prostate cancer patients.
Introduction
The standard treatment for metastatic prostate cancer is androgen deprivation 
therapy (ADT) with a symptomatic and/or objective response in approximately 
80% of patients [1]. Because many patients are on ADT for several years, the 
toxicity plays an important role. The treatment is associated with several side 
effects, including hot flushes, loss of libido, erectile dysfunction, cognitive 
dysfunction, fatigue, depression, osteoporosis, gynaecomastia, anaemia, loss 
of muscle mass, and metabolic syndrome with an increased cardiovascular risk 
[2-4]. The concept of intermittent androgen deprivation therapy (IAD) has been 
developed in preclinical studies aiming at the delay of the castrate resistant state 
[5,6]. Another goal was the reduction of toxicity, during the off-treatment phase, 
and improvement of quality of life (QOL), which was shown for the first time in early 
clinical studies and was ascribed to the recovery of serum testosterone levels [7,8]. 
However, these results were preliminary and patient numbers were small. Indeed, 
the exact relation of changing testosterone levels during IAD and QOL has been 
discussed in few reports so far. The remaining question is whether it is possible 
to identify a subgroup of patients, based on certain disease characteristics, which 
could benefit from IAD. Since a recent study has shown that the PSA response 
on ADT is a strong predictor of survival [9], our hypothesis is that PSA may also 
facilitate to identify patients that are suitable for IAD.
The goals of this study are to analyze the predictive value of PSA levels for 
progression and the role of testosterone kinetics on QOL in patients with 
metastatic prostate cancer during continuous or intermittent hormonal treatment. 
Further, the influence of baseline performance status (PS) and pain on progression 
is assessed.
Continuous vs intermittent androgen deprivation therapy
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Patients and Methods
Study design
The data from the Therapy Upgrading Life in Prostate cancer (TULP) study are used 
for this analysis. The TULP study is a multicenter, open, randomized controlled 
trial in which 43 centers from 12 countries have participated. The study has been 
approved by an Independent Ethics Committee and the Institutional Review 
Boards of participating clinics. A written informed consent of each patient has 
been obtained. All patients who already had received hormonal treatment for 
prostate cancer or had a neoplasm other than non-melanoma skin cancer were 
excluded. Other exclusion criteria were hepatic or renal dysfunction and the 
use of medication interfering with the interpretation of therapy results. Previous 
radiation therapy or surgery of the prostate was allowed. The primary objective 
of the original study was to determine whether time to clinical progression during 
IAD is equivalent to time to clinical progression during continuous androgen 
deprivation (CAD) in metastatic prostate cancer patients. Secondary objectives 
were to determine QOL, side effects, and overall survival.
Patients were included between January 1998 and September 2001 and the 
median follow-up from randomization was 31 months (range 0.8 – 47 months). 
Eligible patients had histologically proven prostate cancer with positive lymph 
nodes or distant metastases (T2-4N1-3M0 or T2-4NxM1), an Eastern Cooperative 
Oncology Group (ECOG) performance score of 0–2, and a general life-expectancy 
of at least 18 months. A total of 290 patients were enrolled and received the study 
medication. 
Patients were treated for a 6-month induction course of maximal androgen 
blockade (MAB) consisting of busereline 6.6 mg (Suprefact), a 2-monthly 
subcutaneous depot, and oral nilutamide 300 mg (Anandron) (once a day for the 
first 4 weeks and 150 mg daily thereafter). At the end of the induction course, 
patients without clinical progression and a PSA level < 4 ng/ml (n=193) were 
centrally randomized between CAD (n=96) and IAD (n=97). Non-responding 
patients (n=97), who either failed to achieve or maintain PSA < 4 ng/ml during 
the induction course or had clinical progression, were excluded from the study 
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protocol and were not followed for survival. These patients were treated off-
study according to the treating physician’s choice. At the time of study design 
(mid-1990s), there was little experience with IAD. The rationale for randomizing 
patients who reached a PSA threshold < 4 ng/ml was empirical and based on 
preliminary reported data. Also, the moment of reinstitution of androgen 
deprivation during off-therapy intervals when a PSA rise ≥ 10 ng/ml (M0 disease 
at baseline) or ≥ 20 ng/ml (M1 disease at baseline) occurred, was chosen on the 
basis of available data. In patients randomized for IAD, the ADT was discontinued 
and reinstituted when PSA reached the aforementioned values. Each subsequent 
IAD cycle consisted of a variable period of MAB, until PSA level reached < 4 ng/
ml again, and an off-treatment phase. In both randomization groups, MAB was 
administered continuously once clinical progression occurred. Patients were 
provided with medication during the study protocol, consisting of a maximum of 
three cycles of IAD. Clinical progression was assessed according to the European 
Organization for Research and Treatment of Cancer (EORTC) criteria used in the 
1990s (Table 1) [10]. PS was scored at months 2, 4, 5, and 6, and 2-monthly after 
randomization. Clinical evaluation for tumor stage or progression was performed 
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Table 1
EORTC criteria (1989) for clinical progression in prostate cancer
Progression
-  Any lesion increases in size or any new lesion appears, regardless of what the 
response of the other lesions has been
- Increase in any measurable deposit by more than 25%
- Increase in volume of primary tumor by more than 50%
-  Significant deterioration in symptoms, decrease in weight, or decrease in  
performance status
-  Increase in acid or alkaline phosphatase alone is not to be considered an  
indication of progression
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at randomization and 6-monthly thereafter or as clinically indicated until the 
end of the study. Tumor dimension assessment was performed by digital rectal 
examination or transrectal ultrasonography and radiological evaluation by bone 
scan, chest X-ray, ultrasonography or computerized tomography of the abdomen. 
QOL assessment was done with the EORTC general health related quality of life 
questionnaire (EORTC QLQ-C30-version 2.0). Also a validated disease specific 
questionnaire (EORTC module for prostate cancer, QLQ-PR24) was used. Every six 
months, plus at month 8, patients filled out these questionnaires. Laboratory tests 
were performed 2-monthly at an independent central laboratory (Bio-Inova Life 
Sciences International, Plaisir, France) and contained a hematologic and chemistry 
profile, including PSA and testosterone values. The post-study analysis of PSA and 
testosterone values in 2010 has been performed by an independent biostatistician 
(B.S.) at Factum Statistics (Offenbach/Main, Germany).
Statistical analysis methods
The objective of this analysis is to determine if PSA values are predictive for 
progression in men treated with ADT and to identify patients that are suitable for 
IAD. The variables studied were dichotomized for analysis of clinically relevant 
thresholds: (1) baseline PSA value at enrolment; (2) PSA decline to < 4 ng/ml 
during the induction course, divided into ‘fast’ decline and ‘slow’ decline, with 
a cut-off of 60 days; and (3) PSA nadir value after the induction course to either 
≤ 0.2 ng/ml or > 0.2–4 ng/ml. The influence of baseline PS and pain medication 
on progression rates was also evaluated. A 2-year risk of progression could be 
calculated from the follow-up data. Further, testosterone kinetics during ADT and 
the subsequent correlation with QOL during CAD and IAD were analyzed.
Cox proportional hazard regression analyses of time to clinical progression by 
randomization group showed that the proportional hazards assumption was not 
met based on visual inspection and scaled Schoenberg residuals. Parametric 
multivariate regression analysis subsequently showed no differences in incidence 
rate ratios comparing the two randomization groups with or without adjustments 
for pretreatment cancer type (distant metastasis: yes or no), pretreatment 
performance status (increase of 1 category on WHO scale), and pretreatment 
pain medication (increase of 1 category on pain scale). Therefore, we decided 
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to use univariate Kaplan-Meier survival analysis and log rank tests to visualize 
and compare the risk of clinical progression for all predictive factor analyses. 
Differences between the 2 treatment groups were tested for statistical significance 
by calculating a log rank test or X² test. The analyses were performed with the 
Statistical Analysis System (SAS, Cary, NC) ver. 8.2 and the statistical software SPSS 
for Windows (release 15.0.0) SPSS Inc., Chicago, IL. No corrections or adjustments 
were made for missing data.
Results
Patients’ characteristics
Patient demographics and medical history showed no differences between 
randomization groups, except for age [in the IAD (n=97) group 66.8 years (SE 0.8); in 
the CAD (n=96) group 69.1 years (SE 0.8)]. This difference was considered clinically 
irrelevant for the risk of progression, since age is not a known prognostic factor 
for efficacy during hormonal therapy. Tumor characteristics in the randomized 
patient groups were similar, except for the number of distant metastases with 
more multiple, mainly bone metastases in the CAD group (Table 2). The non-
responder group (n=97) was excluded from further analysis. This non-responder 
group showed more T4 tumors compared with the randomization group (33% 
vs. 17%, respectively). Also, a worse baseline PS and more painful metastases 
were seen. Close accountability of study drug consumption during the hormonal 
therapy intervals confirmed the good compliance with treatment. Because of 
protocol violation in 5 patients, testosterone analyses could be performed for the 
remaining 188 patients. For the calculation of the predictive value for progression 
of PSA, 20 patients of the initial 193 were lost to follow-up (13 in the CAD group; 
7 in the IAD group), leaving 173 patients for analysis.
PSA values
In Table 3, the 2-year risk of progression for all evaluated predictive factors is 
shown. Considering baseline PSA, a significant difference was seen in the 2-year 
risk of progression for higher PSA values in both the CAD group (Log rank: 
P = 0.03) and the IAD group (P = 0.006). The associated Kaplan-Meier curves are 
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Not 
randomized 
group (n=97)
CAD 
(n=96)
IAD 
(n=97)
X2 test (P)
Tumor stage
T1 - 1
P = 0,79
T2 15 25 27
T3 50 54 51
T4 32 15 18
Tx 2 0
N0 40 44 39
P = 0,51N1-3 36 38 38
Nx 21 14 20
M0 11 19 18
P = 0,97
M1 86 77 79
Distant metastases
Single 4 7 20
P = 0,013
Multiple 82 70 59
Bone 85 74 71
P = 0,60Visceral 6 1 3
Missing 7 5 11
Gleason
2-4 9 13 13
P = 0,60
5-7 44 47 40
8-10 43 35 41
Gx 1 1 3
Not 
randomized 
group (n=97)
CAD 
(n=96)
IAD 
(n=97)
X2 test (P)
PSA
Median (ng/ml) NA 108  
(11-8173)
98 
(7-3006)
P = 0,58 *
Testosterone 
Median (ng/ml) NA 4.0 
(1.8 - 8.0)
4.1 
(1.4 - 8.5)
P = 0,55 *
ECOG
0 35 70 72
P = 0,951 42 19 19
2 20 7 6
Pain medication
No analgesics 55 76 76
P = 0,94
Non-narcotic analgesics 
irregular use
17 9 10
Non-narcotic analgesics 
regular use
11 7 6
Narcotic analgesics  
irregular use
4 2 3
Narcotic analgesics 
regular use
10 2 2
Table 2
Tumor characteristics at enrolment. (table 2, continued)
T = tumor; N = lymph node metastases; M = distant metastases;  
PSA = prostate specific antigen; ECOG = Eastern Cooperative Oncology Group;  
NA = not available.
X2 test for statistical analysis of differences between randomization groups (P value).
* Mann-Whitney U-test.
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shown in Figure 1. To estimate the influence of PSA decline on clinical outcome, 
the 2-year risk of progression was calculated for the ‘fast’ and ‘slow’ decline groups 
in both randomization groups. No significant differences were seen per group. 
Concerning the CAD group, the predictive role of PSA nadir was evaluated, and 
a significantly lower 2-year risk of progression was seen for PSA nadir ≤ 0.2 ng/
ml compared with PSA > 0.2–4 ng/ml (Log Rank: P < 0.001). For the IAD group 
a difference was seen, but numbers were not statistically significant (P = 0.31). 
Overall, patients with IAD showed a trend of higher progression rates compared 
to CAD, but the only significant difference was seen in patients with PSA nadir 
≤ 0.2 ng/ml with a 2-year risk of progression of 53% vs. 31% (P = 0.03), respectively. 
Patients without pain medication at enrolment had a significantly lower 2-year risk 
of progression in both groups. Patients without physical impairments seemed to 
do clinically better than the impaired ones but differences were not statistically 
significant. 
Testosterone kinetics
After 2 months of the induction course, the median testosterone value was 0.2 ng/
ml in both randomization groups. All patients had reached castrate testosterone 
(< 0.5 ng/ml) levels within 4 months of MAB and the median time to reach the PSA 
nadir was 4 months. In the CAD group, the median serum testosterone remained 
stable at castrate level (0.2 ng/ml) during the complete study period. The median 
serum testosterone in the IAD group started to rise above 0.2 ng/ml at 10 months 
to normal levels at 12 months, i.e., 8 months after the last busereline injection. 
From 12 months onwards, testosterone levels were fluctuating, showing the nature 
of IAD. In every cycle, after reintroduction of ADT, the median time to reach the 
nadir testosterone level was consistently 2 months.
The mean duration of the first IAD cycle was 19 months, with an off-treatment 
interval of 13 months. During this interval, the mean duration of castrate 
testosterone level was 7 months, and patients had a normal testosterone for 6 
months. The percentage time off-therapy decreased with successive cycles (Table 
4). During the off-treatment intervals of cycles 2 and 3, the mean duration of 
castrate testosterone level was 4.7 months and 1.2 months, respectively. In the 
remaining time of these intervals, patients had a normal testosterone, but the 
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Predictive factor CAD (n=83) IAD (n=90) Log rank  
test (P)
PSA baseline
< 50 ng/ml 25%  (± 8.9) 38%  (± 9.7) P = 0.41
50 - < 500 ng/ml 55%  (± 10.6) 64%  (± 8.3) P = 0.82
≥  500 ng/ml 76%  (± 18.0) 85%  (± 13.1) P = 0.20
P = 0.03 P = 0.006
PSA decline to < 4 ng/ml
Fast 47%  (± 10.4) 61%  (± 9.8) P = 0.31
Slow 47%  (± 8.5) 57%  (± 8.1) P = 0.62
P = 0.64 P = 0.96
PSA nadir
≤  0.2 ng/ml 31%  (± 8.3) 53%  (± 7.6) P = 0.03
> 0.2 – 4 ng/ml 70%  (± 9.5) 68 %  (± 10.6) P = 0.11
P < 0.001 P = 0.31
Performance status
No physical impairment 43%  (± 8.6) 53%  (± 6.9) P = 0.32
Restricted 67%  (± 12.2) 76%  (± 11.6) P = 0.82
P = 0.11 P = 0.12
Pain
No analgesics 39%  (± 8.0) 50%  (± 6.8) P = 0.21
Analgesics 79%  (± 10.4) 80%  (± 11) P = 0.97
P < 0.001 P < 0.01
Table 3
Two-year risk of progression (percentage ± SE) for predictive factors.
Fast decline PSA < 60 days; slow decline PSA ≥ 60 days. SE = standard error.
Log rank test for statistical analysis of differences between randomization groups (P value).
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duration was negligible. When ADT was reintroduced, at the end of the first cycle, 
92% of patients had a normalized serum testosterone. This means that 8% had 
castrate levels of testosterone and rising PSA. At the end of the second cycle, the 
number of patients with castrate testosterone levels and rising PSA was 46%.
QOL
Overall, there was no clinically significant difference in QOL scores between 
patients. Further, no consistently significant difference for any single QOL 
Chapter 8
parameter was found between the treatment groups (data not shown). As required 
for valid analyses, across all patients, more than 70% of QOL scale scores were 
available, indicating a reliable QOL assessment. A large number of patients had 
one or more concurrent side effects during treatment (Table 5); 91 (95%) in the 
CAD group and 88 (91%) in the IAD group. Overall, a trend of more side effects 
like hot flushes, nausea, constipation, dyspnea, and depression was seen in CAD 
patients.
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Figure 1a
Kaplan-Meier curves of clinical progression in IAD for different baseline PSA levels.
Figure 1b
Kaplan-Meier curves of clinical progression in CAD for different baseline PSA levels.
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Table 4
Duration treatment intervals and testosterone levels during IAD.
Cycle 1
(n=97)
Cycle 2
(n=51)
Cycle 3
(n=13)
Time on-therapy (months)
Mean ± SD 6 ± 0.5 4,5 ± 2.9 3,8 ± 3
Time off-therapy (months)
Mean ± SD 13 ± 6 5 ± 5 0,6 ± 1,2
Percentage time off-therapy (%)
Mean ± SD 65 ± 14 40 ± 34 14 ± 24
Total cycle duration (months)
Mean ± SD 19 ± 5.9 9,5 ± 4.9 4,5 ± 2.9
Castrate testosterone 
(< 0.5 ng/ml) during  
off-treatment interval (months)
Mean ± SD 7 ± 2.8 4,7 ± 3.9 1,2 ± 1.5
SD = standard deviation.
Table 5
Side effects
 No. pts. (%) 
Events CAD (n=96) IAD (n=97)  X2 test (P)
Hot flushes 57 (59) 49 (50) P = 0,28
Visual disturbances 32 (33) 32 (33) P = 0,92
Nausea 19 (20) 11 (11) P = 0,15
Constipation 16 (17) 7 (7) P = 0,07
Dyspnea 12 (12) 6 (6) P = 0,20
Erectile dysfunction 10 (10) 9 (9) P = 0,98
Depression 11(11) 6 (6) P = 0,30
Liver enzyme increase 5 (5) 8 (8) P = 0,58
Gynaecomastia 7 (7) 4 (4) P = 0,52
Anaemia 5 (5) 4 (4) P = 0,99
Alcohol intolerance 4 (4) 3 (3) P = 0.99
X2 test for statistical analysis of differences between randomization groups (P value).
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Discussion
In this study, comparing intermittent to continuous ADT for metastatic prostate 
cancer, the predictive value of PSA for progression and the role of testosterone 
kinetics on QOL were assessed. It is shown that high baseline PSA, pain, and high 
PSA nadir, after a 6-month induction course, are strong predictors of progression 
with hormonal therapy. Therefore, in these patients research should focus on 
alternatives for hormonal treatment. Overall, the negative impact on the risk of 
progression for all predictive values was more outspoken in the IAD group.
Consistent with our results, Prapotnich et al. [11] showed in a cohort study that 
patients with initial bulky tumors, numerous lymph nodes or bone metastases, 
baseline PSA > 100 ng/ml, rapidly progressive PSA slope (> 5 ng/ml per month), 
or severe pain are poor candidates for IAD, because they frequently achieve 
only a partial or short-term response. In the Finnish multicenter study [12] for 
intermittent therapy, patients with high baseline PSA and alkaline phosphatase, 
T4 and poorly differentiated cancers, and metastatic disease with more than 5 
skeletal hotspots showed inadequate initial PSA response to ADT and were not 
considered good candidates for IAD. These patients with initial bad response to 
ADT were excluded from our study, leading to a selection bias towards relatively 
good prognosis patients. Intermittent therapy may be more useful in early stage 
disease, i.e., localized or local recurrent disease as already discussed by Grossfeld 
and associates [13].
Using data from the Southwest Oncology Group Trial 9346, Hussain et al. [9] 
evaluated the absolute PSA value after 7 months of ADT and found that 69% 
of patients had a PSA < 4 ng/ml at the end of the induction course, which is 
similar to our findings (67%). The PSA nadir appeared to be a strong independent 
predictor of survival in metastatic prostate cancer, with a median survival of 13 
months for patients with PSA of > 4 ng/ml, 44 months for PSA > 0.2 to ≤ 4 ng/
ml, and 75 months for PSA ≤ 0.2 ng/ml. In our study, patients with PSA nadir ≤ 0.2 
ng/ml showed lower progression rates than PSA nadir > 0.2 to 4 ng/ml. It also 
appeared that IAD patients with low PSA nadir had significantly higher 2-year risk 
of progression than CAD patients. Therefore, these patients do not seem to be 
good candidates for IAD. To our knowledge, this finding has not been reported 
before and supports CAD treatment for good-responders on ADT induction.
Considering testosterone kinetics and QOL, two phase II studies on intermittent 
therapy have supported that testosterone levels normalize in many, but not all, 
patients when they are off-therapy [14,15]. After 6 months of luteinizing hormone-
releasing hormone (LHRH) analogue treatment, 90% of patients had a normalization 
of testosterone level within 18 weeks [14]. A median 12.9 weeks was needed for 
recovery of testosterone above castrate level, and older patients needed more 
time for recovery. Tunn et al. [15] found a normalization of testosterone in 91% of 
patients at the end of the first treatment cycle, and less recovery of testosterone 
levels in subsequent cycles. These results are similar to our findings. In our series, 
a median 4 months was needed for testosterone to rise above castrate level 
after the induction course. After median 6 months, normal levels were reached. 
This relatively slow recovery of testosterone may be explained by high age and 
a prolonged release of the busereline implant. A testosterone suppression of 
minimal 6 months was already proven for a 3-month implant 9.45 mg [16].
The majority of phase II studies have shown that IAD regimens have promising 
toxicity profiles as a result of testosterone recovery eliminating the side effects of 
ADT. Early phase III results suggested a better toxicity profile and also QOL [17], 
particularly with respect to sexual function. Not all studies have demonstrated 
between-group differences for QOL [18]. A Cochrane review commented that IAD 
appears to be slightly better than CAD in terms of reducing the levels of erectile 
dysfunction [19]. In our study, a bias is seen in sexual function measurement as very 
few patients had erections at baseline, after previous surgery, or radiation therapy. 
No differences for QOL were seen at the time of first measurement (month 8). At 
the second measurement (month 12), although testosterone levels in IAD were 
rising, the median testosterone had still not fully recovered and there were no 
QOL differences. The next QOL measurement was performed at 18 months, when 
most patients had normal serum testosterone levels. Interestingly, even then, no 
significant difference in any QOL parameter was measured. The reason for this is 
unclear, but may be due to high age and better acceptance of side effects. In another 
study, evaluating the general health-related QOL of 250 patients treated with IAD, 
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a trend of progressive improvement paralleling testosterone recovery was shown 
[20]. However, the rate of recovery was slower than the rate of deterioration during 
ADT and the maximum recovery was seen only after 9–12 months. In general, by 
using the PSA limits that we used for re-starting of hormonal therapy, the recovery 
time for testosterone may be simply too short to detect an improvement in QOL. 
In successive cycles of our study, the off-therapy interval became shorter, leading 
to less recovery time for testosterone. Numbers of patients with a normalized 
testosterone at the end of each cycle therefore decreased.
In our study, the specific moment of side effects occurring was not analyzed 
but overall a trend of more side effects in CAD patients was seen. This favors 
intermittent therapy, although some of the toxicity like dyspnea and visual 
disturbances were specifically nilutamide-related and may be less prominent 
with other anti-androgens. These side effects, though, certainly affect QOL in 
an adverse way. It still remains unclear whether IAD can prevent long-term side 
effects of ADT and this needs further study. Another obvious advantage of IAD is 
economical, with our patients being off-therapy 40% of the time.
Our study has several limitations: Although only two large phase III trials with more 
than 500 patients were reported [9,18], this is a relatively small study with 193 
randomized patients and consequently limited statistical power. The intermediate 
follow-up duration (31 months) makes an evaluation of cancer-specific survival 
impossible, as only a few patients had died and, therefore, clinical progression 
was chosen as the endpoint for the predictive value analysis. Clinical progression 
was measured with the EORTC criteria that were introduced in 1989 [10]. Most 
metastatic patients have disease limited to the bone, which is notoriously difficult 
to assess for response. Therefore, future trials should include other criteria for 
progression, including, for instance, time to PSA progression according to the 
Prostate Cancer Working Group criteria for castrate resistant prostate cancer [21]. 
One should realize that although the association of biochemical progression and 
overall survival in metastatic prostate cancer has been confirmed at the individual 
patient level during hormonal therapy, PSA as surrogate endpoint for overall 
survival could not be statistically validated in trials of hormonal treatment [22]. The 
analysis of PSA and testosterone was not part of the original study protocol, which 
explains why these results are reported late. The progression data of 20 patients 
were lost to follow-up and although unfortunate, these numbers do not seem to 
influence the results. PSA and testosterone measurements, and QOL assessments 
were performed at fixed 2-monthly and 6-monthly intervals, respectively. This 
monitoring frequency interferes with a more detailed analysis of PSA decline during 
hormonal treatment and the assessment of the exact correlation of testosterone 
kinetics and QOL.
The empirical choice of reinstituting ADT based upon a static PSA number rather 
than PSA kinetics could bias towards undertreatment of more aggressive cancers, 
and this is limiting the study. On the basis of a meta-analysis of IAD [23], showing 
a longer survival in patients in whom treatment was re-started when PSA level 
reached 15 ng/ml than in whom it was allowed to rise higher, our criteria may also 
need adjustment on the expense of less time for testosterone recovery.
Conclusions
Metastatic prostate cancer patients with high baseline PSA, pain, and high PSA 
nadir, after a 6-month induction course, have a poor prognosis with hormonal 
therapy. Overall, in this study patients on IAD seem to do worse than CAD. Also, 
IAD patients with low PSA nadir had significantly higher progression rates than 
CAD. After the induction course, serum testosterone values remain at castrate 
level for 4 months and testosterone recovery during the off-treatment phase is 
incomplete. This may explain why no benefit for QOL was found for IAD, even 
though more side effects occurred during CAD. Therefore, IAD is not a good 
treatment option for many metastatic prostate cancer patients.
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Chapter 9 Summary
Prostate cancer is diagnosed in more than 9.000 men in the Netherlands each year. 
A shift is seen towards younger age and more cancers are treated at an early stage. 
Ultimately, this may improve cancer specific survival but currently this remains 
uncertain. A downside of aggressive treatment of the patient are the associated 
side effects, which should be considered when treatment is discussed. The aim of 
this thesis is to evaluate the developments in prostate cancer treatment that focus 
on improving complication rates without compromising the oncological outcome.
In chapter 2 the development of high-precision radiotherapy with the aid of fiducial 
gold markers is described. Clinical trials have shown a dose-response relationship 
in radiotherapy for prostate cancer. However, dose escalation potentially increases 
toxicity of the surrounding tissues, e.g. bladder, rectum, and anal canal by the 
high-dose exposure. The prostate is a moving organ with a few millimeters 
displacement on a day-to-day basis. Together with the patient set-up variations 
this demands certain treatment margins around the gland for adequate coverage 
of the target organ. Intraprostatic gold markers have an excellent visibility on daily 
electronic portal images during radiotherapy. This enables precise verification 
and correction of the prostate position, and smaller treatment margins. In this 
study, the influence of gold markers on treatment volume and radiation doses 
to surrounding tissues was investigated. Three historical treatment margins were 
reconstructed to show the reduction of Planning Target Volume: PTV 10 mm (no 
markers), PTV 7 mm (markers), and PTV 7/5 mm (markers and online correction). 
With the planning computed tomography (CT) scan system the treatment volume 
and radiation doses were calculated. A significant PTV reduction of 27% was 
achieved with gold markers. Subsequently, mean radiation dose reductions of 17% 
(±4.5%) to the bladder, 19% (±4.7%) to the anal canal and 12% (±3%) to the rectal 
wall were seen. Although it seems reasonable to presume that gold markers have 
a favorable impact on late toxicity profiles, this needs further clinical studies.
As the procedure of gold marker implantation is invasive, it can only be justified 
if complication rates are low. Therefore, in chapter 3 complication rate and risk 
factors of transrectally implanted gold markers are analyzed. In 209 consecutive 
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men with localized prostate cancer, four fine gold markers were inserted under 
ultrasound guidance, and the side effects were analyzed with questionnaires. 
Thirteen men (6.2%) had a moderate complication, consisting of pain and fever 
that resolved with oral medication. In 1.9% of men, minor voiding complaints were 
observed. Other minor transient complications, such as hematuria more than 3 
days, hematospermia, and rectal bleeding, occurred in 3.8%, 18.5%, and 9.1%, 
respectively. Complications were seen more often in patients with advanced tumor 
stage, younger age, and shorter duration of hormonal therapy. In conclusion, the 
transrectal gold marker implantation is safe and well tolerated.
A potential curative treatment option for a biochemical recurrence after radical 
prostatectomy is salvage radiotherapy of the prostate bed. Also, patients with 
positive surgical margins and high-risk disease benefit from adjuvant radiotherapy. 
For these specific patient groups, image-guided radiotherapy with gold markers 
in the prostate bed and electronic portal imaging has been introduced recently. 
No large series have been described yet and experience with the implantation 
procedure is therefore limited. In chapter 4, the technique and complication rate of 
post prostatectomy ultrasound-guided transrectal implantation of gold markers are 
described. In 77 consecutive men with a biochemical recurrence or positive surgical 
margins after radical prostatectomy, and high-risk prostate cancer, three fine gold 
markers were implanted in the prostate bed. The feasibility of marker implantation 
was analyzed and marker migration was recorded with imaging. For complication 
rate measurement, the patients filled out questionnaires. Minor complications were 
rectal bleeding for one day in ten patients (13%), and voiding complaints in one 
patient. Moderate complications, like rectal discomfort resolving spontaneously 
within 7 days (n=2), nausea for two days (n=1), abdominal discomfort (n=1), and 
pain requiring analgesics (n=4), were seen in 8 patients (10%). The mean VAS score 
during implantation was 3.7 on a scale of 1 to 10. Postoperative strictures, which 
were considered to be a surrogate for fibrosis in the operation field, did not cause 
significant more pain during implantation. Transrectal gold marker implantation in 
the prostate bed, as part of post prostatectomy radiotherapy, is therefore feasible 
and safe. Pain is slightly more prominent, especially in younger patients, than with 
intraprostatic gold markers and analgesics could be advocated. No risk factors 
were found for bleeding or pain.
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In chapter 5, a literature review is given after a Pub med search for data on primary 
and salvage cryosurgery of the prostate. It appeared that the introduction of gas-
based third-generation cryotechnology has decreased side effects significantly, 
with similar oncological results compared to older cryosurgery techniques. The 
occurrence of severe complications like rectourethral fistulas (< 1%) has almost been 
eradicated, but the rates of erectile dysfunction remain high (90%). With salvage 
cryosurgery more side effects can be expected with an average incontinence 
rate of 8%, and fistulas up to 3.4%. Nevertheless, this minimal invasive treatment 
remains an option for radiotherapy recurrent prostate cancer because salvage 
prostatectomy has a high complication rate. However, the current cryosurgery data 
in literature are of low-level evidence which should be discussed when counseling 
the patients. Focal cryosurgery is considered experimental, but is an interesting 
new development in cryosurgery to improve complication rates. The performance 
of randomized trials with long-term follow-up should be advocated to define the 
ultimate role of cryosurgery in the treatment of localized prostate cancer.
Chapter 6 offers a review on the role of androgen deprivation therapy (ADT) in 
the neoadjuvant and intermittent setting. This chapter is the introduction to the 
clinical studies that are discussed in chapters 7 and 8. For locally advanced prostate 
cancer and high-risk patients neoadjuvant hormonal therapy gives better local 
tumor control and disease-specific survival when it is combined with radiotherapy 
compared with radiotherapy alone. Therefore, it should be considered standard 
care for these patients. The necessary duration of hormonal pretreatment, however, 
is a matter of debate and lies in between 3–6 months. The role of neoadjuvant 
ADT before surgery is limited. In patients with advanced or metastatic prostate 
cancer intermittent hormonal therapy has been proven feasible. Progression-free 
survival seems comparable with patients on continuous ADT. The off-treatment 
intervals lead to a reduction of costs and an improvement of sexual function, 
and sometimes quality of life. The effect of intermittent therapy on long-term 
complications of hormones, for instance osteoporosis and metabolic syndrome, 
is unknown. Chapter 7 deals with the optimal duration of neoadjuvant ADT for 
prostate volume reduction before radiotherapy. In very large prostates, ADT 
before radiotherapy can downsize the prostate for improvement of dosimetric 
parameters, and a reduction of radiation dose to surrounding tissues. Twenty 
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consecutive patients with cT2-3No/xMo prostate cancer, who were scheduled for 
radiotherapy, were treated with 9 months of neoadjuvant ADT. Repeated CT scan 
examinations for prostate volume measurement were performed 3-monthly until 
the start of radiation therapy. The baseline median volume was 82 cc, with a median 
reduction of 31% after 3 months of ADT. Between 3 and 6 months, an additional 
median volume reduction of 9% was observed. The effect was more pronounced 
in large prostates (> 60 cc). After 6 months no significant reduction of volume 
was seen. From this study we have concluded that the most significant volume 
reduction is achieved after 3 months of ADT, and the maximum reduction after 6 
months. Therefore, the optimal duration of neoadjuvant ADT for prostate volume 
reduction seems 6 months. In chapter 8 the predictive value of PSA for progression, 
and the role of testosterone for QOL in patients on continuous or intermittent 
ADT for metastatic prostate cancer are described. As expected, patients with high 
baseline PSA, pain, and high PSA nadir appear to have a poor prognosis with ADT. 
Furthermore, even patients with a low PSA nadir, after a 6-month induction course 
of maximal androgen blockade, did significantly worse on intermittent therapy 
than on continuous ADT. Also, testosterone level remains low for long periods 
of time after withdrawal of hormones. The incomplete testosterone recovery, 
after a 6-month induction course, may explain why quality of life (QOL) was not 
improving in the off-treatment phase. Although more side effects were seen in 
the continuous treatment group no QOL differences were found between groups. 
Therefore, intermittent hormonal therapy seems a suboptimal treatment option 
for many metastatic prostate cancer patients.
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Hoofdstuk 9 Samenvatting
In Nederland wordt jaarlijks bij meer dan 9.000 mannen prostaatkanker 
geconstateerd. Er is een trend waarneembaar naar het diagnostiseren op 
jongere leeftijd en vaker worden de tumoren in een vroeg stadium behandeld. 
Uiteindelijk zal dit mogelijk de kankerspecifieke overleving verbeteren, maar 
momenteel is dat nog onvoldoende duidelijk. De keerzijde van agressief 
behandelen is dat er bijwerkingen te verwachten zijn voor de patiënt die altijd 
meegewogen moeten worden tijdens de bespreking van het behandelvoorstel. 
Het doel van dit proefschrift is een evaluatie te verrichten van de ontwikkelingen in 
prostaatkankerbehandeling die zich richten op de vermindering van complicaties 
met behoud van de oncologische resultaten.
In hoofdstuk 2 wordt de ontwikkeling van ‘high-precision’ radiotherapie met 
behulp van goudmarkers beschreven. Uit klinische studies is een dosis-respons 
relatie gebleken voor radiotherapie van prostaatcarcinoom. Dosis-escalatie 
kan mogelijk echter door de blootstelling aan hoge doses de toxiciteit van de 
omliggende weefsels, zoals de blaas, het rectum en anale kanaal verhogen. 
Bovendien is de prostaat een bewegend orgaan dat dagelijks een paar millimeter 
verplaatst. Samen met de variaties in positionering van de patiënt vergt dit 
bepaalde behandelmarges rond de prostaat voor een adequate dekking van 
het doelorgaan. Goudmarkers in de prostaat zijn uitstekend zichtbaar op de 
dagelijkse elektronische ‘portal images’ tijdens de bestraling. Hierdoor zijn 
een exacte verificatie en correctie van de prostaatpositie en daardoor kleinere 
marges mogelijk. De invloed van goudmarkers op het behandelvolume en op de 
bestralingsdosis van de omliggende weefsels werd in deze studie onderzocht. 
Om de afname van het planning doelvolume (PTV) te tonen werden drie in de 
historie gebruikte behandelingsmarges gereconstrueerd: PTV 10 mm (zonder 
goudmarkers), PTV 7 mm (met markers) en PTV 7/5 mm (met markers en online 
correctie). Het behandelingsvolume en de bestralingsdoses werden met 
het computertomografie (CT) scanningsysteem berekend. Door het gebruik 
van goudmarkers werd een significante afname van PTV van 27% bereikt. 
Dientengevolge werd ook een afname gezien in de gemiddelde bestralingdosis 
van 17% (±4.5%) van de blaas, 19% (±4.7%) van het anale kanaal en 12% (±3%) van 
het rectum. Hoewel het zeer aannemelijk is te veronderstellen dat goudmarkers 
een positief effect hebben op de late toxiciteit van bestraling dient dit verder 
onderzocht te worden in klinische trials.
Aangezien de goudmarkerimplantatieprocedure invasief is, is deze alleen te 
rechtvaardigen als de complicaties hiervan gering zijn. In hoofdstuk 3 worden 
daarom de complicaties en de risicofactoren voor complicaties van transrectaal 
geïmplanteerde goudmarkers geanalyseerd. Bij 209 opeenvolgende mannen 
met gelokaliseerd prostaatcarcinoom werden onder echogeleide vier kleine 
goudmarkers geplaatst en de complicaties hiervan werden geanalyseerd met 
vragenlijsten. Bij 13 mannen (6.2%) kwam een matig ernstige complicatie voor 
die bestond uit pijn of koorts die kon worden behandeld met orale medicatie. 
Bij 1.9% van de mannen werd een geringe mictieklacht gezien. Andere geringe 
voorbijgaande complicaties zoals hematurie meer dan 3 dagen, hematospermie 
en rectaal bloedverlies kwamen voor bij respectievelijk 3.8%, 18.5% en 9.1% van 
de mannen. Bij patiënten met een uitgebreid tumorstadium, jonge leeftijd en 
korte duur van de hormonale behandeling werden vaker complicaties gezien. De 
conclusie is dat de transrectale implantatie van goudmarkers veilig is en goed 
wordt verdragen door de patiënt.
Een potentiële curatieve behandelmogelijkheid van een biochemisch lokaal 
recidief na radicale prostatectomie is ‘salvage’ radiotherapie van de prostaatloge. 
Patiënten met positieve snijvlakken en een hoogrisico prostaatcarcinoom hebben 
voordeel van adjuvante radiotherapie. Voor deze specifieke patiënten is recent 
de beeldgeleide radiotherapie geïntroduceerd met goudmarkerimplantatie 
in de prostaatloge en elektronische ‘portal imaging’. De ervaring met deze 
implantatietechniek is beperkt en er zijn vooralsnog geen grote series 
beschreven. In hoofdstuk 4 worden de techniek en het aantal complicaties van 
echogeleide transrectale implantatie van goudmarkers na radicale prostatectomie 
beschreven. Bij 77 opeenvolgende mannen met een biochemisch recidief of 
positieve chirurgische snijvlakken na een radicale prostatectomie en hoogrisico 
prostaatkanker werden 3 kleine goudmarkers geïmplanteerd in de prostaatloge. 
De haalbaarheid van markerplaatsing werd geanalyseerd en de markermigratie 
werd gescoord met behulp van beeldvormende technieken. De patiënten vulden 
SamenvattingHoofdstuk 9
160 161
vragenlijsten in voor de registratie van het aantal complicaties. Weinig ernstige 
complicaties waren onder meer rectaal bloedverlies gedurende een dag bij 10 
patiënten (13%) en mictieklachten bij een patiënt. Weinig ernstige complicaties 
zoals een ongemakkelijk gevoel rectaal met spontaan herstel binnen 7 dagen 
(n=2), misselijkheid gedurende twee dagen (n=1), een ongemakkelijk gevoel in 
de buik (n=1) en pijn waarvoor pijnstillers noodzakelijk waren (n=4) werden bij 
8 patiënten gezien (10%). De gemiddelde VAS score bij implantatie, op een 
schaal van 1 tot 10, was 3.7. Postoperatieve stricturen, die als maat voor fibrose 
van het operatiegebied werden beschouwd, leidden niet tot significant meer pijn 
tijdens de implantatie. Transrectale goudmarkerimplantatie in de prostaatloge, 
als onderdeel van de bestraling na radicale prostatectomie, is daarom haalbaar 
en veilig. Vooral bij jonge patiënten staat de pijn iets meer op de voorgrond dan 
tijdens de goudmarkerplaatsing in de prostaat zelf en daarom is het te adviseren 
om vooraf pijnstillers te geven. Er werden overigens geen risicofactoren voor 
bloedingen en pijn gevonden.
In hoofdstuk 5 wordt een literatuuroverzicht gegeven, na screening van Pub 
med, van primaire en ‘salvage’ cryochirurgie van de prostaat. Hieruit blijkt dat met 
de introductie van gasgebaseerde derde-generatie cryotechnologie het aantal 
bijwerkingen significant is afgenomen vergeleken met oudere cryochirurgie 
technieken met behoud van oncologische resultaten. Het optreden van ernstige 
complicaties zoals rectourethrale fistels (< 1%) is bijna verdwenen, maar het aantal 
patiënten met erectiele disfunctie blijft hoog (90%). Bij ‘salvage’ cryochirurgie zijn 
meer bijwerkingen te verwachten zoals een gemiddeld incontinentie percentage 
van 8% en fistels tot 3.4%. Desondanks blijft deze minimaal invasieve behandeling 
een optie voor recidief prostaatcarcinoom na radiotherapie aangezien de 
‘salvage’ radicale prostatectomie een hoog complicatiegetal kent. De huidige 
data in de literatuur over cryochirurgie zijn echter van ‘low-level evidence’, wat 
bij consultatie van de patiënt verteld moet worden. Focale cryochirurgie wordt als 
experimenteel beschouwd maar het is een interessante nieuwe ontwikkeling in de 
cryochirurgie met als oogmerk vermindering van complicaties. Het verrichten van 
gerandomiseerde studies met langetermijn follow-up moet worden gestimuleerd 
om uiteindelijk de rol van cryochirurgie voor de behandeling van gelokaliseerde 
prostaatkanker duidelijk te maken.
Hoofdstuk 6 biedt een literatuuroverzicht van de rol van androgene 
deprivatietherapie (ADT) in de neoadjuvante en intermitterende setting. 
Dit hoofdstuk is een introductie voor de klinische studies die in hoofdstuk 
7 en 8 worden besproken. Neoadjuvante hormonale therapie geeft bij 
lokaal uitgebreide prostaatkanker en hoogrisico patiënten een betere lokale 
tumorcontrole en ziektespecifieke overleving als het gecombineerd wordt 
met radiotherapie vergeleken met alleen radiotherapie. Het moet daarom 
als standaardtherapie worden beschouwd bij deze patiëntengroepen. De 
noodzakelijke duur van de voorbehandeling is echter een punt van discussie 
en ligt ergens tussen de 3–6 maanden. De rol van neoadjuvante ADT voor 
chirurgie is beperkt. Bij patiënten met uitgebreide of gemetastaseerde 
prostaatkanker is hormonale therapie in een intermitterend schema haalbaar 
gebleken. De progressievrije overleving lijkt vergelijkbaar met die van patiënten 
die continue ADT krijgen. Door de intervallen waarin geen therapie wordt gegeven 
is er een reductie van kosten mogelijk. Er is een verbetering van seksuele functie en 
wellicht kwaliteit van leven haalbaar. Het effect van intermitterende behandeling 
op de complicaties van hormonale therapie op lange termijn, zoals osteoporose 
en metaboolsyndroom, is onbekend. Hoofdstuk 7 gaat over de optimale duur 
van neoadjuvante ADT voor de reductie van prostaatvolume voorafgaand aan 
radiotherapie. Bij een zeer groot prostaatvolume kan ADT voor radiotherapie een 
‘downsizing’ effect van de prostaat geven ter verbetering van de dosimetrische 
parameters en een vermindering van bestralingsdosis op de omliggende weefsels. 
Bij 20 opeenvolgende patiënten met een cT2–3No/xMo prostaatcarcinoom, die 
radiotherapie gingen krijgen, werd gedurende 9 maanden neoadjuvante ADT 
gegeven. Elke 3 maanden werd een CT scan onderzoek verricht voor de bepaling 
van het prostaatvolume tot aan de start van de radiotherapie. Het uitgangsvolume 
was mediaan 82 cc met een mediane reductie van 31% na 3 maanden ADT. Tussen 
3 en 6 maanden werd een additionele mediane volumereductie van 9% gezien. 
Bij grote prostaten (> 60 cc) was het effect duidelijker. Na 6 maanden werd geen 
significante afname van volume gezien. De conclusie van deze studie was dan 
ook dat de meest significante volumereductie na 3 maanden ADT optreedt 
en de maximale reductie na 6 maanden. De optimale duur van neoadjuvante 
ADT voor de reductie van het prostaatvolume lijkt dan ook 6 maanden te zijn. 
In hoofdstuk 8 worden de predictieve waarde voor progressie van PSA en de 
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rol van testosteron voor de kwaliteit van leven van patiënten beschreven tijdens 
continue of intermitterende ADT voor gemetastaseerd prostaatcarcinoom. 
Volgens verwachting bleken patiënten met een hoog uitgangs-PSA, pijn en een 
hoge PSA nadir een slechte prognose te hebben met ADT. Zelfs patiënten met 
een lage PSA nadir, na 6 maanden inductietherapie met maximale androgene 
blokkade, deden het significant slechter op intermitterende therapie dan op 
continue ADT. Verder bleef testosteron laag gedurende lange periodes na het 
onttrekken van de hormonen. Het incomplete herstel van testosteron na de 6 
maanden inductieperiode, verklaart misschien waarom de kwaliteit van leven 
niet verbeterde in de periode waarin geen hormonen werden gegeven. Er 
werden geen verschillen in kwaliteit van leven tussen de groepen gevonden, 
ondanks het feit dat meer bijwerkingen optraden in de continue behandelgroep. 
Intermitterende hormonale therapie lijkt daarom een suboptimale behandeling 
voor veel patiënten met gemetastaseerde prostaatkanker.
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Chapter 10 Future perspectives
Image-guided radiotherapy
Oncological aspects & toxicity
For better oncological outcome after prostate radiotherapy dose escalation has 
been introduced. In several randomized trials, an increased radiation dose led 
to significantly improved biochemical progression-free survival, but also to more 
gastro-intestinal toxicity [1-3]. The aim of new radiation techniques for prostate 
cancer is an improved tumor control with low complication rates. One of these 
new techniques is intensity-modulated radiation therapy (IMRT), which may reduce 
acute and late toxicity by precisely focusing the high-dose to the prostate with 
subsequently decreased doses to surrounding tissues [4]. For this highly conformal 
radiation therapy, the daily target localization procedure is the cornerstone of the 
approach. A small shift in prostate position can lead to significant under dosage of 
the target volume. In recent years, fiducial gold marker implantation has become 
a standard of care for daily target position verification and correction. In this 
thesis, the reduction of target volume due to gold markers and the subsequent 
beneficial effect on radiation doses to surrounding healthy tissues are described, 
suggesting that marker application might reduce toxicity rates. However, although 
the advantages of gold marker-based position verification and correction of the 
prostate for high-precision radiotherapy are evident, no randomized studies have 
been performed to confirm this. These studies will probably never be performed, 
and therefore future research should focus on the long-term clinical outcome, i.e., 
tumor control rate and normal tissue toxicity, in patients receiving both primary 
radiotherapy and radiotherapy in the adjuvant post prostatectomy setting, with 
daily gold marker-based correction procedures.
Gold markers may also have a future role in focal prostate radiotherapy, for 
example magnetic resonance spectroscopy (MRS)-guided brachytherapy with 
a boost to a dominant intraprostatic lesion (DIL). The tumor control probability 
is shown to be high, with the potential to spare normal tissues, especially the 
urethra [5]. Implanting a gold marker MRI-guided inside the DIL could help for 
daily position verification during the procedure without the need of daily magnetic 
resonance imaging.
Complications
Complication rates of gold marker implantation should be low for high acceptance 
of the patients and to prevent deterioration of quality of life. In this thesis, we have 
shown that the complication rates are indeed low, and they seem to be acceptable 
for their purpose. Potential serious complications, like urosepsis, are effectively 
prevented by antibiotic prophylaxis [6]. Increasing antibiotic-resistant Escherichia 
coli bacteria have been observed worldwide [7], and growing concern exists about 
the number of septic complications after prostate biopsies. Therefore, alternative 
prophylactic antibiotics for gold marker implantation should be investigated. The 
pain experienced during marker implantation is high in only a small percentage of 
patients. From prostate biopsy studies it is known that young patients have more 
pain during the procedure than older ones [8,9]. In our study on post prostatectomy 
gold marker implantation a similar trend was observed. It would be of interest to 
investigate further if an age cut-off can be defined for prophylactic analgesics. 
With the implantation of intraprostatic gold markers this trend was not found. The 
minimal invasive aspect of gold marker implantation makes it highly acceptable to 
patients, but when serious complications are increasing this may change.
New markers
Refinements of radiation technique have been introduced and other means 
of image-guided radiotherapy were developed. For instance, the Calypso 4D 
localization system, consisting of an electronic array which is placed above the 
patient, localizes and tracks electromagnetic transponders, implanted in the 
prostate, that respond to electromagnetic signals. This results in continuous 
information about the transponders’ position in three dimensions, thereby 
representing the intrafraction prostate motion. These transponders have the same 
long-term stability as gold markers [10]. In fact, treatment with electromagnetic 
prostate positioning and monitoring is a continuous, real-time adaptive way of 
radiotherapy [11]. This may allow for even smaller treatment margins than with 
gold markers. Clinical studies have shown that transponders are implanted using 
the same procedure as for gold markers, with similar and acceptable complication 
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rates [12,13]. The transponders are inserted with a 14-gauge needle, which could 
result in more pain during implantation because of the larger diameter of the 
needle, but the data are hard to compare with our results because the literature 
does not provide information about VAS scores or the need for analgesics [11]. 
Furthermore, the implantation of electromagnetic transponders following radical 
prostatectomy has been reported very recently [14]. Complications after the 
implantation procedure seem minor but more data on this subject are expected 
in the nearest future.
Cryosurgery
Curative prostate cancer treatment leads to a substantial number of complications, 
like incontinence and erectile dysfunction. Therefore, new minimal invasive 
treatment modalities, i.e., cryosurgery and high-intensity focused ultrasound 
(HIFU) have been developed as an alternative for radical prostatectomy and 
radiotherapy. Complication rates of salvage radical prostatectomy, after local 
radiotherapy recurrent disease, are even higher than in primary surgery. Especially 
incontinence rates are significant and up to 45% of patients [15]. When developing 
alternative treatment options, oncological results should not be compromised, 
and complications should be less. Indeed, with the latest third-generation 
cryosurgery machines, the results are comparable to previous techniques, and 
complication rates have improved. In large patient series treated with cryosurgery 
the complication rates were low. However, one should realize that these reports 
are biased because they come from highly experienced centers. The introduction 
of this treatment should be done with the utmost care not to harm the patient. 
Cryosurgery is a technically demanding procedure and has a long learning curve 
[16]. It should be advocated to treat patients in clinical trials, and initial procedures 
must be performed after adequate training and preferably be accompanied by an 
expert in the field.
There is a growing interest in focal therapy of prostate cancer, especially in the 
light of stage shift and younger age of the patients. From autopsy studies it is 
known that up to 20%–30% of prostate cancers are solitary tumors [17]. These 
patients could benefit from focal cryosurgery targeting one lobe only. Also, the 
feasibility of nerve-sparing cryosurgery by active warming of the neurovascular 
bundle has been evaluated in an experimental animal setting [18]. Few patients 
so far have been actually treated with focal cryosurgery, and this treatment should 
therefore be regarded as experimental. Further, modern imaging techniques, like 
dynamic contrast enhanced MRI and MRS with image-guided biopsies will play 
an important role in diagnosing the disease, in prostate tumor delineation during 
treatment and in follow-up. To get a clear inside in the oncological results of 
cryosurgery, treatment should be monitored by histological examination, because 
PSA and imaging alone seem to be insufficient. For now, cryosurgery appears to 
be a good alternative option for salvage procedures. We need long-term follow-
up of oncological outcome in multicenter studies to evaluate the performance of 
primary and focal cryosurgery.
Hormonal therapy
Neoadjuvant androgen deprivation therapy
In prostate cancer, androgen deprivation therapy (ADT) can be administered 
combined with radiotherapy to improve oncological control and for downsizing 
reasons. In our series, the optimal duration of neoadjuvant ADT from a 
downsizing point of view was 6 months. There is, however, conflicting evidence 
for overestimation of prostate volume measurement by computed tomography 
(CT), compared to ultrasound and MRI, which could lead to longer continuation 
of ADT than necessary. This can be corrected for with CT-MRI matching, but this 
modality is not routinely available in most institutions. The clinical implications of 
overestimation of prostate volume need further research, and consideration of 
costs for extra imaging procedures should be included.
From an oncological point of view, in several randomized trials for locally advanced 
and high-grade localized disease an improved local tumor control rate, disease-
free survival, distant metastases-free rate [19,20], and even overall survival [21-24] 
were shown with ADT combined with radiotherapy. Bolla et al. [21] showed that 
long-term treatment for high-risk disease (d’Amico classification) should consist 
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of 3 years of adjuvant ADT. The advantages of ADT in low and intermediate risk 
disease have been questioned. New randomized trials on the optimal duration of 
neoadjuvant ADT showed that patients with high-risk disease benefit from longer 
neoadjuvant ADT, but in low-, and intermediate risk patients 3-months [19,25] or 
4-months [26] of neoadjuvant ADT seemed enough to improve overall survival. 
Whether long-term adjuvant ADT compared to short-term neoadjuvant ADT can 
provide an additional survival benefit for patients with high-risk prostate cancer 
requires further study. Reports about the increased risk of diabetes, cardiovascular 
disease, and accelerated time to cardiac death in men exposed to even a short 
course of ADT [27,28] have provoked additional discussion of the true benefit of 
this treatment regimen. Some have shown that treatment-related morbidity was 
not increased, 5 years after randomization, for patients on 3, and 6 months of ADT 
compared with patients without neoadjuvant ADT [19]. Therefore, 6 months of 
neoadjuvant ADT combined with radiotherapy seems adequate for men who are 
at risk for micrometastatic disease and with pre-existing metabolic comorbidities 
that could be exacerbated by prolonged ADT.
A multicenter randomized study initiated by the Canadian Urologic Oncology 
Group, comparing ADT with or without radiotherapy, for patients with locally 
advanced prostate cancer, addressed whether radiotherapy adds to overall 
survival [29]. Formal publication is awaited, but preliminary reports have shown 
a substantial benefit in overall and disease specific survival for the combined 
treatment modality. The value of neoadjuvant treatment in the context of high-
radiation doses remains unproven and needs further study. The discussion is 
ongoing whether dose-escalated radiotherapy techniques can improve survival 
and if long-term adjuvant ADT is still necessary with higher radiation doses. So 
far, several phase III trials have demonstrated that higher radiation doses reduce 
the risk of biochemical failure [30,31], but none have demonstrated differences as 
significant as those shown in, for instance, the RTOG 8610 trial [32]. Dose-escalation 
harbors the risk of increased toxicity to surrounding organs and downsizing of the 
prostate by ADT may be of paramount significance, but this needs reconfirmation. 
Therefore, more research is needed to show the exact impact of prostate volume 
reduction on rectal volumes receiving high-dose radiation. Furthermore, the 
question whether the use of neoadjuvant luteinizing-hormone releasing hormone 
(LHRH) agonist alone instead of the combination with antiandrogens may be 
enough for a survival benefit is unanswered.
In conclusion, administering 6 months of neoadjuvant ADT combined with 
radiotherapy for locally advanced or high-risk prostate cancer, without nodal 
metastasis, seems advisable to improve oncological outcome, and to reduce 
volume in large prostates. This may enable sparing of surrounding healthy tissues. 
Side effects may be significant even in the setting of short neoadjuvant treatment 
and therefore low- and intermediate risk patients should not routinely receive 
neoadjuvant ADT, or for a period of only 3 months, except in very large prostates 
for improved dosimetric parameters. These patients may benefit more from high-
dose radiation and future research will hopefully reveal if combined ADT is still 
necessary.
Intermittent androgen deprivation therapy
In metastatic prostate cancer patients, ADT is often administered for long periods 
of time. The side effects of hormonal therapy are considerable, which resulted in 
the development of intermittent androgen deprivation therapy (IAD). In our study, 
we have identified patient groups that are not suitable for intermittent therapy, 
based on certain predictive variables for progression. Others have found similar 
findings and therefore it seems advisable to reserve intermittent hormonal therapy 
for patients with moderately elevated PSA and a relatively low burden of disease, 
preferably non-metastatic. Patients with local recurrent disease or those who are 
unfit for curative treatment could benefit from IAD, although these patients might 
not need hormone therapy for several years without affecting survival. Indeed, one 
study has shown no difference in prostate cancer specific survival in patients, who 
were unfit for radical therapy, and were randomized for immediate or deferred 
ADT when progression occurred [33]. In that study, 26% of patients in the delayed 
arm died without ever needing treatment. This suggests that active surveillance 
may actually be a good alternative treatment for ADT, or even for IAD in patients 
with low burden disease. In this setting we need further evidence that intermittent 
hormonal therapy is needed for better survival, as it actually might harm the 
patient because of side effects. An alternative option could be to administer 
antiandrogens alone to avoid side effects of chemical castration.
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In general, patients needing hormonal treatment who have bad predictive factors 
might benefit more of an early switch to alternative treatments and future research 
should focus on currently available new medications for this patient group. Of 
course, survival is the only important endpoint in prostate cancer therapy with all 
others being surrogate endpoints. Our study was underpowered and follow-up 
was too short to show a survival difference, and we used clinical progression as 
a surrogate endpoint. Future research and ongoing trials on intermittent therapy 
might provide us with more information on survival differences. In fact, new phase 
III trials seem necessary to confirm that IAD does not jeopardize prostate cancer 
specific survival. We found that patients with low PSA nadir had a significantly 
higher risk of progression with IAD than with continuous ADT. So, withholding 
ADT seems to actually harm these patients. This is a remarkable outcome and is 
contradictory to the finding that PSA nadir is a strong predictor of survival [34]. To 
our knowledge this has not been reported before and needs validation in other 
clinical trials.
Apparently, in our study IAD had no QOL benefit probably because of incomplete 
testosterone recovery in the off-treatment phase, although side effects were less. 
This is hard to explain and needs further research. We should realize that study 
outcomes of QOL and side effects measurement are biased because double blind 
placebo-controlled studies have never been performed. The knowledge of being 
in the intermittent arm can influence the side effect profile. The long castrate 
level, after LHRH agonists induction course, is another factor influencing QOL 
measurements. Future research may therefore focus on intermittent therapy with 
antiandrogens only. Data on the long-term consequences for side effects of IAD 
are unavailable, but are expected in the near future when ongoing trials have 
reached maturity.
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Hoofdstuk 10 Toekomstverwachtingen
Beeldgeleide radiotherapie
Oncologische aspecten & toxiciteit
Dosis-escalatie is geïntroduceerd om de oncologische resultaten van radiotherapie 
van de prostaat te verbeteren. In verschillende gerandomiseerde studies 
leidde een hogere bestralingsdosis tot een significant betere biochemische 
progressievrije overleving, maar ook tot meer gastro-intestinale bijwerkingen [1-3]. 
Het doel van nieuwe bestralingstechnieken voor prostaatkanker is de verbetering 
van de lokale tumorcontrole en vermindering van complicaties. Een van deze 
nieuwe technieken is intensiteit-gemoduleerde radiotherapie (IMRT), waarbij de 
acute en late toxiciteit verminderd kunnen worden door de precieze instelling 
van de hoge dosis op de prostaat en dientengevolge een vermindering van de 
hoge dosis op de omliggende weefsels [4]. De dagelijkse lokalisatieprocedure 
van het bestralingsdoel is bij deze conformele bestralingstherapie een essentieel 
onderdeel van de benadering. Een kleine verplaatsing in de positie van de 
prostaat kan leiden tot een significante onderdosering van het doelvolume. In de 
laatste jaren is de implantatie van goudmarkers een standaard manier geworden 
voor het dagelijks verifiëren en corrigeren van de positie van het bestralingsdoel. 
In dit proefschrift worden de afname van het doelvolume door het gebruik van 
goudmarkers en het positieve effect op de bestralingsdosis van de omgevende 
gezonde weefsels beschreven. Dit suggereert ook dat goudmarkergebruik de 
toxiciteit vermindert. Hoewel de voordelen van positieverificatie en correctie van 
de prostaat met behulp van goudmarkers voor precisie-radiotherapie evident zijn, 
zijn tot nog toe geen gerandomiseerde studies verricht die de afname van toxiciteit 
bevestigen. Omdat dit soort studies waarschijnlijk nooit zal worden verricht 
moet toekomstig onderzoek, bij patiënten die zowel primaire radiotherapie als 
radiotherapie in de adjuvante setting na een radicale prostatectomie krijgen met 
de dagelijkse op goudmarker gebaseerde correctieprocedure, zich richten op 
de klinische uitkomsten op lange termijn zoals de lokale tumorcontrole en de 
toxiciteit op normale weefsels.
Goudmarkers zullen mogelijk in de toekomst ook een rol krijgen bij focale 
radiotherapie van de prostaat zoals bij magnetische resonantiespectroscopie 
(MRS)-geleide brachytherapie met een ‘boost’ op een dominante intraprostatische 
laesie (DIL). Er werd al aangetoond dat de mogelijkheden van lokale tumorcontrole 
groot zijn met potentiële bescherming van de normale weefsels zoals de urethra 
[5]. Het MRI-geleid implanteren van een goudmarker in de DIL zou kunnen helpen 
bij het dagelijks verifiëren van de tumorpositie tijdens de procedure zonder de 
noodzaak om ook dagelijks MRI te hoeven inzetten.
Complicaties
Het aantal complicaties van goudmarkerimplantatie moet laag zijn voor een hoge 
acceptatiegraad van de patiënten en om een aantasting van de kwaliteit van 
leven te voorkomen. In dit proefschrift wordt getoond dat het aantal complicaties 
inderdaad laag is en ook acceptabel lijkt met het oog op het doel van de plaatsing. 
Potentiële ernstige complicaties zoals urosepsis worden effectief voorkomen door 
middel van antibioticumprofylaxe [6]. Er wordt wereldwijd echter een toenemende 
antibioticaresistentie van Escherichia coli bacteriën gezien [7] en daardoor nemen 
de zorgen over het aantal septische complicaties na bijvoorbeeld prostaatbiopten 
toe. Alternatieve antibioticumprofylaxe voor goudmarkerimplantatie moet 
daarom worden onderzocht. Ernstige pijn tijdens markerplaatsing is slechts in een 
klein percentage patiënten aantoonbaar. Uit prostaatbiopsiestudies is bekend dat 
jonge patiënten meer pijn hebben tijdens de procedure dan ouderen [8,9]. Een 
soortgelijke trend werd gezien in onze studie naar goudmarkerimplantatie in de 
prostaatloge. Het zou interessant zijn om verder onderzoek te verrichten naar een 
afkapwaarde van de leeftijd voor preventieve pijnstilling. Bij de implantatie van 
goudmarkers in de prostaat werd deze trend overigens niet gezien. Het minimaal 
invasieve karakter van goudmarkerimplantatie maakt het een zeer acceptabele 
procedure voor patiënten, maar als het aantal ernstige bijwerkingen toeneemt, 
zou dit weleens kunnen veranderen.
Nieuwe markers
De bestralingstechnieken zijn verder verfijnd en andere vormen van 
beeldgeleide radiotherapie werden ontwikkeld. Een voorbeeld is het Calypso 
4D lokalisatiesysteem dat bestaat uit een elektronische opstelling die boven de 
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patiënt wordt gepositioneerd en waarmee elektromagnetische bakens in the 
prostaat, die op elektromagnetische signalen reageren, worden gelokaliseerd. 
Hierdoor is er continu informatie beschikbaar over de 3D positie van de bakens en 
daardoor is de beweging van de prostaat tijdens iedere bestralingsfractie bekend. 
Deze bakens hebben dezelfde stabiliteit op lange termijn als goudmarkers [10]. 
De behandeling met elektromagnetische positionering en het monitoren van 
de prostaat is feitelijk zelfs een continue, ‘real-time’ en adaptieve manier van 
radiotherapie [11]. Hierdoor zijn waarschijnlijk nog kleinere behandelingsmarges 
mogelijk dan met goudmarkers. Uit klinische studies is gebleken dat de bakens 
volgens dezelfde methode worden geïmplanteerd als goudmarkers, met 
vergelijkbare en acceptabele complicatiegetallen [12,13]. De bakens worden 
geplaatst met een 14-gauge naald, die door de grotere diameter mogelijk 
meer pijn geeft tijdens implantatie, maar de beschikbare data hierover zijn 
moeilijk vergelijkbaar met onze resultaten omdat in de literatuur geen informatie 
beschikbaar is over VAS scores of de behoefte aan pijnstilling naderhand [11]. 
Verder is zeer recent de implantatie van elektromagnetische bakens na radicale 
prostatectomie beschreven [14]. De complicaties na deze implantatieprocedure 
lijken minimaal, maar in de nabije toekomst worden meer gegevens over dit 
onderwerp verwacht.
Cryochirurgie
Curatieve behandeling van prostaatkanker leidt in een aanzienlijk aantal gevallen 
tot complicaties, zoals incontinentie en erectiele disfunctie. Om die reden zijn 
nieuwe minimaal invasieve behandelingen, zoals cryochirurgie en hoge-intensiteit 
gefocusseerde echografie (HIFU) ontwikkeld, als alternatief voor de radicale 
prostatectomie en radiotherapie. De aantallen complicaties na ‘salvage’ radicale 
prostatectomie, voor een lokaal recidief na radiotherapie, zijn veel hoger dan na 
primaire chirurgie. Vooral het percentage incontinentie is significant en loopt op 
tot 45% van de patiënten [15]. Bij de ontwikkeling van alternatieve behandelingen 
moet het aantal complicaties juist lager liggen, met behoud van oncologische 
resultaten. Met de laatste derde-generatie cryochirurgie-apparatuur zijn de 
resultaten vergelijkbaar met eerdere technieken en de complicatiegetallen zijn 
verbeterd. Bij grote patiëntenseries zijn de complicaties na cryochirurgie laag 
gebleken. Men moet zich echter realiseren dat deze resultaten een bias vertonen 
omdat zij zijn verkregen uit centra met uitgebreide cryochirurgie ervaring. De 
introductie van deze therapie moet met grote voorzichtigheid worden omkleed om 
de patiënt niet te schaden. Cryochirurgie is een technisch veeleisende procedure 
en het heeft een lange leercurve [16]. Het zal verder bevorderd moeten worden 
om patiënten in klinische trials te behandelen en het wordt geadviseerd om de 
procedure in het begin bij voorkeur in het bijzijn van een erkende expert op dit 
gebied en slechts na adequate training uit te voeren.
De interesse voor focale therapie van prostaatkanker groeit, zeker in het licht van 
de verschuiving van stadium en leeftijd van de patiënt bij diagnosestelling. Uit 
obductiestudies is gebleken dat het bij 20%–30% van alle prostaatkankerpatiënten 
solitaire tumoren betreft [17]. Deze patiënten kunnen voordeel hebben van 
focale cryochirurgie gericht op één prostaatkwab. Verder is de haalbaarheid 
van zenuwsparende cryochirurgie door middel van actieve verwarming van de 
neurovasculaire bundel geëvalueerd in een dierexperimenteel model [18]. Tot nu 
toe zijn slechts enkele patiënten daadwerkelijk behandeld met focale cryochirurgie 
en daarom moet deze therapie als experimenteel worden beschouwd. Moderne 
beeldvormende technieken zoals dynamische contrast versterkte MRI en MRS, met 
beeldgeleide biopsie, zullen een belangrijke rol spelen bij het diagnostiseren 
van de ziekte, bij de afbeelding van de prostaattumor tijdens de behandeling 
en tijdens de follow-up. Voor een goed inzicht in de oncologische resultaten 
van cryochirurgie moet de behandeling worden geëvalueerd door middel van 
histologie, omdat PSA en beeldvorming alleen nog onvoldoende zekerheid 
geven. Cryochirurgie lijkt op dit moment een goede alternatieve behandeloptie 
voor ‘salvage’ procedures. Langetermijn follow-up van oncologische resultaten 
in multicentrische studies is echter onontbeerlijk ter evaluatie van het succes van 
primaire en focale cryochirurgie.
 
Hormonale therapie
Neoadjuvante androgene deprivatietherapie
Androgene deprivatietherapie (ADT) kan bij prostaatkanker worden toegepast 
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in combinatie met radiotherapie ter verbetering van de oncologische controle 
en om de prostaat te verkleinen. Vanuit het oogpunt van prostaatverkleining is 
de optimale duur van neoadjuvante ADT in onze serie 6 maanden. Er zijn echter 
tegenstrijdige berichten in de literatuur over overschatting van prostaatvolume 
meting door middel van CT in vergelijking met echografie en MRI, die zou kunnen 
leiden tot het langer continueren van ADT dan nodig is. Dit is te corrigeren met 
de combinatie CT-MRI, maar deze is niet routinematig beschikbaar in de meeste 
klinieken. Voor de implicaties van overschatting van het prostaatvolume in de 
kliniek is verder onderzoek noodzakelijk en hierbij dient ook het kostenaspect van 
extra beeldvormende procedures te worden meegenomen.
Vanuit een oncologisch standpunt is er in verschillende gerandomiseerde trials 
voor lokaal uitgebreid en hooggradig gelokaliseerd prostaatcarcinoom een 
verbeterde lokale controle, ziektevrije overleving, metastasevrije overleving [19,20] 
en ook totale overleving [21-24] aangetoond door gebruik van ADT in combinatie 
met radiotherapie. Bolla en anderen [21] toonden aan dat langdurige hormonale 
behandeling voor hoogrisico ziekte (d’Amico classificatie) uit 3 jaar adjuvante 
ADT moet bestaan. De voordelen van ADT voor laag- en intermediair-risico 
ziekte zijn meer een punt van discussie. Nieuwe gerandomiseerde studies naar 
de optimale duur van neoadjuvante ADT hebben aangetoond dat patiënten met 
hoogrisico prostaatkanker voordeel hebben van langere neoadjuvante ADT, maar 
in laag- en intermediair-risico is 3 [19,25] of 4 maanden [26] neoadjuvante ADT 
waarschijnlijk genoeg voor een verbetering van de totale overleving. Er is verder 
onderzoek nodig om te verduidelijken of langdurige adjuvante ADT vergeleken 
met kortdurende neoadjuvante ADT een extra overlevingsvoordeel oplevert bij 
patiënten met hoogrisico prostaatkanker. De berichtgeving over het verhoogde 
risico op diabetes, cardiovasculaire ziekten en een verkorting van de tijd tot 
overlijden door cardiaal falen bij mannen die slechts kort worden blootgesteld 
aan ADT [27,28] heeft meer discussie los gemaakt over het werkelijke voordeel van 
deze behandelingsstrategie. Er is echter door enkele onderzoekers aangetoond 
dat 5 jaar na randomisatie de behandelingsgerelateerde morbiditeit niet was 
toegenomen bij patiënten met 3 en 6 maanden ADT in vergelijking met patiënten 
zonder neoadjuvante ADT [19]. Daarom lijkt 6 maanden neoadjuvante ADT in 
combinatie met radiotherapie zinvol en verantwoord bij mannen die een hoog 
risico hebben op micrometastasen en met pre-existente metabole comorbiditeit 
die verergerd kan worden door langdurige ADT behandeling.
Er werd een multicentrische gerandomiseerde studie verricht op initiatief van de 
Canadian Urologic Oncology Group ter vergelijking van ADT met radiotherapie 
en alleen ADT bij patiënten met lokaal uitgebreid prostaatcarcinoom met als 
primair eindpunt de bijdrage van radiotherapie aan de totale overleving [29]. 
De formele publicatie is nog niet beschikbaar, maar uit de voorlopige resultaten 
komt een aanzienlijk voordeel in totale en ziektespecifieke overleving voor de 
combinatietherapie. De waarde van neoadjuvante behandeling bij hogedosis 
radiotherapie is nog onduidelijk en hiervoor is meer onderzoek vereist. De discussie 
is gaande of radiotherapietechnieken met dosis-escalatie de overleving kunnen 
verbeteren en of langetermijn adjuvante ADT nog wel noodzakelijk is bij deze 
hogere bestralingsdoses. Tot nu toe hebben verschillende fase III trials bewezen 
dat hogere doses van bestraling het risico op biochemisch recidief reduceren [30, 
31], maar een verschil zo groot als bijvoorbeeld in de RTOG 8610 studie, is nooit 
aangetoond [32]. Het risico van dosis-escalatie is een toename van de toxiciteit op 
de omliggende weefsels en daarom is verkleining van het prostaatvolume door 
middel van ADT wellicht van doorslaggevend belang, hoewel dit nog in verder 
onderzoek bevestigd moet worden. Aanvullend onderzoek is dan ook vereist 
om de precieze invloed van prostaatvolume reductie op het rectumvolume, dat 
een hogedosis bestraling krijgt, aan te tonen. Ook de vraag of het gebruik van 
alleen een neoadjuvante LHRH agonist in plaats van de combinatie met een 
antiandrogeen voldoende is voor een overlevingswinst is nog onbeantwoord.
Concluderend is het te adviseren om voor lokaal uitgebreide en hoogrisico 
prostaatkanker, zonder lymfekliermetastasen, 6 maanden neoadjuvante ADT 
in combinatie met radiotherapie te geven ter verbetering van de oncologische 
resultaten en ter verkleining van het volume van de prostaat. Hierdoor wordt 
wellicht het omliggende gezonde weefsel gespaard van hogedosis bestraling. 
Zelfs bij kortdurende neoadjuvante behandeling kunnen de bijwerkingen 
aanzienlijk zijn en daarom wordt dit niet routinematig of voor slechts een periode 
van 3 maanden geadviseerd bij laag- en intermediair-risico patiënten, tenzij het 
prostaatvolume erg groot is en een verbetering van de dosimetrische parameters 
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wordt nagestreefd. Deze patiënten hebben waarschijnlijk meer voordeel van 
hogedosis bestraling en hopelijk komt uit toekomstig onderzoek naar voren of 
een combinatie met ADT nog noodzakelijk is.
Intermitterende androgene deprivatietherapie
Bij patiënten met gemetastaseerd prostaatcarcinoom wordt vaak langdurige ADT 
gegeven. De bijwerkingen van hormonale therapie zijn aanzienlijk en dit heeft 
geleid tot de ontwikkeling van intermitterende androgene deprivatie (IAD). In 
onze studie werden groepen van patiënten geïdentificeerd die niet geschikt zijn 
voor intermitterende hormonale therapie, gebaseerd op enkele variabelen met 
predictieve waarde voor progressie. Door anderen werden overeenkomstige 
bevindingen gedaan en daarom is het aan te raden om intermitterende hormonale 
therapie te reserveren voor bij voorkeur patiënten met niet-gemetastaseerde 
ziekte met een licht tot matig verhoogd PSA en een relatief laag ziektevolume. 
Patiënten met een lokaal recidief of diegenen die niet sterk genoeg zijn voor 
curatieve therapie kunnen voordeel hebben van IAD, hoewel deze patiënten 
mogelijk jarenlang geen hormonale therapie nodig hebben zonder nadelige 
invloed op hun overleving. In één studie werd geen verschil gevonden in 
prostaatkanker-specifieke overleving bij patiënten, die niet sterk genoeg waren 
voor curatieve therapie, na randomisatie voor directe of uitgestelde ADT bij 
progressie [33]. In deze studie overleed 26% van de patiënten in de uitgestelde 
arm zonder ooit therapie te hebben gehad. Dit suggereert dat actief vervolgen 
een goede alternatieve behandeling voor ADT of zelfs voor IAD kan zijn, bij 
patiënten met laagvolume ziekte. Er is meer bewijs nodig voor deze situaties dat 
intermitterende hormonale therapie kan leiden tot een betere overleving, zeker 
omdat het de patiënt kan schaden door de bijwerkingen die optreden tijdens de 
behandeling. Een andere optie zou kunnen zijn om alleen een antiandrogeen te 
geven ter voorkoming van bijwerkingen van chemische castratie.
Patiënten met slechte prognostische kenmerken en hormonale therapie hebben 
mogelijk meer voordeel van een vroegtijdige omzetting naar alternatieve 
behandelingen en toekomstig onderzoek voor deze patiënten moet zich 
richten op de huidige nieuwe medicamenten. Uiteindelijk is de overleving het 
belangrijkste eindpunt voor prostaatkankerbehandeling en alle andere eindpunten 
dienen als surrogaat. De follow-up duur in onze studie is kort en er is sprake van 
‘underpowering’ zodat geen overlevingsverschil kon worden aangetoond en 
bovendien werd klinische progressie als surrogaat eindpunt gebruikt. Toekomstig 
onderzoek en lopende studies naar intermitterende therapie kunnen ons wellicht 
meer informatie verschaffen over de verschillen in overleving. Nieuwe fase III trials 
zijn feitelijk noodzakelijk ter bevestiging dat IAD de overleving van prostaatkanker 
niet in gevaar brengt. Wij hebben gevonden dat patiënten met een lage PSA nadir 
een significant hoger risico op progressie hebben met IAD dan met continue ADT. 
Dus bij deze groep lijkt het erop dat het achterhouden van ADT de patiënt kan 
schaden. Dit is een opmerkelijke uitkomst en tegenstrijdig met de bevindingen 
door anderen dat PSA nadir een sterke voorspellende factor is voor overleving 
[34]. Dit is voor zover bekend nooit eerder gerapporteerd en deze bevinding 
moet gevalideerd worden in nieuwe klinische trials.
In onze studie is er geen voordeel van kwaliteit van leven gebleken waarschijnlijk 
door een incompleet testosteronherstel in de tussenliggende periodes zonder 
hormonen ondanks een vermindering van de bijwerkingen. De verklaring 
hiervoor is onduidelijk en vraagt meer onderzoek. Men dient zich te realiseren 
dat studie-uitkomsten van kwaliteit van leven en bijwerkingen een bias bevatten 
omdat dubbelblinde placebo-gecontroleerde studies nooit zijn uitgevoerd. De 
wetenschap van de patiënt dat hij zich in de intermitterende arm bevindt kan 
invloed hebben op het bijwerkingen profiel. Een andere factor met invloed 
op de kwaliteit van leven meting is het langdurige castratieniveau na de LHRH 
agonist inductieperiode. Onderzoek in de toekomst moet zich daarom mede 
richten op intermitterende therapie met alleen een antiandrogeen. Data over 
de consequenties van IAD op lange termijn wat betreft de bijwerkingen zijn niet 
beschikbaar, maar worden wel verwacht in de nabije toekomst als van de lopende 
trials de eindresultaten beschikbaar komen.
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Abbreviations
ADT  androgen deprivation therapy
Ar  Argon gas
BDFS  biochemical disease-free survival
CAD  continuous androgen deprivation therapy
CRT  conformation radiotherapy
CT  computerized/computed tomography
DIL  dominant intraprostatic lesion
3D-CRT  threedimensional-conformation/conformed radiotherapy
EBRT  external beam radiotherapy
GI  gastrointestinal
GU  genitourinary
Gy  Gray
HIFU  high-intensity focused ultrasound
IAD  intermittent androgen deprivation therapy
IMRT  intensity-modulated radiotherapy
IQR  interquartile range
LHRH  luteinizing hormone-releasing hormone
LN  liquid nitrogen
LP  laparoscopic prostatectomy
LUTS  lower urinary tract symptoms
MAB  maximal androgen blockade
MRI  magnetic resonance imaging
MRS  magnetic resonance spectroscopy
NA  not available
NADT  neoadjuvant androgen deprivation therapy
NVB  neurovascular bundle
OP  open prostatectomy
PS  performance status
PSA  prostate specific antigen
PTV  planning target volume
QOL  quality of life
RALP  robot-assisted laparoscopic prostatectomy
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RT  radiotherapy
SD  standard deviation
TRUS  transrectal ultrasound
TURP  transurethral resection prostate
UTI  urinary tract infection
192 193
Dankwoord
Op de dag van de promotie sta je er alleen voor, maar het onderzoek dat leidt tot 
het schrijven van een proefschrift komt niet in je eentje tot stand. Ik ben dan ook veel 
dank verschuldigd aan iedereen die heeft bijgedragen aan dit proefschrift. Zonder 
de goede ideeën die werden aangedragen en de logistieke ondersteuning zou 
het niets zijn geworden. Ook de toestemming van patiënten voor dataverzameling 
en hun enorme bereidheid om bij te dragen aan het onderzoek zijn onontbeerlijk 
geweest voor de verschillende studies. Zonder iemand te kort te willen doen, wil 
ik een aantal mensen persoonlijk bedanken.
Prof. dr. J.A. Witjes, beste Fred. Het stond voor mij vast dat ik zou promoveren 
toen ik van Amsterdam naar Nijmegen kwam. Dat dit echter meer een endogene 
motivatie bleek te zijn en jij geen verplichtingen stelde als opleider was toch 
verrassend. Al snel zag ik in dat het een academische carrière of werken in een 
groot perifeer ziekenhuis met opleiding ging worden. Het leek daarom verstandig 
ook maar snel met een proefschrift te beginnen. Je zei wat ongelovig “als je dat er 
echt bij wilt doen, dan gaan we ervoor”. In de loop van de opleiding kreeg het idee 
gestalte en nu is het boekje een feit. Bedankt voor je grote enthousiasme in de 
kliniek, eerst als opleider en nu als collega en het vertrouwen dat je hebt gehouden 
in het afkomen van dit proefschrift. Je was razendsnel met het corrigeren van de 
manuscripten en haarscherp in de beoordeling. Het is een genoegen tot nu toe 
met je te hebben kunnen samenwerken. Als collegae houden we veel interactie 
en niet alleen over horloges en snelle auto’s maar vooral over urologie. Ik kijk uit 
naar de verdere samenwerking met hopelijk veel discussies over het al dan niet 
open of laparoscopisch opereren.
Prof. dr. P.F.A. Mulders, beste Peter. Eindelijk is dan nu de ‘s’ weggepoetst, zoals 
jij pleegt te zeggen. Je bent een bron van inspiratie geweest voor het onderzoek 
door jouw streven naar verbetering en het leveren van prestaties. Soms kwam er 
een idee dat nogal wat voeten in de aarde bleek te hebben, zoals bij de ‘Duitse’ 
studie maar dankzij het doorzettingsvermogen is hier nu toch het resultaat. Jij 
was zelf veel jonger tijdens je promotie en ik heb een iets ander pad gevolgd, 
maar des te meer bewonder ik je carrière en grote inzet voor de afdeling, het 
onderzoek en je visie op het geheel. Sinds mijn toetreding tot de staf heb ik de 
ruimte gekregen voor verdere ontwikkeling, op onderzoeksgebied maar ook op 
de operatiekamer. De samenwerking voor de nierkankerpatiënten, die wij vanuit 
verschillende invalshoeken benaderen is mijns inziens zeer sterk en hoop ik te 
kunnen blijven voortzetten. Ook mijn wetenschappelijke ontwikkeling lijkt hiermee 
een nieuwe richting te gaan krijgen.
Dr. E.N.J.Th. van Lin, beste Emile. Ik ben jou veel dank verschuldigd voor de 
begeleiding van de verschillende klinische studies naar goudmarkers in dit 
proefschrift. Wij hebben geprobeerd de radiotherapeutische inzichten voor 
urologen te verduidelijken. In deze tijd van multidisciplinaire benadering geen 
vreemd verschijnsel, maar het bleek geen gemakkelijke opgave en leverde soms 
teleurstellingen op bij de beoordeling van manuscripten. Toch denk ik dat wij 
hebben getoond dat prostaatkankerbehandeling gezamenlijk moet worden 
aangepakt en begrip over en weer bijdraagt aan de kwaliteit voor de patiënt. Ik 
hoop dat jij je blijft inzetten voor het onderzoek, ondanks de moeilijke momenten 
die er voor je zijn geweest.
Prof. L.A.L.M. Kiemeney, beste Bart. Lambertus, ik blijf het een geweldige naam 
vinden. Ik dank je zeer voor jouw inspanningen. Aan de stapels manuscripten en 
e-mails op je bureau te zien ben ik slechts een van de velen die je met raad en 
daad ondersteunt. De uitleg op statistisch gebied was altijd erg goed te bevatten. 
Later dacht ik vaak hoe legde Bart dit ook alweer uit? Je zei dikwijls dat iedereen 
pas nadat het onderzoek af is bij jou komt aanwaaien voor de statistische 
onderbouwing ervan. Steeds beloofde ik de volgende keer voor aanvang van een 
studie langs te komen. Dat is er niet altijd van gekomen, maar je nam desondanks 
altijd ruim de tijd voor discussie en steevast hoorde daar een kopje koffie bij. Ook 
jouw interesse voor het fietsen deel ik en je uitzonderlijke prestatie op de Alpe 
d’HuZes bewonder ik zeer.
Drs. R.J. Smeenk, beste Robert Jan. Veel dank voor jouw hulp bij de 
totstandkoming van Hoofdstuk 2 van dit proefschrift. Wij hebben het onszelf 
lastig gemaakt door het plan om aan urologen het belang van goudmarkers voor 
bestraling van de prostaat te willen uitleggen. Jouw kennis en heldere uitleg van 
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bestralingstechnieken waren voor mij als relatieve leek op dit gebied essentieel 
om de materie te begrijpen. Dank ook voor de beoordeling van andere delen van 
dit boekje. Veel succes met de verdediging van je eigen proefschrift.
Ir. A.L. Hoffmann, beste Aswin. Bij de volumereductiestudie was jouw inbreng 
essentieel en ik heb veel aan je kennis van de statistiek gehad. Je bent zelf druk 
bezig met een proefschrift en hoewel ik volstrekt niets begrijp van de materie 
waar jij je mee bezig houdt beloof ik het toch te gaan lezen als het op de deurmat 
valt. Laten we hopen dat dit binnenkort gebeurt.
G.M. McColl, M.S., beste Gill. Vanaf het prille begin van het onderzoek naar 
goudmarkerimplantatie in de prostaat heb jij mij enorm ondersteund met de 
vragenlijsten, de follow-up en het doorspitten van patiëntendossiers. Je draagt 
veel bij aan onderzoek van anderen, maar ik hoop ooit toch ook een proefschrift 
van jou te kunnen lezen.
Drs. R. Donker, beste Remco. Je was meteen enthousiast om samen de complicaties 
van goudmarkerplaatsing na een radicale prostatectomie te gaan onderzoeken 
en zeer bereidwillig om de data uit Alkmaar hiervoor ter beschikking te stellen. 
Je hebt dit uitstekend gefaciliteerd en hiervoor mijn grote dank. Het artikel wacht 
nog op acceptatie, maar ik ben ervan overtuigd dat het goed komt.
D. Badhauser, M.S., dear Dirk. When I presented my research on the EAU in Milan 
2008 you asked me to do join a research project on intermittent hormonal therapy 
with the aid of the TULP study data. I visited you and mr. Schaaf in Frankfurt and we 
exchanged the ideas for the study after some great pizza. We immediately started 
working on the subject, but it turned out to be quite a lot of work to get the job 
done. Finally, we succeeded to get the article being published and it has become 
an important part of this thesis. Thank you for the excellent cooperation. I wish 
you all the best in your new job and hope to meet again soon. Auf wiedersehen.
Dr. H. Vergunst, beste Henk. In mijn periode als AIOS urologie in het CWZ heb ik 
de start van cryochirurgie van de prostaat meegemaakt. Jij hebt deze therapie in 
Nederland nieuw leven ingeblazen en hoewel het niet gemakkelijk is als pionier 
te moeten beginnen, heb je getoond dit met toewijding te willen doen. Er is een 
fraai overzichtsartikel uit voortgekomen met medewerking van Eveline Broers, 
in een sterk tijdschrift. Ik hoop dat je blijft vernieuwen en het onderzoek op dit 
gebied continueert. Dank voor je enthousiasme en de gedachtenwisselingen die 
we gedurende mijn tijd in het CWZ hebben gehad.
Medewerkers van de afdeling radiotherapie. Ik wil mijn dank uitspreken aan 
iedereen die een bijdrage heeft geleverd aan dit proefschrift met betrekking tot 
het verstrekken van patiëntendossiers, statistische ondersteuning, beoordeling 
van manuscripten, het intekenen van bestralingsschema’s en het berekenen van 
prostaatvolumina. Vooral dank aan professor Hans Kaanders, Robert Louwe, Peter 
van Kollenburg, Lisette van der Vight, Andries Visser en Ilse Spitters-Post.
Medewerkers van de afdeling urologie. Aan allen die mij hebben ondersteund 
bij het verrichten van het onderzoek en het opschrijven ervan wil ik mijn dank 
uitspreken. Vooral noem ik de administratie van de poli voor hulp bij het verzamelen 
van statussen en patiëntengegevens en het secretariaat voor de verzameling van 
de vragenlijsten.
Collega stafleden afdeling urologie UMC St. Radboud. Afina, Barbara, Inge, 
John, Kathleen, Michiel, Robert, Toine en Wout. Jullie zijn een dagelijkse bron 
van inspiratie. Gelukkig blijven de discussies scherp en is de sfeer uitstekend, 
voldoende reden om nog een tijd te blijven.
Kamergenoot, beste Frank. Nu kan eindelijk dat bordje naast de deur worden 
aangepast en misschien kun je als chef de policlinique ook een nieuw naambordje 
regelen? Jij hebt wezenlijk bijgedragen aan dit proefschrift door mij te leren over 
Reference Manager, door vaak te zeggen dat jij zelf toch echt het promotie-
onderzoek ’s nachts deed en dat het dus altijd erger kon en door mij telkens 
weer te moeten complimenteren als ik zei ”daar gaat weer een publicatie naar 
een topblad“. Bedankt voor de goede samenwerking en alles wat je mij hebt 
geleerd op laparoscopie en endourologie gebied. De pijler staat als een huis en 
ik vertrouw op een mooie toekomst.
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Leden van de manuscriptcommissie. Hooggeleerden Jelle Barentsz, Ad Hermus 
en Jeroen van Moorselaar zeer veel dank voor het beoordelen van het manuscript 
en de positieve woorden.
Vrienden en familie. Het is van een afstand moeilijk te beoordelen wat iemand die 
promotie-onderzoek doet nu eigenlijk uitvoert. Hopelijk krijgen jullie nu een idee, 
ondanks de specialistische materie. Dank voor de interesse in de vorderingen van 
het proefschrift en jullie steun.
Paranimfen. Mijn grote broer Kees. Bedankt voor je steun als paranimf. We delen 
veel interesses, onderzoek is daar niet een van. Toch ben je altijd geïnteresseerd 
geweest in het verloop ervan en dat onderzoek maar een aspect is van ons vak 
weet jij heel goed. Het is geen vereiste om een uitstekende arts te zijn en dat 
bewijs jij dagelijks in je vak als KNO arts, waarin jij uitmunt in patiëntenzorg, 
operatieve vaardigheden en organisatie.
Coen, goede vriend. Nog een dokter en een die uitzonderlijke dingen heeft 
gedaan zoals vliegen in F-16’s en uitzendingen naar Irak ondanks een tweeling 
op komst. Even leek het erop dat jij een academische carrière als cardioloog zou 
gaan krijgen, maar je interesse nam een andere wending en nu ben je alsnog als 
huisarts verbonden aan de universiteit. Je was getuige op ons huwelijk, maar je 
kon er niet bij zijn door een verplichte buitenlandse missie. Dit is je herkansing en 
ik ben blij dat je paranimf wilt zijn.
Mijn ouders. Als dank voor alles draag ik dit proefschrift aan jullie op. 
Lieve mam, altijd zorgzaam en bezorgd. Zeer begaan met het lot van de 
onderzoeker en clinicus. Je hebt veel over het onderzoek gehoord en altijd intens 
meegeleefd. Eindelijk iets tastbaars van wat ik allemaal doe. Bedankt voor je 
toewijding en steun. 
Pap, jij bent altijd een groot voorbeeld geweest door je wetenschappelijke 
interesse, relativeringsvermogen en rustige benadering van vraagstukken. Je 
hoopte dat wij iets anders zouden kiezen, maar toch werden beide zoons dokter 
en nu ook nog doctor. Het heeft zo moeten zijn. Bedankt voor je continue steun. 
In het begin was je mijn trouwste reviewer. Jouw vader heeft helaas net je eigen 
promotie niet meegemaakt. Ik ben blij dat jij er bij bent en nog wel in de corona.
Martje, Peer en Taeke. Het leven is simpel. Jullie bestaan is het allerbelangrijkste. 
Het dagelijkse uitzwaaien en jullie lieve gezichtjes bij thuiskomst zijn onmisbaar. 
Dat is het voornaamste dat telt.
Jik. Mede dankzij jou is de opmaak van het boekje erg mooi geworden. Bedankt 
voor het geloof in mijn werk en je steun onder alle omstandigheden. Ik hoop op 
een lang leven samen. Tot nu toe is het een feest.
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Advanced diagnostics for prostate cancer have 
enlarged the top of the iceberg, which may lead 
to more curative treatments and complications.
